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Abstract 
Macrophage polarization is a key feature of innate immunity that gives rise to a plethora of 
macrophage subtypes. Broadly, pro-inflammatory (classic, M1) and anti-inflammatory 
(alternative, M2) activation patterns have been described in the past. The polarization process 
is enabled by inherent macrophage versatility, and it is subject to tight regulation. Failure of 
this surveillance can lead to inappropriate polarization that can potentiate a skewed immune 
response and thus aggravate a disease. Due to this complex nature of activation, macrophages 
are at the core of a number of diseases as various as cancer and allergy. The precise analysis 
of macrophage subtype manifestation necessitates a global investigation of parameters, e.g. 
mRNA or microRNA (miRNA) profiling, since individual markers considered in isolation 
hold little information about the subtype in question. 
In this thesis, I aim to point out some features of macrophage polarization in the pathogenesis 
of allergic asthma. The chosen approach started with the establishment of subtype-
characteristic mRNA and miRNA profiles of prototypical in vitro polarized human 
macrophages. In a second step, the miRNA patterns were used in an attempt to interpret the 
polarization status of isolated lung macrophage phenotypes from a murine model of asthma. 
At the outset, in vitro polarization of human blood-derived macrophages was performed. 
Classic activation was achieved by administration of IFNγ and LPS, while IL4 and IL13 
induced alternative activation. Cellular signal transduction patterns and bactericidal capacity 
were tested to assess polarization efficiency. Subsequently, polarized macrophages were 
isolated cytometrically by positive selection for subtype-specific surface markers (classic 
activation: CD80; alternative activation: CD23). Global mRNA and miRNA profiling of the 
purified populations established a broad data base for subsequent investigation. The 
magnitude of response on the transcriptional level appeared to be much greater in classic 
macrophages as compared to alternative macrophages. In classic macrophages, hallmark 
genes such as TNFα, IL6 and IL1β were induced, whereas in alternative macrophages, an up-
regulation of CD209 and PPARγ could be observed. Prominent miRNAs that were up-
regulated in classic macrophages included hsa-miR-187-3p, hsa-miR-155-5p and hsa-miR-
146a-5p. In contrast, hsa-miR-193b-3p and hsa-miR-511-5p were induced in alternative 
macrophages. In-depth in silico correlation of the mRNA and miRNA expression patterns was 
carried out in cooperation with Dr. Annalisa Marsico (MPI for Molecular Genetics, Berlin). 
On the basis of these data, putative mRNA/miRNA interaction partners were identified and 
experimentally validated in a luciferase-based reporter assay. In this setting, affirmative 
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candidates included hsa-miR-187-3p as a regulator of SH2B2 and the pair of hsa-miR-187-3p 
and hsa-miR-155-5p as cooperative regulators of LAMP2. While the precise function of the 
scaffold molecule SH2B2 in macrophages is currently unknown, LAMP2 is closely associated 
with lysosomal organization and activity and therefore centrally involved in macrophage 
biology. Under physiologic conditions, hsa-miR-187-3p was able to down-regulate SH2B2 
transcript. However, no impact of either hsa-miR-187-3p or hsa-miR-155-5p, or a 
combination of both, on LAMP2 mRNA or protein could be observed.  
While they revealed no functional interaction, the gathered systemic mRNA and miRNA data 
constitute a potential tool to assess the polarization status of in vivo macrophages in the 
context of a disease. Allergic asthma is one of the most severe forms of allergic diseases of the 
airways, and it poses a substantial socio-economic burden. Long neglected, macrophages have 
recently been credited with a central role in several forms of asthma, since they seem to 
determine disease progression by means of their polarization status. 
In this study, the miRNA profiles of murine lung macrophages from the bronchoalveolar 
lavage fluid and from digested lung tissue were established. These profiles were employed in 
a comparative analysis of healthy mice and mice suffering from acute Ovalbumin-induced 
eosinophilic airway inflammation. It was hypothesized that the pattern of miRNA expression 
might yield clues as to the polarization status of inflammation-associated macrophages when 
assessed on the basis of the prototypical human in vitro data. Individual miRNAs that were 
regulated in response to Ovalbumin were identified, e.g. mmu-miR-21a-5p and mmu-miR-
155-5p (up-regulated), as well as mmu-miR-126-3p and mmu-miR-146a-5p (down-
regulated). 
Although the gathered murine miRNA data could only in part be compared to the human 
reference samples due to a limited intersection of the significantly regulated candidates, they 
still suggest a mixed macrophage phenotype in eosinophilic airway inflammation, as they 
show characteristics of both M1- and M2-associated miRNA patterns. This was represeneted 
most prominently in the concomitant reciprocal expression of mmu-miR-155-5p (up-
regulated) and mmu-miR-146a-5p (down-regulated). 
Keywords: macrophage, polarization, microRNA, asthma 
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Zusammenfassung 
Die Polarisierung von Makrophagen ist ein zentraler Mechanismus der angeborenen Immuni-
tät, der in einer Vielzahl verschiedener Makrophagen-Subtypen resultiert. Vereinfachend sind 
in der Vergangenheit pro-inflammatorische (klassische, M1) und anti-inflammatorische 
(alternative, M2) Aktivierungsmuster beschrieben worden. Die Polarisierung ist Ausdruck der 
Vielseitigkeit von Makrophagen und verdeutlicht die Notwendigkeit, diese Vielseitigkeit zu 
regulieren. Ein Versagen dieser Kontrolle kann dazu führen, dass Makrophagen durch 
fehlgeleitete Polarisierung eine gestörte Immunantwort verstärken und somit einen 
Krankheitsverlauf negativ beeinflussen können. Damit sind Makrophagen grundlegend an so 
diversen Krankheitsbildern wie Krebs und Allergie beteiligt. Eine genaue Analyse der 
Ausprägung von Makrophagen Subtypen erfordert ein globales Erfassen von Parametern, wie 
z.B. von mRNA oder microRNA (miRNA) Expressionsmustern, da die isolierte Betrachtung 
von einzelnen Markern wenig Aussagekraft über den betrachteten Subtyp enthält. 
In der vorliegenden Studie beabsichtige ich, die Makrophagen-Polarisierung in der Patho-
genese von allergischem Asthma darzulegen. Am Beginn des hierzu gewählten Vorgehens 
stand die Etablierung von Subtyp–charakteristischen mRNA und miRNA Expressionsprofilen 
in vitro polarisierter, humaner blutstämmiger Makrophagen. In einem zweiten Schritt wurde 
überprüft, ob sich die miRNA Expressionsdaten eignen, um den Polarisierungsstatus isolierter 
Lungenmakrophagen in einem Mausmodell des Asthmas zu ermitteln. 
Initial wurden humane blutstämmige Makrophagen in vitro durch Gabe von IFNγ und LPS 
(M1) bzw. IL4 und IL13 (M2) polarisiert. Zur Beurteilung der Polarisierungseffizienz wurden 
zelluläre Signaltransduktionsmuster und die bakterizide Kapazität untersucht. In der Folge 
wurden polarisierte Makrophagen mit Hilfe von spezifischen Oberflächenmarkern (M1: 
CD80, M2: CD23) zytometrisch isoliert, und es wurden globale mRNA und miRNA Profile 
erstellt. In M1 Makrophagen war die transkriptionelle Antwort auf den Stimulus deutlich 
umfassender als in M2 Makrophagen. Charakteristische Gene, wie z.B. TNFα, IL6 und IL1β, 
waren in M1 Makrophagen induziert, während in M2 Makrophagen eine verstärkte 
Expression von CD209 und PPARγ beobachtet werden konnte. Unter den maßgeblich herauf-
regulierten miRNAs befanden sich hsa-miR-187-3p, hsa-miR-155-5p und hsa-miR-146a-5p 
(M1) bzw. hsa-miR-193b-3p und hsa-miR-511-5p (M2). Eine in silico Korrelation der mRNA 
und miRNA Expressionsmuster wurde im Rahmen einer Kooperation von Dr. Annalisa 
Marsico durchgeführt (MPI für Molekulare Genetik, Berlin). Diese Daten lieferten die 
Grundlage für eine Identifizierung hypothetischer mRNA/miRNA Interaktionspartner, die 
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anschließend in einem Luciferase-basierten Reportermodell überprüft wurden. Bestätigte 
Kandidaten waren u.a. hsa-miR-187-3p als Regulator von SH2B2 und hsa-miR-187-3p sowie 
hsa-miR-155-5p als kooperative Regulatoren von LAMP2. Während die genaue Funktion des 
Scaffold Moleküls SH2B2 in Makrophagen noch unbekannt ist, ist LAMP2 mit Aufbau und 
Aktivität des Lysosoms assoziiert und damit wesentlich in die Makrophagenbiologie einge-
bunden. Es konnte gezeigt werden, dass hsa-miR-187-3p unter physiologischen Bedingungen 
in der Lage ist, SH2B2 auf Transkriptebene herunter zu regulieren. Auf der anderen Seite 
konnte weder ein Einfluß von hsa-miR-187-3p oder hsa-miR-155-5p, noch einer Kombination 
von beiden, auf LAMP2 mRNA oder Protein beobachtet werden.  
Obwohl kein funktioneller Zusammenhang gezeigt werden konnte, sind die erhobenen 
systemischen mRNA und miRNA Daten potentiell von Wert, um den Polarisierungsstatus von 
primären Makrophagen im Kontext einer Krankheit zu bestimmen. Allergisches Asthma ist 
eine ernstzunehmende Atemwegserkrankung mit schweren sozio-ökonomischen 
Implikationen. Makrophagen wurde erst in jüngerer Vergangenheit eine zentrale Rolle in 
verschiedenen Formen von Asthma zugesprochen, die durch ihren Polarisierungsstatus 
bestimmt wird. 
In der vorliegenden Studie wurden die miRNA Profile von murinen Lungenmakrophagen 
erhoben, die aus der bronchoalveolären Lavage und aus verdautem Lungengewebe gewonnen 
wurden. Diese Profile wurden in einer vergleichenden Analyse von gesunden Mäusen und 
Mäusen mit akuter Ovalbumin-induzierter eosinophiler Atemwegsentzündung eingesetzt. Es 
wurde postuliert, dass das miRNA Expressionsprofil Hinweise auf den Polarisierungsstatus 
Entzündungs-assoziierter Makrophagen beinhalten könnte, wenn es in Anlehnung an die 
prototypischen humanen in vitro Daten analysiert wird. Einzelne in der Immunantwort auf 
Ovalbumin regulierte miRNAs waren z.B. mmu-miR-21a-5p und mmu-miR-155-5p (herauf 
reguliert), sowie mmu-miR-126-3p und mmu-miR-146a-5p (herunter reguliert).  
Obwohl die erhobenen murinen miRNA Daten aufgrund einer geringen gemeinsamen 
Schnittmenge nur teilweise mit den humanen Referenzproben vergleichbar waren, kann 
dennoch ein gemischter Makrophagen-Subtyp postuliert werden, da sowohl M1 als auch M2 
assoziierte miRNA-Muster gefunden werden konnten. Dies zeigte sich vor allem in der 
gleichzeitigen reziproken Regulation von mmu-miR-155-5p (herauf reguliert) und mmu-miR-
146a-5p (herunter reguliert). 
 
Schlagworte: Makrophagen, Polarisierung, microRNA, Asthma 
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1 Introduction 
1.1 The macrophage as a central cell type of the innate immune system 
1.1.1 Innate immune cell lineages 
The human immune system is composed of an innate and an adaptive branch. Innate 
immunity is the body´s first line of defence against pathogens and other insults from the 
environment. Besides chemically and physically protective surfaces, such as mucosa, and 
humoral proteins, e.g. the complement system, it includes a cellular constituent. Cells of the 
innate immune system stem from a universal progenitor cell, the hematopoietic stem cell 
(HSC) [1]. The HSC is generated in the bone marrow and migrates between bone marrow, 
blood and peripheral tissues [2]. It gives rise to the hematopoietic tree (Fig. 1-1), which is 
bifurcated into a myeloid and a lymphoid branch. While the lymphoid axis of the 
hematopoietic tree spawns lymphocytes (B-cells, T-cells), the myeloid axis generates 
granulocytes (neutrophils, eosinophils, basophils) and monocytes, which are all effector cells 
of innate immunity. Monocytes are precursor cells and establish the mononuclear phagocyte 
pool upon maturation via multiple, not yet fully understood lineages. Circulating monocytes 
in the blood constitute the pool from which resident macrophages are in part recruited. Upon 
entering the tissue, monocytes adopt a characteristic morphology and differentiate into 
functional organ-specific macrophages.  
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Figure 1-1: The hematopoietic tree. The canonical lineage maturation of HSC-derived myeloid cells is 
separated into a lymphoid and a myeloid branch that originate from the respective progenitor cell. HSC: 
hematopoietic stem cell; CMP: common myeloid progenitor; GMP: granulocyte-macrophage progenitor; MEP: 
megakaryocyte-erythroid progenitor; CLP: common lymphoid progenitor. (Adapted from D. Metcalf, Immunity, 
2007) 
1.1.2 Mononuclear phagocyte heterogeneity 
In humans, circulating monocytes in the blood have been broadly classified into three 
subgroups by their most prominent surface molecules, CD14 and CD16. Classical monocytes 
are defined as CD14++CD16-, intermediate monocytes as CD14++CD16+ and non-classical 
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monocytes as CD14+CD16++. This nomenclature was officially proposed to replace 
misleading denomination such as “inflammatory monocyte”, because the heterogeneity and 
migratory fate of monocytes in vivo do not necessarily match in vitro observations [3]. Until 
now, there is no evidence that the fate of a maturing monocyte is defined by its CD14/CD16 
lineage. Instead, the diversity of mature subtypes is suggested to result of the plasticity that is 
inherent to all mononuclear phagocytes [4]. Whether a mononuclear phagocyte is classified as 
a dendritic cell (DC) or a macrophage largely depends on surface marker decoration and 
tissue localization; yet there is still considerable debate over the guidelines to differentiate 
between macrophages and dendritic cells. It has been proposed to define macrophages as cells 
that descend from blood-borne monocytes. In contrast, dendritic cells are suggested to stem 
from their own dedicated precursor cell [5]. 
In mice, monocytes are classified into two major subgroups, being CCR2+CX3CR1+Ly-6Chi 
and CCR2-CX3CR1++Ly-6Clo [6]. Murine Ly-6Chi monocytes have been described to 
resemble human CD14++ monocytes, whereas Ly-6Clo monocytes appear to share features 
with human CD14dimCD16+ cells [7]. Furthermore, murine monocyte subtype manifestation 
appears to be in part caused by differential microRNA expression [8]. 
Besides these canonical monocyte lineages, a common bone marrow progenitor for 
monocytes, some macrophage subsets and resident spleen dendritic cells has been described 
to originate from the HSC in mice. It has been named macrophage and dendritic cell 
progenitor (MDP) [9]. It is on the one hand committed to the generation of a common DC 
precursor (CDP) that gives rise to classical and plasmacytoid dendritic cells. On the other 
hand, it directly spawns monocytes. These two paths have been described as strictly separated 
[10]. Thus, a murine monocyte-independent DC lineage seems to exist. 
Another study conducted in mice recently revealed an alternative, bone marrow-independent 
lineage from which macrophages can arise [11]. This lineage originates from the embryonic 
yolk sac. These macrophages have been found in an attempt to elucidate why some tissue-
resident macrophages remain unaffected by bone marrow transplantation. The exact 
contribution of HSCs and yolk sac to the adult´s macrophage pool remains unknown. In 
humans, such a lineage awaits identification [12]. 
The macrophage, its versatility and plasticity being of particular interest in the present study, 
will be focused on hereafter. 
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1.2 Regulation of macrophage function in the immune defense 
Macrophages, populating the various organs of the body in their manifold subtypes, serve as 
sentinels of the immune system. Their diversity manifests in subtypes such as Kupffer cells in 
the liver or alveolar macrophages in the lung, to name only two. The key cytokine that is 
involved in monocyte production, recruitment and maturation is the macrophage colony-
stimulating factor M-CSF (CSF-1) [13]. M-CSF is produced by endothelial and by local tissue 
cells and acts on monocytes and macrophages via the CSF-1 receptor tyrosine kinase (CSF-
1R) [14]. In homeostasis, the M-CSF stimulus ensures a stable macrophage count and 
distribution throughout the body. In contrast to the monocytes that permanently replenish the 
resident macrophage sentinel population in good health, there is amplified recruitment to sites 
of acute or chronic inflammation. This process requires elaborate cell-to-cell communication 
in order to orchestrate a coordinated immune response, which is achieved by ligand-receptor 
interaction. 
1.2.1 Macrophage receptor signaling 
Like many tissue cells, cells from the immune system are equipped with invariable surface 
and intracellular receptors that detect patterns common to pathogens (pathogen associated 
molecular patterns, PAMPs) or to sterile threats (danger associated molecular patterns, 
DAMPs). The most prominent PAMP receptor type is the germ-line encoded Toll like receptor 
(TLR) family. Originally discovered to determine dorsoventral polarity in Drosophila 
melanogaster in 1985, it was later associated with host defence in Drosophila and also in 
mammals [15]. Thirteen mammalian TLR genes have been identified so far, 10 of which are 
functionally expressed in humans [16]. They recognize a plethora of different PAMPs, such as 
lipopolysaccharide (LPS) from gram-negative bacteria (via TLR4), peptidoglycan from gram-
positive bacteria (via TLR2), the bacterial motility protein flagellin (via TLR5), nucleic acids 
of bacterial or viral origin, such as unmethylated CpG motifs (via TLR9), double-stranded 
RNA (via TLR3) and single-stranded RNA (via TLR7). 
All TLRs share a cytoplasmic Toll/interleukin-1 receptor (TIR) domain, a transmembrane 
domain and leucine rich repeat motifs (LRRs) on the extracellular/intravesicular side. These 
LRRs are responsible for PAMP detection. Upon PAMP binding, TLRs dimerize, bringing 
their cytoplasmic TIR domains into close spatial proximity. This process creates the binding 
sites necessary for adapter molecule binding. Association of myeloid differentiation primary 
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response protein 88 (MyD88) or TIR-domain-containing adapter-inducing interferon-β 
(TRIF) to the dimerized TIR domains triggers a signalling cascade, involving mitogen 
activated protein kinases (MAPK), nuclear factor kappa B (NFκB) and interferon regulatory 
factors (IRF), which eventually leads to the activation of pro-inflammatory genes that 
establish an unspecific immune reaction against the detected threat. 
LPS is a structure of three subunits, the hydrophobic region (lipid A), a core oligosaccharide 
and a distal oligosaccharide [17]. TLR4, the LPS receptor, requires co-factors for dimerization 
and subsequent intracellular signalling. Myeloid differentiation factor 2 (MD2), an auxiliary 
protein, and CD14, a surface molecule with no intracellular domain, both assist in TLR4 
homodimer formation. LPS can be detected only if it is bound to a soluble LPS-binding 
protein (LBP) [18]. Altogether, this multimeric structure triggers a pro-inflammatory 
signalling cascade via the dimerized TIR domains of TLR4 and MyD88, which bears a C-
terminal TIR domain that engages in homotypic interaction with TLR4 [1, 19]. At the N-
terminus, MyD88 possesses a death domain, which is required to recruit Interleukin-1 
receptor-associated kinase 4 (IRAK4). By its kinase activity, IRAK4 phosphorylates IRAK1, 
which in turn associates with TNF receptor associated factor 6 (TRAF6). Subsequent 
downstream signalling events via TAB2 lead to the activation of transforming growth factor-β 
(TGFβ) activated kinase 1 (TAK1) by lysine 63 (k63)-linked ubiquitin [20, 21]. TAK1 is able 
to trigger two distinct signalling pathways [22]. One is the NFκB pathway, which is initiated 
by activation of the IκB kinase complex (IKKα,β,γ) [23, 24]. IKK phosphorylates the 
inhibitor of kappa B alpha (IκBα), which inhibits NFκB entry into the nucleus in steady state. 
IκBα is degraded upon phosphorylation. This enables NFκB to shuttle into the nucleus and 
participate in the initiation of pro-inflammatory gene transcription [23]. The other pathway 
which TAK1 is able to initiate is the MAPK cascade, culminating in the MAP kinase kinase 6 
(MKK6)-mediated phosphorylation and activation of p38 kinase and c-Jun N-terminal kinase 
(JNK) [22]. Both factors also participate in inflammatory gene transcription by 
phosphorylating transcriptional regulators. 
Further receptors that are present on cells of the innate immune system recognize autologous 
messenger molecules such as interleukins and interferons, both of which belong to the 
cytokine family. As cytokines are produced by cells of the innate and adaptive immune system 
alike, they represent a means of crosstalk between innate and adaptive immunity. Cytokines 
that are typically produced by cells of the adaptive immune system are e.g. Interleukin-4 
(IL4), Interleukin-13 (IL13) by TH2 cells and Interferon-γ (IFNγ) by TH1 cells. IL4 is 
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recognized via the dimeric type I receptor, consisting of the IL4Rα chain and a common 
gamma chain (IL4Rα/γc), or the dimeric type II IL4Rα/IL13Rα1 receptor, while IL13 is 
sensed exclusively by the type II receptor [25]. Macrophages, unlike most other cells, express 
both the type I and the type II receptor. Even though IL4 and IL13 work in a very similar way 
and even share the IL4Rα receptor chain, they have some non-redundant functions which can 
at least in part be explained by receptor sensitivity, which is higher for IL4 [26]. Receptor 
binding leads to Janus kinase 1 and 3 (JAK1/3) activation and subsequently to signal 
transducer and activator of transcription 6 (STAT6) phosphorylation. Upon phosphorylation, 
STAT6 dimerizes and enters the nucleus, where it serves as an activator of transcription [26]. 
The gene products, e.g., peroxisome proliferator-activated receptor gamma (PPARγ) and 
krueppel like factor 4 (KLF4), participate in insulin metabolism and immunomodulation. 
Unlike these interleukins, IFNγ signalling gives rise to a distinctly pro-inflammatory gene 
transcription. Upon binding to the IFNγ receptor (IFNGR), a dimer consisting of the IFNγR1 
and IFNγR2 chain, JAK1 and JAK2 are activated by tyrosine residue phosphorylation [27]. 
The transcription factor STAT1 is recruited to these phospho-tyrosines, and subsequently, 
JAK1 and JAK2 mediate STAT1 phosphorylation and dimerization. As a homodimer, STAT1 
can translocate into the nucleus and initiate the transcription of pro-inflammatory mediators, 
such as CCL2, CCL5 and CXCL10 [28]. 
A key feature of macrophages is the phagocytosis of cellular debris or pathogens, mediated by 
different receptors: Surface receptors such as the IgG receptor (FcγRI) mediate engulfment of 
non-self structures opsonized with antibodies. Scavenger receptor CD163 is involved in the 
clearance of free haemoglobin. The mannose receptor CD206 is responsible for glycoprotein 
disposal and also recognition of glycostructures on pathogens. Phagocytosis thus serves as 
both a disposal system for debris and as a mechanism of defence. The ingested material is 
engulfed by a vesicle, the phagosome. Neutralization of the potentially harmful phagosome 
content is achieved by fusion to a lysosome, yielding a phagolysosome. Lysosomes are 
vesicles that contain toxic compounds such as reactive oxygen species and nitric oxide, or 
lytic enzymes such as elastase and cathepsins [1]. Since these enzymes require a pH between 
4 and 5, the phagolysosome is actively acidified by an ATP-dependent proton pump [29], 
which further supports pathogen incapacitation. In order to fully activate the phagolysosomal 
machinery, macrophages require an IFNγ stimulus from TH1 cells [30]. After chemical 
pathogen breakdown, remaining fragments are displayed on IFNγ-induced major 
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histocompatibility complex type II (MHC II) surface molecules, which raises the MHC II 
affinity to T cells equipped with a matching T cell receptor. 
1.2.2 Macrophage activation by the adaptive immune system 
Macrophages participate in the induction and maintenance of the adaptive immune response 
and also require its stimuli for subtype manifestation. The initiation of an adaptive immune 
response necessitates the presentation of antigen to the memory and effector cells of the 
immune system. The cells that ingest, process and present antigen are the antigen presenting 
cells (APCs), which are mostly mononuclear phagocytes. They sample antigen and present 
antigen fragments on their type II MHC surface molecules. Upon activation by antigen 
encounter, macrophages mount a local and unspecific immune response. Secretion of lipid 
mediators such as leukotrienes and prostaglandins induce an inflammatory state. The release 
of cytokines like TNFα, IL1β, IL8 and CCL2 promotes further recruitment of leukocytes, 
such as neutrophils and additional monocytes, to the affected tissue. Resident dendritic cells 
take up antigen material at the site of an infection and migrate to the T cell zones of proximal 
lymphoid organs via lymphatic vessels and activate CD4+ T helper cells equipped with a 
compatible T cell receptor. By this match, T cells pass a positive selection process and are 
clonally expanded, a process that makes them available in great numbers to fight the source of 
the antigen they were selected for. A portion of these T cells leaves the lymph node and enters 
the blood stream. At the site of infection, T cells cross the endothelial barrier by a selectin- 
and integrin-mediated process. Activated CD4+ T helper cells can develop into CD4+ Type 1 
(TH1) or Type 2 (TH2) helper cells, depending on the microenvironment they encounter in the 
tissue. At the inflamed site, these T helper cells mediate further activation and maintenance of 
other immune cells, such as macrophages. TH1 cells produce IFNγ, while TH2 cells produce 
IL4, IL5 and IL13. These cytokines reinforce the respective T cell activation status while 
inhibiting the opposite one. Furthermore, these cytokines shape the macrophage activation 
status by paracrine stimulation. 
1.2.3 Macrophage polarization 
Macrophages can be activated in a variety of different ways, and the TH1 and TH2 cell 
subtypes have a profound impact on directing and maintaining macrophage activation. TH1 
cells bind to macrophages that carry intracellular pathogens such as Listeria and Leishmania 
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in vesicular compartments. These macrophages interact with TH1 cells via CD80-CD28, 
CD40-CD40L and MHCII-T cell receptor interaction and release of IL12 [1]. Subsequent 
IFNγ release by TH1 cells activates macrophages in a pro-inflammatory way, a process that 
has been termed M1 polarization [31], thus rendering them capable of fighting intracellular 
pathogens. 
In contrast, the TH2 response is elicited in response to allergens or parasites such as helminths 
and can also be mounted in response to a weak antigen that is not sufficiently immunogenic to 
trigger a TH1 response. TH2 cells can activate macrophages by secretion of IL4 and IL13. 
Unlike activation by IFNγ, IL4 and IL13 trigger an alternative activation of macrophages, 
which has been termed M2a polarization. This macrophage subtype is associated with allergy 
and TH2 inflammation [32]. In addition to the M2a subtype, further distinct polarization states 
have been described to be inducible in vitro, referred to as M2b and M2c. The focus herein 
will lie on M2a-stimulated macrophages, which will henceforth be denominated M2, as the 
M2a/b/c nomenclature has been discouraged (see below). 
In vivo, the M1 and the M2 states represent two extremes of a broad spectrum of phenotypes 
that a macrophage can adopt [33]. Macrophages both require and promote a certain 
microenvironment, and their transient phenotype is a product of this delicate interplay. The 
pro-inflammatory microenvironment that arises at the site of an ongoing infection is primarily 
established by macrophages and leads to immune cell recruitment from the blood into the 
tissue and to the subsequent formation of the pro-inflammatory M1 macrophage subtype. The 
M1 macrophage actively participates in killing invading pathogens and infected cells by 
phagocytosis and lysis. The highly aggressive properties of this subtype need to be tightly 
controlled in order to prevent an excessive and inappropriate response to the present threat 
that might become deleterious to the host. Upon clearance of the infection, the cytokine 
microenvironment gradually shifts from pro-inflammatory to immunomodulatory, leading to a 
change of macrophage behavior. Phagocytosis of apoptotic cells primes macrophages to 
release anti-inflammatory mediators such as IL10 and TGFβ [34, 35]. This newly arising 
immunoregulatory subtype has long been considered to be inactive, but it has increasingly 
become clear that even though many pro-inflammatory functions are switched off, these so-
called M2c macrophages show a defined pattern of activity that helps restoring the 
physiological state of the inflamed site. Their contribution to angiogenesis, wound repair and 
extracellular matrix restoration is crucial for the re-establishment of homeostasis. The effector 
cell that is required for these processes is the myofibroblast whose activation is triggered and 
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maintained by M2 macrophage-derived TGFβ and platelet-derived growth factor (PDGF). 
Furthermore, M2 macrophages can directly contribute to tissue rebuilding by phagocytosis of 
cellular debris [36]. It has recently been emphasized that the term “alternatively activated” 
should be used for TH2-associated macrophages only, while “immunoregulatory” and “wound 
healing” macrophages are also entities of their own, respectively [37]. This differentiation is 
reflected in the M2a/b/c nomenclature as it was proposed in 2004 [32]. However, it has since 
become clear that this discrete attempt of categorization still overly simplifies the versatile 
nature of macrophage biology, which should rather be represented as a continuum of states 
[38, 39].  
Other than in the wake of an M1-dominated inflammation, M2 macrophages can also arise as 
the primary macrophage response of the immune system, e.g. during parasite infection. It has 
been shown that the TH2 response that is initiated as a response to a parasite is able to trigger 
local macrophage proliferation, induced by the TH2 hallmark cytokine IL4. Unlike M1 
macrophages that are thought to accumulate at the site of infection by elevated monocyte 
recruitment, IL4-induced M2 macrophages have been shown to expand in situ [40]. This 
observation discourages the hypothesis of an existing specific M2 monocyte precursor in the 
blood, again stressing the assumption that the plasticity of macrophages lies in their inherent 
versatility, not in lineage commitment. It is still unclear, though, how monocyte differentiation 
and recruitment is altered in the course and aftermath of inflammation to re-establish the 
tissue´s pre-inflammatory cell count and activation status [41]. 
Due to its modulatory properties, the M2 subtype can be found at the root of various diseases 
that are characterized by a skewed or suppressed immune response, such as cancer and 
allergy. Cancerous tissue usually carries a high load of macrophages that are polarized toward 
the M2 phenotype by tumor-derived substances such as CCL2, M-CSF/CSF1, TGFβ and IL10 
[42]. Even though these M2-like tumor-associated macrophages (TAMs) contribute to 
vascularization and immunologic tolerance of the tumor tissue, they have therapeutic 
potential. Efforts to re-polarize these TAMs toward the more aggressive M1 subtype via the 
NFκB axis led to shrinking of the tumor size in a mouse model of IKKβ activity [43]. Similar 
results were obtained in a study using human TAMs purified from ovarian cancer ascites. 
Their M2-like phenotype could be reversed in vitro by IFNγ administration, and the resulting 
M1-like phenotype showed increased tumoricidal properties [44]. 
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1.3 The lung as a model organ for macrophage-associated pathogenesis 
The lung is a lobular organ which is located in the thoracic cavity. In humans, it is ventilated 
through the bifurcated trachea that allows airflow to and from the left and the right lung 
compartment. The tracheal branches form the bronchus principalis dexter and sinister, which 
progressively ramify and ultimately give rise to the alveoli, the effectors of gas exchange. 
They deplete CO2 from the the blood and re-oxygenate it. The right lung is composed of three 
lobes, the lobus superior, the lobus inferior and the lobus medius. With a volume of 
approximately 1500 cm3, it is larger than the left lung, which misses the lobus medius and has 
a total volume of 1400 cm3. The lung is passively ventilated by the diaphragm and various 
accessory muscles, e.g. the musculi scaleni. The airflow to the individual lung compartments 
can be directed by the selective constriction and dilatation of the bronchi by smooth muscle 
cells. Expiration normally occurs by muscle relaxation that leads to shrinking of the lung. It 
can also be forced by activation of auxiliary muscles, e.g the musculi intercostales interni. 
The disturbance of the coordinated breathing process heightens the risk of airflow obstruction 
and may lead to labored breathing.  
1.3.1 Experimental eosinophilic airway inflammation as a model for asthma 
Asthma is a widespread chronic, non-communicable disease with increasing worldwide 
prevalence and significant socio-economic consequences. It is characterized by reversible 
airflow obstruction, airway-hyperresponsiveness, airway inflammation, mucus 
hypersecretion, and subepithelial fibrosis [45]. Clinically, at least two asthma phenotypes 
have been identified, namely allergic (extrinsic, atopic) and non-allergic (intrinsic, non-
atopic) asthma [46]. Allergic asthma arises from an inappropriate immune reaction against 
harmless airborne antigen, e.g. birch pollen, which is initiated and maintained by antigen 
sampling dendritic cells [47]. Immunologically, several asthma phenotypes have been 
described, e.g. eosinophilic, neutrophilic and paucigranulocytic asthma. These types vary in 
severity, persistence and steroid sensitivity [48]. Especially in eosinophilic asthma, symptoms 
are caused in part by cytokines from the TH2 axis of the adaptive immune system, including 
IL4 and IL13 [49, 50]. While they poise airway smooth muscle cells for hypercontractility 
and thereby contribute to air flow obstruction [51], they also induce an M2 skew of airway 
associated macrophages. The involvement of macrophage subtypes in the pathogenesis of 
asthma is still poorly understood [52]. 
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Experimental allergic airway inflammation mimicking eosinophilic asthma can be induced in 
e.g. mice or rats by sensitizing the animal to a non-self antigen (e.g. ovalbumin, OVA, 
coupled to the adjuvant Al(OH)3) and subsequent challenge with nebulized OVA applied 
intratracheally by normal breath intake [53]. Another way of asthma induction is exposure to 
house dust mite extract (HDM) [54]. Besides lung function assessment, airway inflammation 
outcome can be monitored by determining cells and cytokines in the bronchoalveolar lavage 
(BAL) and lung tissue [55]. 
1.3.2 Macrophages of the lung and their putative role in asthma 
The lung, constantly exposed to air flow, needs tight surveillance by the immune system. In 
the airways, alveolar macrophages defend the body against air-borne pathogens. These 
macrophages are recruited from the pool of interstitial (parenchymal) macrophages, which 
reside in the lung tissue [56]. The inital classification of these two populations as distinct was 
solidified by transcriptome studies that highlighted differential gene expression by 
comparison [57]. Furthermore, interstitial macrophages can inhibit dendritic cell maturation 
and migration, whereas alveolar macrophages cannot [58]. Long neglected as an important 
contributor to asthma pathogenesis [50], macrophages have been found to be a crucial part in 
the asthma-related imbalance of the immune system. In a rat model of asthma, adoptively 
transferred naive alveolar macrophages were shown to alleviate asthma symptoms in OVA-
sensitized and -challenged animals that were depleted of their residual macrophages. It was 
hypothesized that the protective effect of macrophages is eliminated in the course of OVA 
sensitization [59]. At least in part, the effect of macrophages on asthma can be attributed to 
IL17. Macrophages, and not TH17 cells, have been identified as the primary IL17 producers in 
asthma. This cytokine was reported to be involved in leukocyte infiltration, neutrophil 
recruitment and -expansion and initiation of allergic inflammation. Its neutralization by 
antibodies or macrophage depletion reduced IL4, IL5, IL13 and IL17 levels in 
bronchoalveolar lavage fluid (BALF) [60]. In another study in rats, alveolar macrophages 
were cultured ex vivo and then re-administered. Re-instillation of ex vivo cultured cells caused 
elevated levels of IL12 and IFNγ in the BAL, which are both cytokines of the TH1 axis. Thus, 
withdrawal of the TH2 environment which the macrophages are exposed to in the asthmatic 
lung seems to deprogram their asthmatic M2 skew. In these animals, asthma was attenuated 
[61], feeding the hypothesis that the M2 polarization state of macrophages promotes asthma. 
Of note, the association of M2-like macrophages with asthma is complicated by the 
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observation that M1 macrophages can promote disease progression in severe cases of asthma 
by being refractory to glucocorticosteroids [49, 62]. Due to the interactions of macrophage 
versatility and asthma heterogeneity, clarification of their mutual dependency has yet to be 
achieved [52].  
1.4 Non-coding RNAs have emerged as regulators of cellular processes 
The field of RNA biology is rapidly expanding. In addition to the classically known protein-
coding messenger RNAs (mRNA), the non-coding transfer RNAs (tRNA) and ribosomal 
RNAs (rRNAs), further RNA species exist which have active regulatory capacities. The 
impact of these RNAs on the immune system with its manifold aspects as outlined above has 
only begun to be revealed. In the following, the central discoveries that have led to the current 
understanding of certain non-coding RNA functions will be highlighted. 
1.4.1 The initial discovery of RNA interference 
The concept of antisense-mediated gene silencing as a tool for genetic engineering in 
eukaryotes was first introduced in 1984. It was shown that transgenic RNA sequences that 
bear Watson/Crick complementarity to the herpes simplex thymidine kinase mRNA can 
inhibit the expression of this kinase in a model using mouse L cells [63]. The mechanism 
relied on a flipped full-length thymidine kinase transgene that was hypothesized to inhibit 
expression by duplex formation with the mRNA. Long antisense transcripts have also been 
described as natural regulators of gene expression in eukaryotes, but only little evidence could 
be gathered to prove that they are functional [64]. Accordingly, experimental introduction of 
full-length antisense RNA often entails specificity and efficacy issues [64, 65]. Furthermore, 
the detailed molecular background of antisense suppression was unresolved [64]. In 1993, 
new light was shed on the mechanisms behind natural antisense-mediated gene silencing by a 
study in Caenorhabditis elegans. 
Established as a model organism for genetic research by Sydney Brenner in 1974 [66], this 
nematode worm has certain peculiarities that make it ideally suited for use as a genetic tool, 
such as eutely (a constant number of somatic cells), ease of handling and transparency. In 
1993, it was discovered that the lin-4 gene encodes a short RNA with incomplete antisense 
complementarity to the lin-14 mRNA in C. elegans [67]. The authors suggested a RNA – 
RNA interaction that negatively regulates translation of lin-14 mRNA, thereby reducing lin-
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14 protein levels. Since lin-4 played a role in developmental timing, it was included in the 
group of small temporal RNAs (stRNAs). Natural antisense mechanisms that inhibit 
translation by interference with ribosomes at the transcript 5´UTR were already known to 
exist and to require broad sequence complementarity with the target [68, 69]. In the case of 
lin-4, the authors proposed a novel mechanism of direct translational inhibition that takes 
place at the transcript 3´UTR and therefore was unlikely to involve ribosome binding. They 
furthermore hypothesized that lin-14 was probably not the only gene whose expression is 
controlled by a small RNA that binds in the 3´UTR. Indeed, Dougherty and Parks listed the 
lin-4/lin-14 interaction as one of a few known natural antisense suppression mechanisms in 
eukaryotes [70]. They suspected it to be part of a cellular surveillance system that keeps 
aberrant or pathogenic RNAs in check via sense and antisense suppression. The obvious 
paradox that could not be solved yet was how a few antisense RNA molecules could confer 
efficient downregulation of a stoichiometrically over-represented target. In an attempt to 
explain the mechanism of antisense suppression, Dougherty and Parks introduced the idea of 
a RNA-dependent RNA polymerase (RdRP) that uses the sense or antisense transgene RNA as 
a template. It would, in their model, synthesize short RNA molecules which then bind and tag 
the endogenous transcript for degradation. 
In 1998, new light was shed on that matter. Fire et al. performed an experiment that turned out 
to revolutionize the field of genetic engineering. They discovered that dsRNA injection of 
unc-22 sense and antisense sequences into C. elegans specifically interfered with the 
expression of unc-22 protein [71]. As Dougherty and Parks, they noted that due to its relative 
paucity, the injected dsRNA could not be responsible for the strong down-regulation of 
protein they observed without the help of an additional boosting mechanism. In order to 
emphasize that what they had found was not a classical antisense phenomenon, they termed 
the mechanism RNA interference (RNAi). For their pioneering work in the field of RNAi, 
Fire and Mello were awarded the Nobel Prize in Physiology or Medicine in 2006. Variations 
of dsRNA administration to C. elegans turned out to be equally effective, e.g. soaking the 
worms in solution containing dsRNA, or feeding them dsRNA-expressing E. Coli [72].  
In the years following the initial discovery, RNAi was hypothesized to ensure genome 
stability in vivo [73] and to take part in the antiviral response [74]. The exact mechanism 
behind the RNAi phenomenon was still a mystery, though. Tuschl et al. confirmed that RNAi 
requires double stranded RNA (as suggested by Fire et al. in 1998) and pointed out the 
sequence specificity of RNAi in a cell free system derived from syncytial blastoderm 
Drosophila embryos [75]. They furthermore observed that the relative inability of single 
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strand RNA to inhibit gene expression was not due to its inherent instability, because capped 
ssRNA failed to induce RNAi, whereas uncapped dsRNA inhibited gene expression. It was 
not until two years after the initial discovery that Zamore et al., using the same cell free 
Drosophila system, finally proposed a mechanism for RNAi (Fig. 1-2). 
 
 
Figure 1-2: A proposed mechanism for RNAi. Long dsRNA molecules are cleaved into fragments and undergo 
strand separation. They subsequently bind mRNA and mediate directed cleavage by recruitment of 
endonucleases. Circles = RNAi-specific proteins; Triangles = nucleases; dsRNA = double-stranded RNA 
(adapted from P. Zamore, Cell, 2000) 
Here, RNAi was described as an ATP-dependent mechanism that cleaves dsRNA into 21 to 23 
nucleotide fragments. It was also noted that the target mRNA was digested at 21 to 23 
nucleotide intervals, even though an interpretation of this observation was still lacking [76]. 
The model partially explained how a small amount of exogenous dsRNA could silence a 
vastly dominating mRNA. If every 21 to 23 nucleotide fragment was an active unit capable of 
RNAi, this would greatly enhance their regulatory potential. One year later, in 2001, the group 
of Fire proposed a refined model of RNAi in C. elegans (Fig. 1-3) [77]. In addition to the 
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concept of cleavage by the endoribonuclease Dicer (DCR-1), they proposed re-use of the 
short RNA molecules and generation of secondary silencing RNAs by an RNA dependent 
RNA polymerase (RdRP) to explain the potency of RNAi. Furthermore, they implemented 
two accessory dsRNA binding proteins into their model that were indispensable for RNAi, 
rde-1 and rde-4, which had already been considered by Zamore et al. They called the effector 
oligomers small interfering RNAs (siRNAs), which were integrated into a protein complex 
with nucleolytic capacities, the RNA-induced silencing complex (RISC) [78]. As they and 
others noted, the model they had proposed was not generally applicable to all species, since 
mammals seem to lack an RNA-dependent RNA polymerase [79]. 
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Figure 1-3: A refined model for RNAi. The model introduces the RISC complex that assists binding of the 
siRNA and the target RNA and subsequent cleavage, as well as the concept of physical amplification by RdRP. 
The generation of multiple catalytic units was hypothesized to explain in part the potency of RNAi. RdRP = 
RNA dependent RNA Polymerase; RDE = RNAi-deficient (accessory dsRNA binding protein); RISC = RNA-
induced silencing complex (Adapted from T. Sijen, Cell, 2001). 
The question was raised whether RNAi was a mechanism that was restricted to pathogen 
response and control of transposable elements, or whether it was also an active regulator of 
physiologically expressed genes [65]. In the following years, it became clear that there are at 
least three endogenous subtypes of small RNAs with regulatory function in C. elegans that 
differ in terms of origin, maturation processes and complementarity to target sequences [80]. 
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Endogenous siRNAs were described to result from Dicer-mediated cleavage of a long double 
stranded RNA precursor. They were reported to be ~22 nucleotides in size, and to be fully 
complementary to their target. Furthermore, they stem from the antisense strand of protein 
coding regions in the genome. This is in contrast to a second class of regulatory RNAs, the 
tiny non-coding RNAs (tncRNAs), which were described to be transcribed from non-coding 
genomic sequences. The term tncRNA was established by Victor Ambros in 2003 in an 
attempt to classify endogenous RNAs with a regulatory function in C. elegans [80]. 
A third class, the microRNAs (miRNAs), are generated by cleavage of a ~70 nucleotide 
single-stranded hairpin precursor RNA [81]. This prompted Ambros to suggest that the main 
difference between miRNAs and endogenous siRNAs lies in their biogenesis and in their 
mode of action (imperfect complementarity in the case of miRNA and tncRNA vs. perfect 
complementarity in the case of endogenous siRNA). The term “microRNA” (miRNA) was 
coined in 2001 by consent of three different groups [82-84]. In contrast to siRNAs that always 
lead to target RNA degradation, it was observed that miRNAs can also act as translational 
repressors, leaving the target transcript intact [85]. The machinery behind its biogenesis was 
thought to be different from siRNA. Dicer, the endonuclease giving rise to siRNAs by 
cleaving double stranded precursors, was suggested to generate miRNAs by digesting stem-
loop precursors. Due to these new insights, the lin-4 RNA described in 1993 was classified as 
a miRNA in retrospect.  
1.4.2 microRNAs are a subclass of non-coding RNAs 
1.4.2.1 microRNA biogenesis and function 
miRNAs are encoded in the genome, either as independent miRNA genes or as parts of an 
annotated gene. In the former case, transcription directly gives rise to a repetitive hairpin 
structure, which is the pri-miRNA. It measures up to several thousand nucleotides in length 
and possesses typical mRNA features, such as a 5´ cap sequence and a 3´ poly-A-tail. This 
pri-miRNA is further processed by the nuclear microprocessor complex, consisting of the 
double-stranded RNA-binding protein DiGeorge syndrome critical region gene 8 (DGCR8) 
and the type III RNAse Drosha [86], yielding ~70-nucleotide pre-miRNA hairpin structures 
(Fig. 1-4). Canonical intron-derived miRNAs are excised from the primary transcript by 
DGCR8 and Drosha prior to splicing. Additional cropping and trimming gives rise to the pre-
miRNA hairpin. Non-canonical intronic miRNAs stem from spliced introns that undergo 
debranching and trimming of single-strand overhangs. Unlike the canonical pathways, this 
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non-canonical procedure does not require the DGCR8/Drosha microprocessor complex. 
Irrespective of their canonical or non-canonical origin, an active shuttle mechanism exports 
the pre-miRNA into the cytosol upon complexation with RanGTP and Exportin 5. Here, 
another type III RNAse, Dicer, cleaves the miRNA precursor into 22-nucleotide double-
stranded RNA fragments. This process requires the assembly of the argonaute proteins 
AGO 1–4, the RNA – binding protein TRBP and Dicer itself [87]. Once cleaved, one strand of 
RNA (the guide strand) remains bound to the AGO proteins, while the other strand (the 
passenger strand) is in the majority of cases degraded. In some cases, accumulation of 
passenger strand was shown to be indicative of later occurring guide strand up-regulation 
[88]. The strand bias is thought to be determined by the thermodynamic stability of the RNA 
duplex. Unlike in Drosophila melanogaster or Caenorhabditis elegans, where different AGO 
proteins discriminate between miRNA duplexes with perfect or imperfect complementarity 
and bind selectively, no such sorting mechanism is suggested in humans [87]. 
Dicer, TRBP and the argonaute proteins form a loading complex (RLC, risc loading complex) 
that incorporates the mature miRNA into the miRNA-induced silencing complex (miRISC), 
consisting of AGO and GW182 family proteins. The miRISC guides the miRNA to the target 
mRNA, where binding occurs predominantly in the 3´UTR. The region determining 
complementarity is a stretch of nucleotide 2-7 at the miRNA 5´ end, the seed region. A match 
of miRNA and mRNA in this region has been shown to be necessary and sufficient for 
translational regulation. GW182 proteins were suggested to recruit deadenylating complexes 
to the miRISC, thereby achieving mRNA deadenylation and destabilization [89]. The 
modification of target mRNA by miRNA-mediated deadenylation has been described as the 
predominant mode of action by which miRNAs achieve down-regulation of protein, since 
initial deadenylation was presumed to precede translational inhibition. Progressive 
deadenylation plus a decreased amount of protective ribosomes on the mRNA then confer 
mRNA destabilization and reduced protein synthesis [90]. Target destabilization can also be 
conferred by endonucleolytic cleavage, exerted by the AGO2 protein. While this mechanism 
is common in plants, it is only of minor importance in the mammalian system [91]. A third 
way of neutralizing transcript is binding and sequestration of mRNA, which renders it 
inaccessible to ribosomes, thereby leaving it intact but translationally silenced [91]. These 
mRNA-miRNA duplexes have been shown to accumulate in designated foci within the 
cytoplasm, termed processing bodies (P-bodies) [92]. In rare cases, miRNAs can enhance 
translation by alleviating repression, as has been described for the impact of miR-10a on 
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ribosomal protein mRNA [93], or by displacing destabilizing mediators, such as tristetraprolin 
(ZFP36) [94]. 
 
Figure 1-4: miRNA biogenesis and function. The long primary pri-miR transcript is cleaved by the RNAse 
Drosha, yielding a pre-miR of ~70 nucleotides in length, which is exported into the cytoplasm. There, it 
undergoes further cleavage by DICER. The resulting 22 nucleotide double strand is opened, and either the 5p or 
the 3p single strand is loaded into the miRISC. This complex can then mediate translational repression, mRNA 
cleavage, and in rare cases translational activation.  DGCR8: DiGeorge syndrome critical region gene 8; 
miRISC: microRNA-induced silencing complex. (Adapted from Iorio, EMBO Mol Med, 2012 and Shyu, 
EMBO, 2008). 
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The clinical relevance of miRNAs lies in their potential as biomarkers. They were 
successfully isolated from various body fluids, such as plasma/serum, urine or saliva [95]. 
This minimally invasive sampling method significantly facilitates diagnosis. The challenge 
remains, though, to link a certain miRNA pattern found in a patient with a specific disease 
diagnosis and prognosis. Some forms of cancer have been characterized by one or more de-
regulated miRNAs [96]. Since their aberrant expression implies their involvement in disease 
manifestation, efforts have been made to target these “oncomiRs” [95] by anti-miRNAs [97, 
98].  
Selective interference with the miRNA setup of a given cell can be basically achieved by two 
methods, ectopic overexpression or ectopic silencing. The introduction of a miRNA precursor 
(pre-miR) leads to an abundance of this miRNA in the cell. Conversely, introduction of a 
reverse complement, the anti-miRNA (anti-miR), confers downregulation of the target by 
antisense suppression. Of note, the global perturbation that occurs in the wake of introduction 
of an artificial RNA into a cell due to saturation and competition effects of the processing 
machinery has been shown to be both detectable and significant [99]. 
1.4.2.2 microRNA nomenclature 
The miRNA nomenclature follows a standardized pattern that allows quick identification of a 
miRNA´s key properties. The name hsa-miR-146a-5p, e.g., contains information about the 
species (“hsa”, homo sapiens), it identifies the molecule as a mature miRNA (capitalization in 
“miR”), it assigns a number to address the family (“146”) and a letter to indicate the specific 
member of that family (“a”). The appendix “5p” reveals that the miRNA comes from the 
5´arm of the mir-146a hairpin (lack of capitalization in “mir” denotes the precursor). 
Depending on the specific miRNA, the 3p or 5p variant may be the guide strand or the 
passenger strand. Originally, the miRNA passenger strand was labeled with an asterisk (“hsa-
miR-146a*”) to highlight its minor importance. This biased nomenclature has been revoked in 
favor of the 3p and 5p annotation, because asterisk-labeled miRNAs have been found to be of 
relevance in some cases, e.g. hsa-miR-19* [100], which has been consequently re-named into 
hsa-miR19-5p. A systematic nomenclature of miRNAs can be retrieved from the miRBase 
database [101]. 
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1.4.2.3 microRNA target prediction requires elaborate bioinformatics 
The likelihood of a miRNA-mRNA interaction can be computed to a certain extent. Publicly 
available databases and algorithms (TargetScan, miRBase, miRanda) combine information 
about e.g. sequence conservation across species and thermodynamic stability of the putative 
miRNA/mRNA duplex and provide a numeric score that is indicative of interaction 
probability [101]. Due to the underlying biological complexity of mRNA-miRNA interaction, 
every target prediction needs to be validated experimentally, since all algorithms produce a 
certain amount of false positive or false negative results. 
1.4.2.4 microRNAs can be targeted to alleviate experimental asthma 
Several miRNAs are up-regulated in models of experimental asthma, in both immune cells 
and cells of the airways. In T cells, miR-21 is among the most prominently expressed. It is 
speculated that this miRNA acts on the TH1/TH2 balance by targeting IL-12p35. This would 
drive the immune response toward the TH2 axis, maybe contributing to the exaggerated TH2 
response seen in many asthma subtypes. Accordingly, miR-21-/- mice were shown to have 
increased levels of TH1 cytokines, reduced levels of TH2 cytokines and less eosinophilia in 
their lungs after OVA allergen challenge [102]. Another miRNA that has been described as 
induced in experimental asthma is miR-126, which was found to be up-regulated in the airway 
wall tissue in response to house dust mite extract in a TLR4/MyD88 dependent manner. The 
TH2 response elicited by HDM was shown to be ablated by antagonizing miR-126, a 
mechanism that essentially relies on GATA3 down-regulation [103]. While these miRNAs are 
experimentally validated to influence asthma pathogenesis, other potential candidates are 
proposed on the basis of prediction [104]. More research is needed to establish a conclusive 
network of interaction that incorporates cellular and molecular components of asthma 
development and progression.  
1.5 Aims of this study 
The goal of this study was to understand the molecular basis of miRNA regulation in 
macrophage polarization, and to translate this knowledge into the context of eosinophilic 
airway inflammation. To this end, the mRNA and miRNA profiles of the prototypical human 
macrophage polarization types were assessed. The exploration of possible mRNA/miRNA 
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interactions was hypothesized to yield clues as to the impact of miRNA regulation on 
macrophage polarization. Furthermore, the global miRNA profiles were envisaged to provide 
generally applicable patterns that can be used to determine the polarization status of 
macrophages isolated from in vivo material. In this study, murine eosinophilic airway 
inflammation was used as an experimental disease model, and lung macrophages were 
isolated to determine their polarization status on the basis of their miRNA pattern. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Instruments and equipment 
7300 Real Time PCR System Life Technologies (Carlsbad, USA) 
7900 HT Real Time PCR System Life Technologies 
autoMACS Pro Separator Miltenyi Biotech (Bergisch-Gladbach, Germany) 
Axio Vert.A1 Fluorescence Microscope Zeiss (Oberkochen, Germany) 
AxioCam MRm Zeiss 
Bioanalyzer 2100 Agilent (Böblingen, Germany) 
Biomate3 Photometer Thermo Fisher Scientific (Karlsruhe, Germany) 
Cell Counting Chamber TC10 Bio-Rad (München, Germany) 
Centrifuge 5424R Eppendorf (Wesseling-Berzdorf, Germany) 
FACS Aria III Cell Sorter BD Biosciences (Heidelberg, Germany) 
FACS Calibur Flow Cytometer BD Biosciences 
Gentle MACS Homogenizer Miltenyi Biotech 
HERACELL 240i CO2 Incubator Thermo Fisher Scientific  
Heraeus Multifuge X3R Thermo  Fisher Scientific 
Lumat LB9501 Luminescene Reader Berthold Technologies (Bad Wildbad, Germany) 
Master Nebulizer Pari (Midlothian, USA) 
Mini Protean Electrophoresis Chamber Bio-Rad 
Mini Protean Tetra System Bio-Rad 
Nanodrop Peqlab Biotechnologie (Erlangen, Germany) 
Neubauer –Improved Counting Chamber Marienfeld (Lauda-Königshofen, Germany) 
MaxQ 6000 Incubated Stackable Shaker Thermo Fisher Scientific 
Odyssey Infrared Imager Li-cor Biosciences (Bad Homburg, Germany) 
PEQPOWER 300V Power Supply Peqlab Biotechnologie  
PEQSTAR 2X Gradient Thermo Cycler Peqlab Biotechnologie 
Pipetman Gilson (Middleton, USA) 
Pipets Gilson 
Precision Scale SI-234 Denver Instrument (Göttingen, Germany) 
Qubit Fluorometer 2.0 Life Technologies 
Quadro MACS Magnetic Stand Miltenyi Biotech 
Surgical Preparation Set Fine Science Tools (Heidelberg) 
TC10 Automated Cell Counter Bio-Rad  
Thermomixer Comfort Eppendorf 
UV Transilluminator Biostep (Jahnsdorf, Germany) 
ViiA™ 7 Real Time PCR System Life Technologies 
Vortex-Genie 2 Scientific Industries (Bohemia, USA) 
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2.1.2 Consumables and plasticware 
0.5 ml, 1.5 ml and 2 ml Reaction Tubes Greiner (Frickenhausen, Germany) 
1 ml Norm-Ject Syringe Henke Sass Wolf (Tuttlingen, Germany) 
10 µl, 20 µl, 100 µl, 200µl and 1000µl Pipet Tips Gilson 
15 ml and 50 ml Reaction Tubes Greiner  
18G Vasofix Safety Permanent Venous Catheter B.Braun (Melsungen, Germany) 
30 µm MACS pre Separation Filter Miltenyi Biotech 
5 ml, 10 ml and 25 ml Serological Pipets Greiner  
12 Well Cell Culture Plate Greiner  
BCYE Agar Plates Oxoid (Hampshire, UK) 
BD Microlance 3 20G BD Biosciences 
GentleMACS C Tubes Miltenyi Biotech 
MACS LS Columns Miltenyi Biotech 
Petri Dish 10 cm Greiner  
RNA Nano Chip Agilent 
Serum Pipets Greiner  
T75 Tissue Culture Flask Sarstedt (Nümbrecht, Germany) 
Taqman Low Density Array Card A v.2.0 human Life Technologies 
Taqman Low Density Array Card A v.2.0 rodent Life Technologies 
Ultra Low Attachment 6-Well Plates Corning (Corning, USA) 
Ultra Low Attachment Petri Dish 10 cm Corning 
Ultra Low Attachment T75 culture flask Corning 
2.1.3 Oligonucleotides 
2.1.3.1 Cloning primers 
Table 2-1: Cloning primers for insert amplification and restriction site integration. Restriction 
sites for NotI (GCGGCCGC) and XhoI (CTCGAG) are underlined. 
Target 3´UTR 
Accession Number, 
Position Sequence (5´-3´) 
DYRK2 
NM_006482.2, 5688-
5908 
fw: GTTTTCTCGAGCGGTAAAGGTTTTAATATTGCC 
rv: GTTTTGCGGCCGCCACAGTTGCAGCATATTACAGTC 
KLF4 
NM_004235.4, 2020-
2112 
fw: GTTTTCTCGAGAAGAGGCATTTTTAAATCCCAG 
rv: GTTTTGCGGCCGCTCATCGGGAAGACAGTGTG 
LAMP2 
NM_002294.2, 4663-
4740  
fw: GTTTTCTCGAGGGATTCATTTTCATTGGTGG 
rv: GTTTTGCGGCCGCTAATGCTGATCAGGAGGTGG 
MRC1 
NM_002438.3, 4491-
5180 
fw: GTTTTCTCGAGCTAGTACCTCAATGCGATTCTG 
rv: GTGCGGCCGCGACCTTGTCTTTAATGTTTATTTCAC 
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PPARγ 
NM_138712.3, 1682-
1748 
fw: GTTTTCTCGAGCAGAGAGTCCTGAGCCACTG 
rv: GTTTTGCGGCCGCTCAGATTTTCCCTCAGAATAGTG 
PTK9 
NM_001242397.1, 
2758-2838 
fw: GTTCTCGAGCTGTACCATCTATGTGCAATTATACTC 
rv: GTTTGCGGCCGCTCACATCTATATTCTGGAATGTCC 
SH2B2 
NM_020979.3, 2048-
2137 
fw: GTTTCTCGAGTGGAGAACCAGTACTCCTTCTACTAG 
rv: GTTGCGGCCGCGCTTTTAATAACATCGTGTCTTCAC 
TREM2 
NM_018965.3, 798-
1053 
fw: GAAAACTCGAGAGGAAGATGATGGGAGGAAAAG 
rv: GAAAGCGGCCGCTCCAGCTAAATATGACAGTCTTGG 
All cloning primers were designed with Primer3plus and custom-made by Metabion 
(Martinsried, Germany). 
2.1.3.2 qPCR primers 
SYBR Green 
Table 2-2:  Custom oligonucleotides for mRNA target detection 
Target Sequence (5´-3´) 
LAMP2 (isotype A) 
fw: CCCTGGGAAGTTCTTATATGTGC 
rv: GAAGTTGTCGTCATCTGCACTG 
RPS18 
fw: CTTTGCCATCACTGCCATTA 
rv: ACACGTTCCACCTCATCCTC 
SH2B2 
fw: GCTGACCTTCAACTTCCAGG 
rv: GAACCACAGATGCTGTACGTG 
TNFα 
fw: GCTGCACTTTGGAGTGATCG 
rv: TCACTCGGGGTTCGAGAAGA 
All SYBR Green primers were designed with Primer3plus and custom-made by Metabion 
(Martinsried, Germany). 
Taqman Probes 
Table 2-3: Commercial Taqman Probes for miRNA detection 
Probe Mature miRNA Sequence (5´-3´) 
hsa-miR34c-5p AGGCAGUGUAGUUAGCUGAUUGC 
hsa-miR146a-5p UGAGAACUGAAUUCCAUGGGUU 
hsa-miR-146b-5p UGAGAACUGAAUUCCAUAGGCU 
hsa-miR155-5p UUAAUGCUAAUCGUGAUAGGGGU 
hsa-miR187-3p UCGUGUCUUGUGUUGCAGCCGG 
hsa-miR-193b-3p AACUGGCCCUCAAAGUCCCGCU 
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hsa-miR-511-5p GUGUCUUUUGCUCUGCAGUCA 
RNU48 GAUGACCCCAGGUAACUCUGAGUGUGUCGCUGAUGCCAUCACCGCAGCG
CUCUGACC 
mmu-miR-21a-5p UAGCUUAUCAGACUGAUGUUGA 
mmu-miR-126-3p UCGUACCGUGAGUAAUAAUGCG 
mmu-miR-146a-5p UGAGAACUGAAUUCCAUGGGUU 
snoRNA202 GCUGUACUGACUUGAUGAAAGUACUUUUGAACCCUUUUCCAUCUGAUG 
All Taqman Probes were provided by Life Technologies. 
2.1.4 Plasmids 
psiCheck2 Vector (Fig. 2-1) Promega (Mannheim, Germany) 
  
2.1.5 Synthetic miRNAs 
Table 2-4: pre-miR sequences 
miRNA Mature miRNA sequence (5´-3´) 
hsa-miR-155-5p-5p UUAAUGCUAAUCGUGAUAGGGGU 
hsa-miR-187-3p-3p UCGUGUCUUGUGUUGCAGCCGG 
  
2.1.6 Antibodies 
2.1.6.1 Flow Cytometry 
Murine 
Table 2-5: Antibody panel for cytometric sorting of murine macrophages 
Specificity Clone Isotype Fluorochrome Isotype Control Clone Company 
CD45 30-F11 Rat IgG2b κ FITC RTK4530 Biolegend 
SiglecF E50-2440 Rat IgG2b κ PE eB149/10H5 BD 
Gr-1 RB6-8C5 Rat IgG2b κ PerCP-Cy5.5 RTK4530 BD 
CD11b M1/70 Rat IgG2b κ Pacific Blue RTK4530 Biolegend 
CD11c N418 Hamster IgG APC-Cy7 HTK888 Biolegend 
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Human 
Table 2-6: Antibody panel for cytometric analysis of human monocytes/macrophages 
Specificity Clone Isotype Fluorochrome Company 
CD14 M5E2 Mouse IgG2a κ FITC BD 
CD23 EBVCS2 Mouse IgG1 κ APC eBioscience 
CD80 3H5 Mouse IgG1 κ PE BD 
     
2.1.6.2 Magnetic beads 
Table 2-7: Magnetic microbeads for cell enrichment by positive selection 
Specificity Company 
CD14 human Miltenyi Biotech 
APC Miltenyi Biotech 
  
2.1.6.3 Western Blot 
Table 2-8: Primary Western Blot antibodies 
Specificity Source Exp. Band Size (kDA) Company 
Phospho-STAT6 Rabbit  110 Cell Signalling 
Phospho-ERK Mouse 42/44 Santa Cruz Biotechnology 
p38α Rabbit 38 Santa Cruz Biotechnology 
Phospho-p38 Mouse 38 Santa Cruz Biotechnology 
Phospho-SAPK/JNK Rabbit  46/54 Cell Signalling 
IκBα Rabbit 35-41 Santa Cruz Biotechnology 
LAMP2 Mouse 105-110 Abcam 
Actin Goat  43 Santa Cruz Biotechnology 
Table 2-9: Secondary Western Blot antibodies 
Specificity Source Conjugate Company 
Rabbit IgG Goat Cy5.5 Rockland Immunochemicals 
Mouse IgG Goat Cy5.5 Rockland Immunochemicals 
Goat IgG Donkey IRDye800 Rockland Immunochemicals 
Mouse IgG Goat HRP Santa Cruz Biotechnology 
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2.1.6.4 Immunofluorescence 
Table 2-10: Immunofluorescence antibodies 
Specificity Source Conjugate Company 
LAMP2 Mouse - Abcam 
Mouse IgG Goat AlexaFluor 555 Invitrogen 
 
2.1.7 Bacterial Strains 
Legionella pneumophila 
(Corby) provided by the Robert Koch Institut (Berlin, Germany) 
Supercompetent E. Coli DH5a New England Biolabs (Ipswich, USA) 
 
2.1.8 Enzymes 
Collagenase D (0.242 U/mg) Roche (Basel, Switzerland) 
DNAse I (3000 Kunitz Units/mg) Serva (Heidelberg, Germany) 
NotI (10.000 U/ml) New England Biolabs (Ipswich, USA) 
Taq DNA Polymerase (5000 U/ml) New England Biolabs 
T4 DNA Ligase (400.000 U/ml) New England Biolabs 
XhoI (20.000 U/ml) New England Biolabs 
 
2.1.9 Stimulants and Cytokines 
Lipopolysaccharide (LPS),  
Salmonella minnesota R595 
Enzo Life Science (Lörrach, 
Germany) 
rhInterferon-γ (E. Coli) Promocell (Heidelberg, Germany) 
rhInterleukin-13 (E. Coli) Promocell 
rhInterleukin-4 (E. Coli) Promocell  
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2.1.10 Analytical Chemicals, Reagents and Kits 
Acrylamide (Rotiphoresis Gel 30, 37.5:1) Roth (Karlsruhe, Germany) 
Actinomycin D Biovision (Milpitas, USA) 
Agarose NEEO Ultra Quality Roth 
Albumin Fraction V Roth 
Aluminum Hydroxide (Al(OH)3) Thermo Scientific 
Ampicillin Sodium Salt Sigma Aldrich (St. Louis, USA) 
Ammonium Persulfate (APS) Roth 
Bacto Agar BD Biosciences 
Purified Bovine Serum Albumin 100X New England Biolabs 
Bromphenol Blue Sigma 
Complete Mini Protease Inhibitor Cocktail Roche  
4,6-Diamin-2-Phenylindol (DAPI) ATT Bioquest (Sunnyvale, USA) 
Dulbeccos´s Modified Eagle Medium (DMEM) Gibco 
Dulbecco´s Phosphate Buffered Saline (PBS) PAA Laboratories (Pasching, Austria) 
Ethylene Diamine Tetra-Acetic Acid (EDTA) Roth (Karlsruhe, Germany) 
Fetal Calf Serum (FCS) PAA Laboratories 
Firefly Luciferase Assay System Promega 
Gentamicin Gibco 
GlutaMAX Gibco 
Glycoblue Life Technologies 
High Capacity Reverse Transcription Kit Applied Biosystems 
Heparin Ratiopharm (Ulm, Germany) 
Human Serum off-the-clot, Type AB Lonza (Basel, Switzerland) 
Isol RNA Lysis Reagent 5Prime (Hamburg, Germany) 
Ketamin  Inresa (Freiburg, Germany) 
LB Agar BD Biosciences 
LB Broth BD Biosciences 
LSM 1077 Lymphocyte Separation Medium PAA Laboratories 
Lysis Buffer Promega 
Milk Powder Roth 
Mouse Fc Block BD Biosciences 
Mowiol 4-88 Roth 
NEBuffer 3 New England Biolabs 
Nonidet P40 BioChemica (Substitute) AppliChem (Darmstadt, Germany) 
Nuclease-Free Water Ambion 
Nucleo Spin Extract II Kit Macherey Nagel (Düren, Germany) 
Nucleo Spin Plasmid Macherey Nagel 
NucleoSpin Gel and PCR Cleanup Kit Macherey Nagel 
Odyssey Blocking Buffer Li-Cor 
Optimem Transfection Medium Gibco/Life Technologies 
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Ovalbumin (grade VI) Sigma Aldrich 
PonceauS Sigma Aldrich 
Purified BSA New England Biolabs 
Qubit Molecular Probes Invitrogen 
Renilla Luciferase Assay System Promega 
RNA 6000 Nano Reagents Agilent 
Rompun Bayer (Leverkusen, Germany) 
Roti-Aqua-PCI Roth 
RPMI 1640 Gibco (Darmstadt, Germany) 
Saponin Roth 
SOC Medium Thermo Fisher Scientific 
Sodium Dodecyl Sulfate (SDS) Roth 
Sodium Orthovanadate Sigma Aldrich 
SYBR Green Master Mix Life Technologies 
T4 Ligase Buffer New England Biolabs 
Taqman 2X Universal PCR Master Mix No 
AmpErase UNG Life Technologies 
Taqman microRNA Reverse Transcription Kit Life Technologies 
Tertraethylmethylenediamine (TEMED) Roth 
Thermopol Reaction Buffer 10X New England Biolabs 
Tris(hydroxymethyl)aminomethane (TRIS) Roth 
Triton X100 Roth 
Trypsin-EDTA 0.05 % (1X) Gibco 
Trypticase Soy Agar BD Biosciences 
Tween 20 Roth 
Xylencyanol Roth 
Yeast Extract BD Biosciences 
  
2.1.11 Chemicals 
β-Mercaptoethanol Sigma Aldrich 
Chloroform Roth 
Ethanol Roth 
Ethidium Bromide  Invitrogen 
Glycerol Roth 
Isopropanol Roth 
Methanol Roth 
Paraformaldehyde Roth 
Sodium Acetate Roth 
Sodium Azide Roth 
Sodium Chloride Roth 
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2.1.12 Buffers and Solutions 
BAL Lavage Solution 2 mM EDTA 
 
in PBS 
 
FACS Wash Buffer 1 % v/v FCS 
 
0.02 % w/v NaN3 
 
in PBS 
 
HEK293 Culture Medium 1 % v/v GlutaMAX 
 10 % v/v FCS 
 
in DMEM 
 
MACS Buffer 0.5 % v/v FCS 
 
0.2 mM EDTA 
 
in PBS 
 
 
Macrophage Culture Medium 1 % v/v GlutaMAX 
 
1 % v/v human off-the-clot AB Serum 
 
in RPMI1640 
 
Laemmli Buffer 13.15 % v/v Stacking Buffer 
 
21.05 % v/v 10 % SDS 
 
10.5 % v/v Glycerol 
 
5.75 % v/v 1 % Bromphenol Blue 
 
LB Agar 3.5 % w/v LB Agar 
 
in aqua dest. 
 
LB Medium 2 % w/v LB Broth 
 
in aqua dest. 
 
Lung Tissue Digestion Buffer 2 mg/ml Collagenase D (> 0.15 U/mg) 
 
0.5 mg/ml DNAseI (>3000 Kunitz 
Units/mg) 
 
in PBS 
 
Phosphoprotein Wash Buffer 2.5 mM Na3VO4  
 
125 mM NaF 
 
18.75 mM Na4P2O7 
 
in PBS 
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RPMI 1640 complete medium 1 % v/v L-GlutaMAX 
 
1 % v/v Penicillin/Streptomycin 
 
1 % v/v FCS 
 
THP-1 Culture Medium 10 % v/v Fetal Calf Serum 
 
in RPMI 1640 
 
Trypticase Soy Agar  4 % w/v Trypticase Soy Agar 
 
in aqua dest. 
 
Western Blot Lysis Buffer 50 mM Tris-HCl pH 7.4 
 1 % v/v Nonidet P40  
 
Complete Protease Inhibitor tablet 
in aqua dest. 
 
Western Blot Running Buffer (5X) 123 mM Tris Base 
 950 mM Glycine 
 
17 mM SDS  
in aqua dest.  
  
Western Blot Resolving Buffer pH 8.8 1.5 M Tris Base 
 
in aqua dest. 
 
Western Blot Stacking Buffer pH 6.8 490 mM Tris Base 
 
in aqua dest. 
 
Western Blot Resolving Gel 10 % 132 mM Tris Base 
 350 mM PAA 
 170 mM Glycerol 
 3.5 mM SDS 
 2.2 mM APS 
 6.7 mM TEMED 
 
in aqua dest. 
 
Western Blot Stacking Gel 5 % 87.5 mM Tris Base 
 174 mM PAA 
 3.5 mM SDS 
 2.2 mM APS 
 6.7 mM TEMED 
 
in aqua dest. 
 
Western Blot Transfer Buffer (10X) 248 mM Tris Base 
 1.9 M Glycine 
 
in aqua dest. 
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Western Blot Transfer Buffer (1X) 8 % v/v 10X Transfer Buffer 
 20 % v/v Methanol 
 
in aqua dest. 
 
2.1.13 PCR and RT Solutions 
 
Volume per Sample [µl] 
 
High Capacity Reverse Transcription 4.2 H2O 
0.8 dNTP (100 mM) 
2 Transcripton Buffer 10X 
1 Multiscribe Enzyme 
2 Random Hexamer Primer 
10 RNA (500 ng – 1 µg) 
 
Taqman microRNA Reverse Transcription 
(Singleplex) 
4.16 H2O 
0.15 dNTP (100 mM) 
1.5 Transcription Buffer 10X 
1 Multiscribe Enzyme 
3 RT Primer (5X) 
5 RNA (1 – 10 ng) 
 
Taqman microRNA Reverse Transcription 
(Multiplex) 
1.01 H2O 
0.3 dNTP (100 mM) 
1.5 Transcription Buffer 10X 
3 Multiscribe Enzyme 
6 RT Primerpool (0.05X per Primer) 
3 RNA (350 ng – 1 µg) 
 
Megaplex Reverse Transcription 0.2 H2O 
0.2 dNTP (100 mM) 
0.8 Transcription Buffer 10X 
0.9 MgCl2 (25 mM) 
1.5 Multiscribe Enzyme 
0.1 RNAse Inhibitor (20 U/µl) 
3 RNA (1 – 350 ng for PreAmplification; 
350 ng – 1 µg for TLDA) 
 
Pre-Amplification 6.25 H2O 
12.5 Taqman PreAmp Master Mix 2X 
Taqman Probe 0.2X 
2.5 µl Megaplex RT Product  
 
Taqman Low Density Array (TLDA) 450 Taqman 2X Universal PCR Master Mix  
444 Nuclease free Water 
6 Megaplex RT Product 
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qPCR (Taqman) 7.5 H2O 
1 Taqman Probe 20X 
10 Taqman 2X Universal PCR Master Mix 
1.5 RT Product 
 
qPCR (SYBR Green) 8.1 H2O 
0.2 forward/reverser Primer (10 µM) 
10 SYBR Green 2X 
1.5 RT Product 
 
2.1.14 Ligation and Restriction Solutions 
 Volume per reaction [µl] 
 
Insert Amplification 28 H2O 
10 Taq Reaction Buffer  
1 dNTP (10 mM) 
1 forward/reverse Primer (10 µM) 
0.25 µl Taq Polymerase (5 U/µl) 
10 cDNA (10 ng/µl) 
 
Insert Digestion 45 Amplification Product 
6 Buffer 3 
6 BSA (100 µg/ml) 
1 XhoI 
1 NotI 
 
Vector Linearization 34.1 H2O 
6 psiCheck2 Vector (8 µg) 
5 Buffer 3 
5 BSA (100 µg/ml) 
1 XhoI 
1 NotI 
 
Insert-Vector Ligation 8.5 H2O 
1.5 T4 Ligation Buffer 
1 T4 Ligase 
2 linearized Vector (15 ng) 
2 restricted Insert (15 ng) 
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2.1.15 Mice strains 
BALB/c Harlan Laboratories (Indianapolis, USA) 
2.1.16 Software 
Adobe Photoshop CS5  Adobe Systems (San Jose, USA) 
Canvas X  ACD Systems (Victoria, Canada) 
FlowJo v. 7.6.5  TreeStar (Ashland, USA) 
GENtle  M. Manske (University of Cologne, Germany) 
GraphPad Prism  GraphPad Software (San Diego, USA) 
LabImage 1D Kapelan BioImaging (Leipzig, Germany) 
Microsoft Office 2010 Microsoft (Redmond, USA) 
NEB Cutter New England Biolabs 
Oligo Melting Temperature Calculator  Weizman Institute (Rehovot, Israel) 
Primer3plus [105]  
R [106]  
  
2.1.17 External Services 
Commercial 
Metabion (Martinsried, Germany) 
MFT Services (Tübingen, Germany) 
Sequence Laboratories (Göttingen, Germany) 
Flow Cytometry Core Facility (Marburg, Germany) 
Cooperative 
Department of Clinical Chemistry (Philipps University Marburg, Germany) 
Max Planck Institute for Molecular Genetics (Berlin, Germany) 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Preparation and cultivation of primary human monocytes 
Monocytes were isolated from donor buffy coats provided by the German Red Cross. All 
donors gave informed written consent for use of their blood samples for scientific purposes. 
The blood sample was diluted 1:2 with PBS and stacked onto a cushion of Pancoll solution. 
Centrifugation for 25 minutes at 800 x g yielded a distinct leukocyte layer. Leukocytes were 
aspirated, resuspended in ambient temperature PBS and washed twice. The pellet was taken 
up in MACS Buffer. An appropriate amount of cells was incubated with anti-CD14 magnetic 
microbeads for 20 minutes at 4 °C. Labeled cells were magnetically retained in a MACS LS 
column and eluted after depletion of unlabeled leukocytes. Eluted cells were >90 % CD14+ 
monocytes as routinely determined by FACS analysis. 7 x 105 cells/ml were left to adhere for 
two hours to ultra-low attachment plates in RPMI medium without supplements. After 2 h, 
adhesion of cells was validated by microscopy, and 1 % of human AB serum was added. 
Monocytes were then incubated for 6 days at 37°C and 5 % CO2, and maturation to 
macrophages was confirmed by microscopy.  
2.2.1.2 Macrophage polarization 
On day 6 of culture, cells were polarized to M1 by administration of IFNγ (20 ng/ml) and LPS 
(100 ng/ml), to M2 by administration of Interleukin 4 and Interleukin 13 (20 ng/ml each) or 
left unpolarized (M0). After 18 h, cells were detached from the flask by carefully rinsing them 
with warm PBS. Polarization was verified by FACS analysis. M1 macrophages were >80% 
CD80+ and M2 macrophages were ~40 % CD23+, whereas M0 macrophages were devoid of 
either marker. In order to obtain an enriched population of CD23+ M2 polarized macrophages, 
M2 cells were sorted for CD23 by autoMACS, yielding a purity of CD23+ M2 macrophages 
of > 80 %. 
2.2.1.3 THP-1 cell culture 
The human monocytic leukemia THP-1 cell line was cultured in THP-1 culture medium at a 
density of 2 x 105 to 1 x 106 cells per ml. Cells were split regularly to maintain the appropriate 
density. Cells were discarded upon exceeding the 20th passage, and the culture was re-
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launched from a frozen stock aliquot. THP-1 cells were used for short-term mRNA decay 
studies upon actinomycin D administration (section 2.2.1.8) 
2.2.1.4 HEK293 cell culture 
Human embryonic kidney cells were cultured in HEK293 culture medium at 70-90 % 
confluency and split regularly to maintain the appropriate density. Cells were discarded upon 
exceeding the 15th passage, and the culture was re-launched from a frozen stock aliquot. Prior 
to usage, cells were detached from the culture flasks by incubation with trypsin-EDTA 0.05 % 
(1X). Subsequently, cells were transfected with miRNA precursors and the psiCheck2 vector, 
and the luciferase-based reporter assay was performed (section 2.2.3)  
2.2.1.5 Automated Magnetic Activated Cell Sorting (autoMACS) 
M2 polarized cells were incubated with anti-CD23-APC FACS antibody as described (section 
2.2.6.1). Anti-APC microbeads were added in a second step to magnetically label CD23+ 
cells. After 25 minutes at 4 °C, cells were washed in MACS Buffer. CD23+ cells were 
positively selected by autoMACS to ensure a quick and gentle enrichment of CD23+ M2 
macrophages with minimal disturbance of the mRNA and microRNA profile. Purity of the 
CD23+ population was afterwards determined by FACS analysis. 
2.2.1.6 Determination of macrophage bactericidal capacity 
2.2.1.6.1 Infection of polarized macrophages with Legionella pneumophila 
Legionella pneumophila Corby was grown on BCYE agar plates for 3 days at 37 °C and 5 % 
CO2. On day three, bacteria were scraped from the plate and resuspended in PBS++ to an 
OD600 of 0.1, which equals 2 x 108 bacteria/ml. Final multiplicity of infection (MOI) was set 
as indicated in the respective experiments. Initial infection of fully polarized macrophages 
(section 2.2.1.2) was carried out for 1 h. If not stated otherwise, extracellular Legionella were 
then killed by administration of gentamicin (50 µg/ml). After 1 h, all supernatant was 
aspirated, and cells were washed three times in PBS. For the remainder of the experiment, 
cells were kept in macrophage culture medium. 
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2.2.1.6.2 Colony forming unit (CFU) assay 
Macrophages were polarized as described (section 2.2.1.2), and the fully developed M0, M1 
and M2 subtypes were infected with Legionella pneumophila at a MOI of one. At indicated 
time points, cells were lysed by rigorous pipetting in 0.1 % saponin. Cell lysis was confirmed 
by microscopy. Lysate was serially diluted in a range from 1:10 to 1:10.000 in H2O and was 
streaked on BCYE agar plates. After three days of incubation at 37 °C and 5 % CO2, 
individual colonies were counted and total bacterial load was calculated. 
2.2.1.7 Transfection of monocytes/macrophages with synthetic microRNA 
Blood-derived macrophages or monocytic THP-1 cells were transfected with double-stranded 
miRNA precursors. Transfection was achieved by cultivating the cells in medium containing 
siPort NeoFX and Optimem in a 1:15 ratio plus the respective miRNA precursors in a final 
concentration of 30 nM. After 6 h, the transfection medium was replaced with growth 
medium, and cells were incubated for an additional 24 h or 48 h, respectively. Overexpression 
of a given miRNA was verified by qPCR. 
2.2.1.8 Transcriptional inhibition by actinomycin D application 
Monocytic THP-1 cells were transfected with miRNA precursors as described (section 
2.2.1.7). Efficiency of miRNA transfection was routinely monitored by qPCR. After 18 h, the 
cytostatic actinomycin D was added to the culture at a final concentration of 10 µM, and RNA 
samples were taken at 0 min, 15 min, 30 min and 45 min. These samples were probed for 
miRNA-enhanced target mRNA degradation by qPCR.  
 
2.2.2 Investigation of the global RNA profile 
2.2.2.1 Isolation of total RNA from cells 
Pelleted cells were lysed in Isol RNA Lysis Reagent and RNA was isolated according to the 
supplier's protocol. Centrifugation steps were carried out at 4 °C. All other steps were 
performed at ambient temperature if not stated otherwise. Samples were mixed with 
chloroform and vigorously shaken. After three minutes of incubation, samples were 
  Materials and Methods 
56 
 
centrifuged at 11.000 x g. The aqueous phase was collected and RNA pellets were obtained by 
isopropanol precipitation at 11.000 x g, assisted by glycoblue. RNA was washed twice with 
ethanol at 7.000 x g and air-dried pellets were resuspended in nuclease-free water. Potential 
RNA secondary structures were dissolved by incubating at 58 °C for 7 minutes. All RNA 
experimentation hereafter was carried out on ice. The RNA concentration was determined by 
Nanodrop or Qubit Fluorometer if higher sensitivity was required. 
2.2.2.2 RNA integrity validation by capillary gel electrophoresis 
Integrity of RNA was verified on a Bioanalyzer 2100, according the manufacturer´s protocol. 
Briefly, RNA 6000 Nano gel matrix was filtered at 1.500 x g for 10 minutes in a spin filter. 
1 µl of fluorescent RNA 6000 Nano dye concentrate was added to 65 µl of filtered gel matrix, 
and the solution was vortexed. Gel-dye mix was applied to a RNA Nano Chip via the fill port 
and dispersed into all wells and the capillary system with the provided plunger. Afterwards, 
5 µl of RNA 6000 Nano marker was added to all sample wells and to the dedicated ladder 
well. Finally, RNA samples and ladder were added to the appropriate wells, the chip was 
vortexed and subjected to analysis. Samples were sequentially driven into the capillary system 
by voltage. In the process, the stained RNA was resolved as a function of size and detected 
upon sensor passage. The fluorescence signal was recorded as a function of the elapsed time. 
The ratio of intact 18s and 28s rRNA was used to calculate a RNA integrity number (RIN). 
RINs of > 8 were considered indicative of sufficient RNA quality. 
2.2.2.3 microRNA analysis by Taqman Low Density Array (TLDA, human)  
500 ng of RNA from M0, M1 and M2 macrophages from 3 different donors were reversely 
transcribed into cDNA using the Taqman microRNA reverse transcription protocol with 
human megaplex primers v. 2.0 (Table 2-11). 
Table 2-11: Megaplex reverse transcription thermo protocol 
Stage Duration  Temperature 
Cycle (40x) 2 min 16 °C 
 1 min  42 °C 
 1 sec 50 °C 
Hold 5 min 85 °C 
Hold ∞ 4 °C 
  Materials and Methods 
57 
 
100 µl of cDNA-containg TLDA reaction mix (section 2.1.13) were loaded into each of eight 
fill ports of a Taqman Low Density Array Card. (Set A, v. 2.0, human). Each fill port is 
connected to two parallel lanes of 24 serially linked wells with a 1 µl reaction volume, 
yielding a total of 384 wells. The individual wells are pre-loaded with Taqman miRNA 
amplification primers (see Appendix for plate layout). The reaction mix was distributed into 
all 384 wells by centrifugation (2 x 1 min at 330 x g). The plates were sealed, and miRNAs 
were detected on a 7900HT Fast Real-Time System (Table 2-12). 
Table 2-12: Taqman Low Density Array thermo protocol 
Stage Duration Temperature 
Hold 2 min 50 °C 
Hold 10 min 95 °C 
Cycle (40x) 15 sec 95 °C 
 1 min 60 °C 
2.2.2.4 microRNA analysis by Taqman Low Density Array (TLDA, murine)  
At least 350 ng of RNA from alveolar and interstitial macrophages from healthy and 
asthmatic mice were reversely transcribed into cDNA using the Taqman microRNA reverse 
transcription protocol with rodent megaplex primers v. 2.0 (Table 2-11). 100 µl of cDNA-
containing reaction mix (2.1.13) were loaded into each of eight fill ports of a Taqman Low 
Density Array Card. (Set A, v. 2.0, rodent). Each fill port is connected to two parallel lanes of 
24 serially linked wells with a 1 µl reaction volume, yielding a total of 384 wells. The 
individual wells are pre-loaded with Taqman miRNA amplification primers (Appendix). The 
reaction mix was distributed into all 384 wells by centrifugation (2 x 1 min at 330 x g).The 
plates were sealed, and miRNAs were detected on a ViiA7 Real Time system (Table 2-12). 
2.2.2.5 mRNA analysis by Illumina HT12 Beadchip MicroArray 
Transcriptome analysis was carried out by MFT Services (Tübingen, Germany). 1 µg of RNA 
as used for TLDA was taken up in nuclease-free water at a concentration of >50 ng/µl and 
sent to MFT Services for further processing. In short, RNA serves as a template to generate 
full-length cDNA. After second strand synthesis, in vitro transcription by a T7 RNA 
Polymerase yields labelled cRNA in multiple copies. This amplified and labelled cRNA is 
then used for direct hybridization with the Illumina HT12 BeadChip, which is equipped with 
47.231 individual probes for whole genome analysis including splice variants and isoforms. 
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2.2.2.6 microRNA and mRNA detection by quantitative real time PCR  
Quantitative real time PCR was performed with cDNA from miRNA or mRNA reverse 
transcription according to the following protocol (Table 2-13). 
Table 2-13: Quantitative real time PCR thermo protocol 
Stage Duration Temperature 
Hold 2 min 50 °C 
Hold 10 min 95 °C 
Cycle (40x) 15 sec 95 °C 
 1 min 60 °C 
2.2.2.6.1 microRNA quantification 
For relative quantification of individual miRNAs, 50 ng of total RNA were reverse 
transcribed using the Taqman microRNA reverse transcription kit and specific primers for 
miRNA and endogenous control according to the depicted protocol (Table 2-14). cDNA was 
subjected to Taqman RT-PCR on a 7300 or ViiA7 Real-Time PCR System. The signal of each 
individual miRNA was normalized to the small noncoding RNA RNU48 (human) oder 
sno202 (mouse). Fold-induction was calculated using the 2-∆∆ct method. 
Table 2-14: miRNA reverse transcription thermo protocol 
Stage Duration Temperature 
Hold 30 min 16° C 
Hold 30 min 42 °C 
Hold 5 min 85 °C 
Hold  ∞ 4 °C 
 
Weakly expressed miRNAs with a threshold cycle of 33 or higher in TLDA were pre-
amplified according to the manufacturer´s protocol in order to robustly detect them in the 
individual validation assay. This additional precycling step (Table 2-15) was performed after 
reverse transcription, using the same Taqman probes that were employed in the subsequent 
qPCR reaction. 
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Table 2-15: Preamplification thermo protocol 
Stage Duration Temperature 
Hold 10 min 95 °C 
Hold 2 min 55 °C 
Hold 2 min 72 °C 
Cycle (12x) 15 sec 95 °C 
 4 min 60 °C 
Hold 10 min 99.9 °C 
Hold ∞ 4 °C 
The quantitative real time PCR for miRNA detection was performed with RNA quantities as 
indicated in section 2.1.13. 
2.2.2.6.2 mRNA quantification 
Total RNA was subjected to reverse transcription using the High Capacity reverse 
transcription kit (Table 2-16). For relative quantification of individual mRNAs, 500 ng of total 
RNA were reversely transcribed using provided random hexamer primers. cDNA was 
subjected to RT-PCR on a 7300 or ViiA7 Real-Time PCR System using the SYBR Green 
detection method. The signal of individual mRNAs was normalized to the ribosomal protein 
S18 mRNA (RPS18). The quantitative real time PCR for mRNA detection was performed 
with RNA quantities as indicated in section 2.1.13. 
Table 2-16: High capacity reverse transcription thermo protocol 
Stage Duration Temperature 
Hold 10 min 25 °C 
Hold 2 h 37 °C 
Hold 5 min 85 °C 
2.2.3 Functional microRNA evaluation by luciferase-based reporter constructs 
2.2.3.1 Construction of reporter vectors 
For the luciferase reporter assay, the listed 3'UTR fragments (Table 2-1) were amplified using 
the indicated primers. Each forward primer carried a XhoI restriction site (CTCGAG), while 
each reverse primer carried a NotI restriction site (GCGGCCGC), as highlighted. The absence 
of XhoI and NotI restriction sites in the sequence of interest was verified by NEBcutter. The 
3´UTR fragments were amplified from M0 cDNA. PCR components were removed by 
column purification (NucleoSpin Extract II Kit), and 45 µl of cleaned PCR product were 
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digested with NotI and XhoI in supplied NEBuffer 3 for 1 h at 37 °C. Restriction enzymes 
were deactivated at 65 °C for 20 minutes. Digested fragments were isolated by gel 
electrophoresis, excised under UV light and extracted from the gel slices by column 
purification (NucleoSpin Gel and PCR Cleanup Kit). The psiCheck2 plasmid (Fig. 2-1) was 
linearized and purified accordingly (NucleoSpin Plasmid Kit). For ligation, 30 ng of insert 
and 15 ng of NotI- and XhoI-treated vector were incubated for 1 h at 37 °C with T4 Ligase at 
a final volume of 15 µl. 
 
Figure 2-1: The psiCheck2 plasmid. The vector is equipped with a sequence encoding for firefly luciferase 
(hluc+) and for Renilla reniformis luciferase (hRluc). The hRluc sequence carries a multiple cloning site that was 
used for integration of the respective miRNA target sequences. For selection purposes, the vector also carries an 
ampicillin resistance gene (Ampr). Vector design by Promega. 
2.2.3.2 Vector amplification by transformation of Escherichia coli  
30 µl of supercompetent DH5α E. Coli were incubated on ice for 30 minutes with 1.5 µl of 
ligation product. Transformation was performed by heat shock at 42 °C for 30 seconds. 
Bacteria were put back on ice for 5 minutes and recovered in SOC medium for 1 h at 37 °C 
with shaking. 70 µl of suspension were plated on pre-warmed trypticase soy broth agar plates 
containing 100 µg/ml ampicillin. After overnight incubation, single colonies were tested by 
colony PCR. For this purpose, a universal forward primer binding in the vector backbone at 
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approximately 30 bp upstream of the cloning site was combined with the respective insert-
specific reverse primers as listed in Table 2-1. Positive clones were grown overnight in LB 
medium containing 100 µg/ml ampicillin at 37 °C. Plasmids were isolated by miniprep and 
700 ng of each construct was sequenced (Sequence Laboratories GmbH) to verify correct 
insert integration. Validated clones were stored at -80 °C in 20 % glycerol.  
2.2.3.3 Quantification of microRNA efficiency by bioluminescence  
HEK293 cells were grown in DMEM containing 10 % FCS and 1 % Glutamine. 1 x 105 
subconfluent cells were reverse transfected with NeoFX siPORT. Cells were simultaneously 
transfected with 300 ng of psiCheck2 plasmid carrying respective inserts and 50 nM of 
miRNA precursor, according to the manufacturer's protocol. Precursors used in this study 
were pre-hsa-miR-187-3p, pre-hsa-miR-155-5p and pre-hsa-miR-34c-5p. In case of presence 
of both a hsa-miR-187-3p and a hsa-miR-155-5p site in the cloned fragment, pre-hsa-miR-
187-3p and pre-hsa-miR-155-5p were co-transfected at 25 nM each. Cells were taken up in 
80 µl of lysis buffer 72 h after transfection. Cell lysate was diluted 1:10 in ice-cold water, and 
80 µl of Renilla luciferase or firefly luciferase substrate was added to 20 µl of lysate dilution. 
After a brief incubation, luminescence was measured using a Lumat LB9501 reader. Relative 
luminescence units (RLU) were calculated by normalizing the Renilla luciferase signal to the 
firefly luciferase signal. Specificity of each individual miRNA precursor was determined by 
control transfection with a non-specific scramble miRNA. 
2.2.4 Semiquantitative protein analysis by Western Blot 
After indicated treatment, cells were washed twice with phosphoprotein wash buffer and lysed 
in western blot lysis buffer. Debris was removed by centrifugation at 10.000 x g for 10 
minutes at 4° C. The protein concentration was determined by Bradford assay. Optical density 
was measured in a spectrophotometer at a wavelength of 595 nm, and the protein 
concentration was calculated. Samples were taken up at a 1:2 ratio in Laemmli buffer and 
denatured for 5 minutes at 95 °C. For protein separation, 10 % SDS gels were used, and 80 µg 
of protein were loaded per lane. A marker lane was included for reference. 80 V were applied 
for the focusing of proteins in the stacking gel and increased to 120 V upon transmigration 
into the resolving gel. 
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Transfer of protein to a nitrocellulose membrane was performed by tank blot for 1 h at 100 V. 
After blotting, protein integrity and transfer efficiency was validated by Ponceau S staining. 
In preparation for antibody staining, the membrane was blocked for 1 h at ambient 
temperature with Odyssey blocking solution. Primary antibody was added as indicated (Table 
2-8) at a 1:1000 dilution and incubated over-night on the membrane at 4° C on a tumbling 
shaker. Unbound antibody was cleared by washing, and an appropriate fluorochrome-
conjugated secondary antibody (Table 2-9) was added for 1 h at ambient temperature. After 
removal of excess antibody, protein signal was detected on a Licor Odyssey fluorescence 
scanner.  
When required, quantification of signal was performed by densitometric analysis, using the 
LabImage 1D software. 
2.2.5 Visualization of intracellular proteins by immunofluorescence 
Macrophages were transfected with synthetic miRNA precursors as described (section 
2.2.1.7). To allow microscopy of transfected cells, cells were seeded on glass cover slips. 
After 12 h, cells were M1-polarized or left unpolarized. Cells were fixed in 4 % PFA and 
permeabilized with 1 % TritonX100. After blocking of unspecific binding sites with 5 % goat 
serum in PBS + 1 % BSA, the primary antibody was added at a 1:500 dilution and incubated 
for 1 h at ambient temperature. After removal of excess antibody, the secondary antibody was 
given at a dilution of 1:5000 and incubated over night at 4 °C. After washing, cells were 
incubated with DAPI to counterstain nuclei, and cover slips were mounted with Mowiol. 
Pictures were taken with a AxioCam MRm on a Axio Vert.A1 Fluorescence Microscope.  
2.2.6 Flow Cytometry 
2.2.6.1 Cytometric analysis of human monocytes and macrophages 
Freshly purified monocytes were resuspended in FACS blocking buffer and incubated with 
anti-CD14 FITC antibody at a 1:100 dilution for 20 min. at 4 °C. Polarized and unpolarized 
macrophages were labeled with anti-CD-80 PE and anti-CD23-APC antibodies accordingly 
(Table 2-6). To ensure specificity of binding, antibodies against surface markers restricted to 
polarized macrophages were applied to unpolarized macrophages. After washing with FACS 
washing buffer, cells were subjected to cytometric analysis on a BD FACSCalibur flow 
cytometer. The data were analyzed using FlowJo v. 7.6.5. 
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2.2.6.2 Fluorescence activated cell sorting (FACS) of murine lung macrophages 
2.2.6.2.1 Antibody labelling of murine macrophages 
Prior to staining, cells were filtered through a 30 µm MACS pre-separation filter. For 
antibody staining, a solution of 1 x 106 cells per 100 µl MACS buffer was created, and 1µl of 
Mouse Fc Block per 100 µl was added. Cells were then stained with 1 µl of antibody per 
100 µl solution in the dark at 4 °C for 25 min (Table 2-5). Single fluorochrome stains and 
appropriate isotype controls were included. 
2.2.6.2.2 Cytometric isolation of murine macrophages  
All FACS experiments were performed at the flow cytometry core facility Marburg. Cells 
were subjected to sorting at a concentration of up to 2 x 107/ml on a FACS Aria III cell sorter. 
Cells were sorted at a maximal rate of 3000 events/second through a 85 µm nozzle into a 
vessel pre-coated with FCS. After sorting, cells were immediately centrifuged at 500 x g and 
4 °C for 10 minutes, lysed with Isol RNA Lysis Reagent and frozen at -20 °C. 
2.2.7 The murine model of eosinophilic airway inflammation 
The mice used for this project were purchased from Harlan Laboratories and kept under 
standardized conditions. A 12 hours dark/light rhythm, an ambient temperature of 20-24 °C 
and an air humidity of 50-60 % were maintained. Mice were housed in individually ventilated 
Type II L cages (IVC) providing food and water ad libitum. For all experiments, 9 weeks old 
female BALB/c mice were used. All studies were approved by the appropriate authorities 
according to German legal requirements (Tierversuchsantrag V54-19c 20-15 (1) MR 20/13 
Nr. 21/2010) 
2.2.7.1 Induction of experimental allergic airway inflammation 
Sensitization of mice to allergen was achieved by intraperitoneal (i.p.) administration of OVA-
Al(OH)3 compound on day 0, 14 and 21. Each time, 10 µg OVA and 2.8 mg Al(OH)3 were 
given per mouse in a PBS solution. For the induction of asthma, 5 ml of a 1 % (w/v) 
OVA/PBS solution were vaporized with a Master Nebulizer over a period of 20 min. Mice 
were subjected to simultaneous group aerosol challenge on day 26, 27 and 28. Induction of 
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experimental allergic airway inflammation was routinely performed by the Department of 
Clinical Chemistry, Philipps University Marburg. 
2.2.7.2 Preparation of murine alveolar and interstitial macrophages  
Mice with acute eosinophilic airway inflammation and healthy control animals were 
sacrificed at 48 h past last challenge by i.p. injection of 7.6 mg Ketamine/1.1 mg 
Rompun/200 IU Heparin per animal. After median sternotomy, mice were tracheotomised 
with a permanent venous catheter, and bronchoalveolar lavage was performed. Two times 
500 µl and four times 800 µl of BAL lavage solution were injected into the lung and re-
aspirated carefully with a 1 ml syringe. Equal inflation and deflation of lung lobes was 
monitored to ensure coverage of all lung compartments. The BAL fluid was kept on ice. The 
aorta abdominalis and vena cava were severed, and the left atrium was punctured to allow 
drainage of blood from the lung. Lungs were perfused by cannulation of the right heart 
ventricle and pulsed application of 20 ml PBS until the lung was white. The lung was excised, 
minced in digestion buffer and incubated for 45 min at 37 °C and orbital shaking at 160 rpm. 
Further homogenization was achieved by forceful pulsed swirling of the homogenate using 
gentleMACS C tubes in a gentleMACS tissue homogenizer. Digestion was stopped by adding 
RPMI1640 complete medium. Cells were washed twice in complete medium at ambient 
temperature. If necessary, an erythrocyte lysis was performed by resuspending the cells in 
ultrapure water for 30 seconds. Lysis was stopped by addition of 15 ml PBS. Cells were then 
resuspended in ice-cold MACS buffer and incubated on ice for 15 min in preparation of 
antibody staining. 
2.2.7.3 Validation of lung eosinophilia in allergic mice 
Mice were sacrificed 48 h past challenge with aerosolized OVA. The extent of lung 
eosinophilia was monitored by quantification of eosinophils in the BAL fluid of healthy and 
asthmatic mice by FACS during the sorting procedure (section 2.2.6.2). 
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2.2.8 Statistical analyses of conventional experimental data 
For comparison of two data columns, the two-tailed Student´s t Test was employed. For all 
tests, Gaussian distribution was assumed, and the confidence interval was set to 95 %. 
2.2.8.1 Statistical analysis of high-throughput data 
The data gained from Taqman low density arrays and Illumina HT12 BeadChip arrays 
required extensive correlation studies and statistical correction for large sample sizes. These 
advanced analyses were carried out by Dr. Annalisa Marsico, assisted by Dr. Brian Caffrey, 
Max Planck Institute for Molecular Genetics, Berlin.  
The analysis of all 9 Illumina HT12 Beadchip Arrays was carried out with the lumi R 
Bioconductor Package, which is especially designed to process Illumina microarray data. 
After background correction, the variance stabilization and normalization procedure from the 
vsn R package was applied. This simultaneous normalization of intensities and variance 
stabilization transformation corrects for the fact that the variance of array replicates is not 
independent from the mean signal intensity, but increases at higher intensities. Differentially 
expressed genes were identified by means of a moderate t-test (R limma package), including 
Benjamin-Hochberg Correction for multiple testing. Genes with an adjusted p-value < 0.1 and 
a linear fold change > 1.5 were considered differentially expressed. 
For interpretation of the TLDA analyses, the HTqPCR R package was used. All miRNAs with 
little or no variation among samples were removed prior to testing for differential expression. 
For each miRNA, the inter-quantile range among samples (IQR) was calculated, and miRNAs 
with an expression level of IQR < 1.2 were not considered for further analysis. The ∆∆Ct 
model was used for quantification of differential expression. Statistical significance of 
miRNA differential expression was assessed by means of a moderate t-test. By converting the 
Ct values to a logarithmic scale (log2 transformation), miRNAs with a |∆∆Ct| > 1 (fold change 
of 2) and a p-value < 0.1 were considered differentially expressed. 
In order to identify functional miRNA targets and reduce as much as possible the number of 
false positives an adjusted ranking score for prediction of microRNA and mRNA interaction 
was employed. The adjusted score was computed using the formula 
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nnadj FfFfFfeEDdcCbBASCORE +++++−+++= ...)1( 2211  
This formula integrates the following parameters: 
• miRSVR (miRanda) prediction score (A) [107] 
• positive target prediction by both miRanda and TargetScan [108] (B) 
• conservation across species (C) 
• Todorovski distance of miRNA and mRNA expression data (D) 
• Published experimental validation (E) 
• Number of miRNA binding sites in the mRNA 3´UTR (Fn) 
Each factor is weighted by a negative coefficient (b, c, d, e, fn). 
Expression values of mRNA and miRNA are given as log2 of linear expression data. This 
transformation corrects for high absolute standard deviation of highly expressed targets, and it 
allows treating the data set as Gaussian, which is a prerequisite for the Student´s t-test. 
2.2.8.2 Principal Component Analysis 
Prerequisites 
In order to visually represent the global sample variation within the mRNA and miRNA array 
experiments, a principal component analysis (PCA) was performed.  
Log2-transformed expression data of genes or dCt values of miRNAs that were determined to 
be subject to significant regulation after treatment were provided by in-depths bioinformatic 
analyses (section 2.2.8.1). Prior to extraction of the first principal components of each dataset, 
a test on sampling adequacy was performed to ensure eligibility of the data for subsequent 
analyses. The Kaiser Meyer Olkin (KMO) Criterion was calculated on the basis of each data 
matrix, here exemplarily termed “transcriptome”. The “paf” command was retrieved from the 
R package rela. 
paf(transcriptome)$KMO 
The KMO is an index value between 0 and 1 for measuring the suitability of the attributes to 
be involved in PCA, higher values being better. The KMO takes into account the inter-sample 
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correlation and is computed on the basis of a correlation matrix. A value > 0.8 indicates low 
partial correlation between the samples, while a value > 0.6 is considered acceptable [109]. 
Such uncorrelated or weakly correlated samples are a prerequisite for PCA. 
Furthermore, the following R command was used to run a measure of sampling adequacy 
(MSA): 
paf(transcriptome)$MSA 
While the KMO provides a single index number to characterize the dataset, the MSA returns 
an individual value for each sample that describes its eligibility for a factor analysis. Like the 
KMO, the MSA takes a value of 1 for uncorrelated values and declines as a reciprocal 
function of partial sample correlation. Value interpretation is analogous to the KMO (see 
above). 
Principal Component Analysis 
A principal component analysis reduces a high-dimensional dataset by summarizing variables 
and expressing them as a single composite numeric value, i.e. a principal component. Once 
the first principal component has been fit to the data, the following principal components are 
incrementally added to the first one at orthogonal axes along the directions of maximum 
variance in the data. Each principal component is an eigenvector of the covariance matrix that 
is computed on the basis of the original data. Once every eigenvector has been added, the 
orthogonal body of eigenvectors is rotated to optimize the fitting of all principal components 
to the variables in the dataset. The principal components with the highest explanatory power, 
i.e. representing the directions of maximum variation, can then be extracted to represent the 
original dataset with both reduced complexity and highest possible fidelity. 
A principal component analysis was performed on the mRNA and miRNA array data using 
the “prcomp” R command. It z-transforms and rotates the data matrix and returns an object 
(“pca”) that contains the list of eigenvectors computed from the covariance matrix (i.e. the 
principal components). 
pca ← prcomp(transcriptome, center = TRUE, scale= TRUE) 
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For a graphic representation, the first principal components (i.e. those with the highest 
explanatory power) were selected in order to achieve an explained variance > 95 %. The 
percentage of explained variance that was contributed by each principal component, i.e. the 
factor loading, was calculated as the ratio of the respective cumulative sum of variance (the 
standard deviation squared) and the sum of total variance. 
var ← pca$sdev^2 
cumsum ← cumsum(var)/sum(var) 
The result identified the explanatory power of the first three principal components to be 
sufficient, as it amounted to > 95 % of total variance. A 3D cube was used for graphic 
representation. The “plot3d” and “spheres3d” commands were retrieved from the R package 
rgl. 
plot3d(pca$rotation[,1:3], xlab = "x") 
Color and shape were given to the data points by 
spheres3d(pca$rotation[,1:3], radius=0.02, col=c("red", "red", "red", "blue", "blue", "blue", 
"darkgreen", "darkgreen", "darkgreen")) 
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3 Results 
3.1 Monocyte isolation from donor samples 
This study aimed at creating a comprehensive molecular background of macrophage 
polarization. As polarization profoundly influences macrophage biology and determines 
macrophage function in health and disease, a better understanding of the underlying 
mechanisms is needed. Here, the focus was set on exploring miRNA/mRNA co-dependency.   
In order to establish a concept of macrophage polarization that closely mimics the physiologic 
conditions, primary human monocytes were used instead of a cell line. These monocytes were 
isolated from donor buffy coats by positive magnetic selection for CD14. Prior to seeding, the 
purity of freshly isolated monocytes was routinely assessed by flow cytometry and reliably 
determined to be approximately 90 % of total cells as shown by CD14 staining (Fig. 3-1).  
 
Figure 3-1: Purity of isolated monocytes by flow cytometry. Positive selection efficiency after magnetic 
activated cell sorting (MACS) was validated by subjecting isolated CD14+ monocytes from the peripheral blood 
mononuclear cell (PBMC) fraction to flow cytometry. 50.000 cells were routinely counted after staining with 
CD14 FITC antibody, and the percentage of CD14+ cells was determined with FlowJo 7.6.5. 
 
3.2 Macrophage polarization assessment 
3.2.1 Western Blot analysis shows activation of key macrophage effector molecules 
A key requirement for the systemic analysis of macrophage polarization is a valid set of 
control parameters, both descriptive and functional, that can be used to test the cellular 
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response to the given stimulus. As the signalling cascades that are activated upon polarization 
are well established (see section 1.2), first assessment of the polarization efficiency was 
conducted by monitoring the activation of effector molecules of the MAPK cascades, the 
JAK/STAT pathway and the NFκB pathway (Fig. 3-2 and 3-3). 
 
Figure 3-2: Western Blot analysis of signalling pathways in M1 macrophages. Macrophages were stimulated 
as indicated (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) and lysed after 15 
or 45 minutes in western blot lysis buffer. From each sample, 80 µg of protein were loaded and transferred to a 
nitrocellulose membrane by wet blot.  Changes in the phosphorylation state were visualized by phospho-specific 
antibodies, while total protein amount was determined by pan – antibodies. Degradation of IκBα or 
phosphorylation of p38, p42/44 and JNK are indicative of M1 signalling pathway activation. Actin and p38 were 
used as loading control, respectively. One representative replicate of three is shown. Image acquisition was done 
on an Odyssey Infrared Imager.  
Short term activation of macrophages with the M1 stimulus for 15 and 45 minutes yielded a 
time dependent phosphorylation and thereby activation of p42/44, p38 and JNK, and a 
degradation of IκBα, which is in accordance with the canonical signalling as outlined (see 
section 1.2.1) Phosphorylated p42/44 (ERK2 and ERK1) yielded a double band at 42 and 
44 kDa, respectively, the 44 kDa band (ERK1) being a more specific marker for M1 
stimulation. Phosphorylated JNK was detected at 46 kDa (p46 SAPK/JNK) and 54 kDa (p54 
SAPK/JNK). A third band of unknown origin was routinely detected below 46 kDa. The 
observed activation of pro-inflammatory signalling was absent from cells polarized with the 
M2 stimulus. In order to test whether macrophages respond to the provided M2 cytokine 
exposure, STAT6 was assayed for phosphorylation (Fig. 3-3) 
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Figure 3-3: Western Blot analysis of the primary signalling pathway in M2 macrophages. Macrophages 
were stimulated as indicated (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) 
and lysed after 15 or 45 minutes in western blot lysis buffer. From each sample, 80 µg of protein were loaded 
and transferred to a nitrocellulose membrane by wet blot. Changes in the phosphorylation state were visualized 
by phospho-specific antibodies, while total protein amount was determined by pan – antibodies. Phosphorylation 
of STAT6 is indicative of M2 signalling pathway activation. Actin was used as loading control. One 
representative replicate of three is shown. Image acquisition was done on an Odyssey Infrared Imager.  
A weak yet specific signal revealed phosphorylation of STAT6, commonly observed in M2 
macrophages. The activation profile of the stimulated macrophages as indicated by 
prototypical signalling pathways thus closely reflected the canonical pathway initiation 
patterns and served as an indicator of solid polarization quality. 
 
3.2.2 Polarized macrophages have different bactericidal potential 
In order to validate the polarization outcome on a functional level, macrophages were infected 
with the intracellular pathogen Legionella pneumophila strain Corby. Phagocytosis efficiency 
and intracellular killing was measured by colony forming unit (CFU) assays. The retrieved 
bacterial units after indicated incubation times are shown (Fig. 3-4). M1 polarized 
macrophages showed the highest uptake of bacteria as assessed 90 min post infection, while 
M2 cells showed the lowest. At 36 h post infection, clearance of bacteria was most prominent 
in M1 cells. In contrast, at 36 h post infection, M2 cells showed no significant difference of 
bacterial load in comparison to unpolarized M0 cells. 
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Figure 3-4: Uptake and elimination of Legionella pneumophila by polarized macrophages. Macrophages 
were polarized for 18 h (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) or left 
un-polarized and then infected with L. pneumophila at a MOI of one. At 90 min and 36 h post infection, the cells 
were lysed by osmotic stress and rigorous pipetting, and the lysate was plated on BYCA agar plates. After three 
days, the bacterial colonies were counted. Phagocytotic (A) and bactericidal capacity (B) is markedly increased 
in M1-polarized macrophages as compared to M0 (§) and M2 (#) cells, while M2 cells show reduced uptake 
capacity vs. M0 (§) (A). Bars indicate mean and standard deviation. §/#p< 0.05; §§§/###p<0.001; §§§§/####p<0.0001 
(n=3). 
 
3.2.3 Cytometric analysis of polarized macrophages shows selective up-regulation of 
surface markers 
The surface marker decoration of cells is both indicative of the cellular activation status and 
readily accessible to isolate specific cell types. Available transcriptome data on polarized 
macrophages [31] were screened for likely candidates. As the presence of a surface molecule 
can not necessarily be inferred by occurrence of transcript, putative markers were validated by 
flow cytometry. An investigation of the candidates led to dismissal of CCR7 and CD86 as 
putative M1 markers and of CD206 as a putative M2 marker, because their occurrence on the 
cell surface was irresponsive to the given stimuli (not shown). Further analysis revealed CD80 
as an exclusive M1 marker and CD23 as an exclusive M2 marker (Fig. 3-5). While M1 
treatment routinely led to the expression of CD80 by 80 - 90 % of the cells, only 50 % of cells 
treated with the M2 stimulus reacted by up-regulation of surface CD23. This required further 
purification to increase the percentage of CD23+ cells for further analysis. To this end, cells 
stained with the CD23-APC antibody were magnetically labelled with anti-APC magnetic 
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beads and subjected to positive selection on an autoMACS Pro Separator. A prevalence of 
approximately 80 % of total cells expressing the respective marker after the appropriate 
stimulus and enrichment procedure was considered to be indicative of a homogenous 
polarization. In an effort to standardize, only samples that matched this criterion were 
considered stably polarized and eligible for subsequent RNA isolation and analysis. 
 
 
Figure 3-5: Surface marker expression of polarized macrophage subtypes. At 18 h after the polarization 
stimulus (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) the cells were 
subjected to cytometric analysis. The type of polarization is indicated in the top right corner of each panel.  
CD80 and CD23 were determined to be specific for M1 and M2, respectively. M2-polarized CD23-stained 
macrophages were further enriched by anti-APC magnetic bead positive selection to meet the purity standard for 
subsequent RNA analysis. 50.000 cells were routinely counted after simultaneous staining with CD80 and CD23 
antibody. One representative replicate of three is shown. The percentage of positive cells was determined with 
FlowJo 7.6.5. 
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3.3 Systemic profiling of macrophage subtypes reveals profound changes on the RNA 
level 
3.3.1 Quality assessment of isolated RNA 
In preparation of global RNA profiling, RNA quality from three independent biological 
replicates of validated and enriched polarized and unpolarized macrophages was determined 
by capillary gel electrophoresis on an Agilent 2100 Bioanalyzer. RNA integrity was computed 
from the 28s and 18s rRNA signals, and deviation from their usual ratio (2.1:1) served as an 
indicator of global RNA degradation. Electropherograms with RNA integrity numbers (RIN, 
underlined) are shown for each sample (Fig. 3-6). According to the manufacturer, a RIN of 10 
reflects perfect RNA quality, while a RIN of 5 means partial degradation. Based on this 
guideline, RINs > 8 were considered to indicate RNA quality sufficient for further analysis 
[110]. 
 
Figure 3-6: Electropherograms of total RNA isolated from three independent biological replicates of 
polarized macrophages. 25 – 50 ng of RNA isolated from three different donors (sample set 1 – 3) were 
analyzed by capillary gel electrophoresis on an Agilent 2100 Bioanalyzer. The respective polarization treatment 
is indicated in the top left corner of each panel (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + 
IL13 (20 ng/ml)). Fluorescence units (FU) peaked when RNA was detected during the 65 second (s) run time. 
Underlined figures in the top right corner of each panel represent the RNA integrity number (RIN), which is 
deduced from the ratio of 18s and 28s rRNA. Peak ①: Marker; Peak ②: small RNA; Peak ③: 18s rRNA; 
Peak ④: 28s rRNA. 
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3.3.2 mRNA analysis identifies characteristic patterns of polarization phenotypes  
mRNA analysis of polarized and unpolarized macrophages was performed on Illumina HT12 
BeadChip Arrays. In a first approach, 1269 genes were found to be up-regulated in response 
to the polarization stimulus, and 1361 genes were determined to be down-regulated.  
 
Figure 3-7: Logical relations of mRNA expression in the three distinct subsets of macrophages. The number 
of genes that were found to be up-regulated (a) or down-regulated (b) in polarized macrophages (M1: 
IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) in comparison to M0 cells is shown. 
Genes with a linear fold change > 2 and an adjusted p value of < 0.1 were included. 
The magnitude of transcriptional response that each polarization subtype exerted upon 
stimulus is displayed (Fig. 3-7). Of note, the stimulus’ impact on the transcriptome is 
markedly stronger in M1-polarized cells as compared to their M2 counterpart. This is in 
accordance with the concept of M1 macrophages being considerably more active in terms of 
gene regulation as compared to M2 macrophages (section 1.2.3)  
The samples were correlated and a heatmap was generated, indicating up- and down-
regulation of transcript as a function of macrophage polarization status (Fig. 3-8). The data 
were considered to be in good agreement with previous transcriptome data [31], which was a 
further confirmation of the solidity of polarization. As shown above (Fig. 3-7), the 
comparatively weak response of M2 polarized macrophages to the stimulus as compared to 
M1 polarized macrophages is reflected in the heatmap. 
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Figure 3-8: mRNA profiling of polarized macrophages on an Illumina HT12 Beadchip Array. 1 µg  of total 
RNA from polarized (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) or un-
polarized macrophages was used for hybridization. 2119 differentially regulated genes were chosen for display 
on the basis of a -∆∆Ct > 0.58 and a p-value < 0.1 across 3 biological replicates. The magnitude of regulation is 
expressed as log2-transformed fold-change, quantile-normalized, background-corrected expression data. For 
graphic representation, expression values beyond -4 and +4 log2 fold change were truncated and set to -4 and +4, 
respectively. 
In order to visualize the mRNA similarities and differences of the polarized and un-polarized 
macrophage subtypes, differentially regulated genes were extracted from the total expression 
data, yielding a high-dimensional matrix of 2119 genes x 9 individual samples. To reduce the 
complexity of these data to a visually accessible level, a principal component analysis (PCA, 
section 2.2.8.2) was performed (Fig. 3-9). The data were found to be eligible for PCA as they 
showed a Kaiser Meyer Olkin (KMO) criterion of 0.88 and individual measure of sampling 
adequacy (MSA) values of > 0.85. The overall sample variance was allocated to the first three 
principal components (i.e. the three eigenvectors of the co-variance matrix with the highest 
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eigenvalues). Principal component 1 (PC1) accounts for 83.91 %, PC2 for 11.93 % and PC3 
for 2.33 % of overall data set variance. The unbiased allocation of all differentially regulated 
genes showed a clear clustering of the respective polarization subtypes.  
 
Figure 3-9: Principal component analysis of global mRNA expression data of M0, M1 and M2 
macrophages. The log2-transformed fold-change, quantile-normalized, background-corrected expression data of 
2119 genes that were found to be regulated in response to polarization treatment (M1: IFNγ (20 ng/ml) + LPS 
(100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) was included in the calculation. By using the first three 
principal components, the explained variance (PCA Mapping) amounted to 98.17 %. Red: M0; blue: M1; green: 
M2 
The identities and regulation of chosen genes out of this data set which were considered to be 
of particular interest for M1 macrophage activation (Fig. 3-10) and M2 macrophage activation 
(Fig. 3-11) are shown. In addition, the top 50 regulated genes as ranked by log2 fold 
expression vs. M0 are provided for each subtype (Appendix). 
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Figure 3-10: Expression levels of hallmark M1 associated genes upon polarization. Macrophages were 
polarized (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) or left un-polarized 
(M0). Global gene expression levels were determined by Illumina HT12 Beadchip Array. Log2-transformed, 
quantile-normalized, background-corrected expression data are shown. Hallmark M1 genes with significant 
regulation between the subtypes were selected. Bars represent the mean and standard deviation (n = 3).  
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IL-6, TNFα and IL1β are very potent cytokines which propagate pro-inflammatory activation 
by paracrine or autocrine signalling. CXCL10 (IP-10), CXCL11 (I-TAC) are C-X-C 
chemokines that belong to the ELR- subclass, while CCL5 (RANTES) is a C-C motif 
chemokine. They attract TH1-activated T cells via CCR3 (CXCL10 and CXCL11) and CCR1, 
CCR3 and CCR5 (CCL5). The cell surface molecule CD80 is also involved in interaction 
with T cells, as it binds co-stimulatory molecules such as CD28 or CTLA-4. C-C motif 
chemokine receptor 7 (CCR7), the receptor for CCL19 and CCL21, has been shown to be not 
functional on human blood derived macrophages and not inducible by pro-inflammatory 
treatment (Prostaglandin E2, PGE2) on the protein level [111]. Nonetheless, it is an 
established mRNA marker of M1-polarized macrophages [112]. Indoleamine-2,3-
dioxygenase1 (IDO1) has on the one hand been described to be induced by IFNγ [113], and 
on the other hand it has been suggested to be involved in immunosuppression by starvation 
due to breakdown of the essential amino acid tryptophan [114]. In summary, this highlights 
both the supporting nature of M1 polarized macrophages in a TH1-skewed inflammatory 
microenvironment and the concomitant activation of regulatory mechanisms.   
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Figure 3-11: Expression levels of hallmark M2 associated genes upon polarization. Macrophages were 
polarized (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) or left un-polarized 
(M0). Global gene expression levels were determined by Illumina HT12 Beadchip Array. Log2-transformed, 
quantile-normalized, background-corrected expression data are shown. Hallmark M2 genes with significant 
regulation between the subtypes were selected. Bars represent the mean and standard deviation (n = 3). 
 
The transcriptome analysis of the M2 polarized macrophages revealed CD23 as the most 
prominently up-regulated transcript (Fig. 3-11). Correspondingly, the CD23 surface protein 
served as the M2 specific surface marker in this study. Furthermore, CD209 (DC-SIGN) was 
strongly up-regulated. CD23 and DC-SIGN have been shown to form a cluster on 
chromosome 19p13 [115] and to be inducible by IL4 [116]. Up-regulated genes with a known 
role in alternatively activated macrophage biology furthermore included 11β-Hydroxysteroid 
Reductase Type 1 (HSD11B1) and Peroxysome Proliferator-Activated Receptor-γ (PPARγ), 
which have been shown to cooperate in alternative macrophage activation [117]. Briefly, 
PPARγ induces HSD11B1 on the transcript level. HSD11B1 has been described to be up-
regulated in human macrophages that were activated by LPS and by IL-4. This bimodal way 
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of induction is reflected here, as HSD11B1 is up-regulated in both M1 and M2 polarized 
macrophages.    
Recently, transglutaminase 2 (TGM2) has been found to be the only consistent and functional 
M2 marker upon IL-4 stimulation on mRNA and protein level in a comparative study of 
human and mouse [118]. It has been implicated in a plethora of processes, such as fibrosis, 
wound healing and apoptosis [119], all of which are closely linked to alternative macrophage 
activation.  
 
3.3.3 microRNA analysis identifies characteristic patterns of polarization 
phenotypes 
In order to correlate changes in mRNA expression to changes in miRNA expression, Taqman 
low density arrays (TLDA) were performed (section 2.2.2.3), using the same RNA samples. 
The data were analysed according to the workflow applied for the mRNA (Fig. 3-7 – 3-9). As 
shown for the mRNA data (Fig. 3-7), M1 macrophages show a higher degree of subtype-
specific miRNA regulation as compared to M2 macrophages (Fig. 3-12). 
 
Figure 3-12: Logical relations of miRNA expression in the three distinct subsets of macrophages. The 
number of miRNAs that were found to be up-regulated (a) or down-regulated (b) in polarized macrophages (M1: 
IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) in comparison to M0 cells is shown. 
In accordance with the mRNA profiling study, the stimulus’ impact on the miRNA pattern is stronger in M1-
polarized cells as compared to their M2 counterpart. 
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Data correlation yielded a heatmap indicating differential miRNA expression (Fig. 3-13). 
 
Figure 3-13: microRNA profiling of polarized macrophage subtypes. 350 – 1000 ng of total RNA from 
polarized (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) or un-polarized 
macrophages was used for megaplex reverse transcription and amplification. 43 differentially regulated miRNAs 
were chosen for display on the basis of a -∆∆Ct > 1, a p-value < 0.1 across three biological replicates and an 
expression level of IQR (inter-quantile range) > 1.2. The magnitude of regulation is expressed as log2-
transformed fold change values as computed by the ∆∆Ct method. 
From these data, miRNAs were determined to be differentially expressed between the 
subtypes by the depicted level of confidence. Their log2 transformed individual relative 
expression levels as compared to M0 are shown (Fig. 3-14).  
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Figure 3-14: Selected miRNAs with a potentially subtype-specific expression pattern. Individual miRNAs 
that were found to be differentially regulated as a function of macrophage polarization (M1: IFNγ (20 ng/ml) + 
LPS (100 ng/ml); M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) were extracted from the miRNA screening 
experiments. The relative regulation as compared to the un-polarized M0 subtype is shown as log2 transformed 
fold-change expression. Expression values were computed by the ∆∆Ct method. p-values as adjusted for 
multiple testing are indicated (n=3).  
 
As above (Fig. 3-9), a principal component analysis of these 43 miRNAs was performed in 
order to visually illustrate the degree of similarity or differences in miRNA expression 
between the individual samples (Fig. 3-15). The data were found to be eligible to PCA, 
showing a KMO criterion of 0.89 and individual MSA values of > 0.85. 
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Figure 3-15: Principal component analysis of miRNA expression data. The ∆Ct values of 43 miRNAs that 
were determined to be regulated in response to polarization treatment (M1: IFNγ (20 ng/ml) + LPS (100 ng/ml); 
M2: IL4 (20 ng/ml) + IL13 (20 ng/ml)) were included. By using the first three principal components, the 
explained variance (PCA Mapping) amounted to 95.8 %. Red: M0; blue: M1; green: M2 
  
It is noteworthy that while sample fidelity across three biological replicates was high in the 
mRNA arrays and the polarization subtypes were clearly distinct (Fig. 3-9), the intra-group 
variance turned out to be higher in the miRNA arrays. This stressed the necessity of individual 
validation of miRNAs by quantitative PCR.  
 
3.3.4 Individual validation corroborates differentially regulated microRNAs 
A chosen set of miRNAs that were shown to be significantly regulated in a subtype-specific 
way by TLDA were individually validated by qPCR in an additional biologically independent 
sample. hsa-miR-146a-5p, hsa-miR146b-5p, hsa-miR-155-5p and hsa-miR-187-3p (M1, Fig. 
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3-16) as well as hsa-miR-193b-3p and hsa-miR-511-5p (M2, Fig. 3-17) were all confirmed to 
be up-regulated in the corresponding subtype as suggested by TLDA results. Due to 
differences in methodology and analysis, these expression data were not combined with the 
TLDA data. No statistics were performed, as these validation experiments were not performed 
in biological replicates. p-values from the TLDA experiments were as indicated (Fig. 3-14). 
While the TLDA results were log2 transformed and analyzed accordingly, the linear fold 
change is used here (Fig 3-16 to 3-18). 
 
 
Figure 3-16: Validation of miRNA expression in M1 macrophages. Verification of miRNAs that were found 
to be significantly regulated in the TLDA experiments upon M1 polarization (IFNγ (20 ng/ml) + LPS 
(100 ng/ml)). An independent biological replicate was investigated. Differential methodology as compared to the 
TLDA analyses precluded an integration of these data into the TLDA results, so no statistics were performed due 
to the solitary nature of the data (n=1). 
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Figure 3-17: Validation of miRNA expression in M2 macrophages. Verification of miRNAs that were found 
to be significantly regulated in the TLDA experiments upon M2 polarization (IL4 (20 ng/ml) + IL13 (20 ng/ml)). 
An independent biological replicate was investigated. Differential methodology as compared to the TLDA 
analyses precluded an integration of these data into the TLDA results, so no statistics were performed due to the 
solitary nature of the data (n=1). 
 
Of note, hsa-miR-511-5p is harboured in the MRC1/MRC1L1 gene in intron 5 [120]. 
MRC1L1 mRNA is significantly up-regulated in the M2 condition (Appendix and Fig. 3-19), 
and the magnitude of regulation matches that of hsa-miR-511-5p. The question whether 
MRC1 and MRC1L1 are two separate genes or not and whether they are subject to regulation 
by hsa-miR-511-5p will be discussed later (section 4.2).  
In contrast to the aforementioned candidates, hsa-miR-34c-5p turned out to be regulated in a 
very volatile way. As this miRNA was almost undetectable and therefore unreliably 
determined to be down-regulated upon M2 stimulus in TLDA, it was pre-amplified prior to 
individual validation (see section 2.2.2.6.1). Due to fluctuation across donors, its regulation in 
the context of polarization could not be conclusively determined. Since it was expressed in 
individual isolates at considerable levels and responded to the M2 stimulus (Fig. 3-18), it was 
included in the screenings for interaction partners.  
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Figure 3-18: Re-investigation of hsa-miR-34c-5p expression. While this miRNA could not be conclusively 
profiled across all investigated samples, it was present in individual isolates and responsive to the M2 stimulus 
(IL4 (20 ng/ml) + IL13 (20 ng/ml)). Differential methodology as compared to the TLDA analyses precluded an 
integration of these data into the TLDA results, so no statistics were performed due to the solitary nature of the 
data (n=1). 
 
3.4 Screening for microRNA/mRNA interaction partners 
3.4.1 Bioinformatics analysis 
3.4.1.1 Laws of microRNA/mRNA interaction 
The likelihood of interaction of a given miRNA/mRNA pair can be expressed numerically on 
a metric scale of interaction scores. The score is always negative as it is a representation of a 
negative correlation between miRNA and mRNA expression levels. An increasing absolute 
score denotes an increased probability of miRNA/mRNA interaction. The score integrates 
various biochemical and biological aspects of miRNA and mRNA duplex formation, such as 
stability and sequence conservation. The putative miRNA/mRNA duplex is influenced by the 
free energy in the system, which, striving for a minimum, determines the thermodynamic 
stability of the nucleotide pairing [121]. Sequence conservation across species also impacts on 
the computational likelihood of interaction, since functional pairing is more likely to be 
conserved throughout evolution by selection pressure than non-functional pairing.  
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3.4.1.2 Theoretical identification of several mRNAs with an increased likelihood 
of microRNA-mediated regulation  
After confirmation of the regulated miRNAs by qPCR, an in silico target prediction was 
performed. Potential mRNA targets that showed inverse expression as compared to the 
corresponding miRNA were identified (Fig. 3-19) and favourably treated by the interaction 
score computation algorithm (Table 3-1).  
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Figure 3-19: Predicted candidates for miRNA-induced regulation as extracted from the Illumina micro 
arrays. Selected mRNAs that were considered likely to be subject to miRNA-mediated degradation are shown 
by their log2 transformed expression intensity. Down-regulation of SH2B2, TREM2, DYRK2 and LAMP2 in the 
M1 phenotype was indicative of subtype-specific degradation of transcript. Correspondingly, up-regulation of 
KLF4, MRCL1L1 and PPARγ in the M2 phenotype was indicative of subtype-specific attenuated transcript 
destabilization. Both effects were bioinformatically linked to concomitant miRNA up- and downregulation, as 
the observed changes in transcript occurrence were hypothesized to be miRNA-induced. p-values as adjusted for 
multiple testing are shown (n=3). 
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In addition to universally applicable parameters (section 3.4.1.1), the adjusted score integrates 
several additional parameters (see section 2.2.8) in order to more accurately predict 
mRNA/miRNA interaction in the given macrophage setup. The publicly available miR SVR 
score (miRanda) as well as the adjusted score are shown for a selection of putative 
mRNA/miRNA interaction partners (Table 3-1). 
 
Table 3-1: Predicted mRNA/miRNA interaction partners 
Gene Symbol Predicted microRNAs miR SVR Score (miRanda) Adjusted Score 
DYRK2 hsa-miR-155-5p-5p 
hsa-miR-187-3p-3p 
-0.82 -2.22 
-0.57 -2.16 
LAMP2 hsa-miR-155-5p-5p 
hsa-miR-187-3p-3p 
-0.63 -1.88 
-0.48 -1.35 
SH2B2 hsa-miR-187-3p-3p -1.11 -2.99 
TREM2 hsa-miR-187-3p-3p -0.57* -1.97 
PPARγ hsa-miR-34c-5p -1.28 -1.56 
MRC1L1 hsa-miR-511-3p -0.41* -1.41 
KLF4 hsa-miR34c-5p -1.03 -1.72 
* = prediction annulled 
 
Asterisk-labelled scores have since been removed from the miRanda database (last update as 
of 2013-09: 2010-11-01), since the prediction has turned out to be invalid, which is in 
accordance with the luciferase-based reporter assay (section 3.4.2.1).  
It has been shown that miRNAs that bind in close proximity to each other, optimally in a 
distance between 13 and 35 nucleotides, synergistically act on their target [122]. In the case of 
DYRK2, hsa-miR-155-5p and hsa-miR-187-3p were determined to bind at a distance of 152 
nucleotides (position 3502 – 3654 in the 3´UTR), whereas in the LAMP2 transcript, their seed 
binding sites were found to lie 43 nucleotides apart (position 439 – 481 in the 3´UTR, Fig. 3-
21), as determined by the miRanda target prediction algorithm. In addition to target 
specificity, the question of synergy was thus addressed in the following validation 
experiments. 
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3.4.2 A subset of considered microRNAs could be corroborated by experimentation 
3.4.2.1 First positive evidence of microRNA/mRNA interaction could be derived 
from a luciferase-based reporter approach 
In order to corroborate the putative miRNA targets that were found by bioinformatic 
prediction, a luciferase-based reporter assay was employed. 3´UTR fragments as described 
(section 2.1.3.1) were cloned into the psiCheck2 vector, and luminescence was determined as 
an indicator of miRNA-dependent mRNA regulation in HEK293 cells. A decrease of 
luminescence reflects a decrease of enzyme, which suggests a functional interaction with the 
respective miRNA, as it initiates mRNA degradation or translational inhibition. Synergy of 
miRNAs was assessed by equimolar co-transfection. Relative luminescence levels were as 
indicated (Fig 3-20 and 3-22). The signal that was detected in the samples transfected with an 
unspecific miRNA scramble sequence was set to 100 %, and the signal intensity from the 
specific transfections was calculated accordingly. For reference, a control plasmid carrying 
the partial 3´UTR of the PTK9 mRNA was co-transfected with hsa-miR-1. This 
mRNA/miRNA pair has been established to be functional, and it serves as a commercially 
available positive control for miRNA transfection experiments [123].  
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Figure 3-20: Luciferase reporter assay with M1-associated miRNAs. Co-transfection of the shown vector 
construct and miRNAs into HEK293 cells was performed. The specific miRNA-sensitivity of Renilla luciferase 
mRNA that carries the 3´UTR insert from the indicated mRNAs was measured as a function of luminescence. 
RLU: relative luminescence units. *p<0.05; **p<0.01 (n=3).  
The DYRK (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase) family protein 
kinases have been associated with several different regulatory processes. DYRK2 has been 
described to trigger proteasomal degradation of the transcription factors c-Jun and c-Myc, 
which are crucial for transition from G1 to S phase. Accordingly, knockdown of DYRK2 leads 
to acceleration of cell proliferation. Macrophages do not undergo cell cycle when kept under 
in vitro conditions, and it has only recently become clear that macrophages can proliferate in 
situ under certain conditions [40]. Hence, the role of DYRK2 in macrophage biology has not 
been described yet. The DYRK2 construct was found to be slightly down-regulated in 
response to hsa-miR-187-3p, although not to a significant extent. Of note, the construct was 
insensitive to hsa-miR-155-5p, even though the adjusted prediction score (-2.22, Table 3-1) 
suggested a robust likelihood of interaction. Accordingly, no synergy could be found by co-
administration of both miRNAs.  
The lysosome associated membrane proteins 1 and 2 (LAMP1 and LAMP2) are situated in 
the membrane of lysosomes. They both possess a heavily glycosylated luminal domain, a 
single trans-membrane domain and a carboxyterminal domain on the cytosolic side. The 
glycosylation accounts for approximately 60 % of their total mass and is thought to render 
them resistant to the constant acidic exposure in the lysosomal lumen [124]. Their function 
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has been hypothesized to be protection of the lysosomal membrane as well as, in the case of 
LAMP2, selective uptake of cytosolic substances bound for lysosomal degradation. 
The LAMP2 plasmid proofed to be slightly responsive to hsa-miR-187-3p, while transfection 
of hsa-miR-155-5p led to a significant decrease of the luminescence signal. Co-transfection of 
both miRNAs conferred the most efficient decrease of signal (approximately 50 %), which 
suggests a synergistic mode of action, an observation that is further corroborated by the close 
spatial proximity of the putative binding sites (43 nucleotides from seed region to seed region, 
Fig. 3-21). 
 
Figure 3-21: miRNA binding site distribution in the LAMP2 transcript 3´UTR. Position 417 to 495 from the 
LAMP2 transcript 3´UTR is shown. Vertical bars represent canonical base pairing (A-U and G-C), while the 
colon indicates a wobble base pair (G-U). The proximity of hsa-miR-187-3p and hsa-miR-155-5p binding sites 
(43 nucleotides) suggests a synergistic mode of miRNA-mediated LAMP2 transcript regulation. 
 
The SH2B adaptor protein 2 (SH2B2 or APS, adaptor molecule containing PH and SH2 
domains) is an adaptor protein with a pleckstrin homology (PH) domain that interacts with 
membrane-bound bi– or tri-phosphorylated phosphatidylinositol, and a src homology 2 (SH2) 
domain that binds to phosphorylated tyrosine residues [125, 126]. Together with SH2-B and 
Lnk, it is part of a family of cytokine and growth factor signalling mediators [127]. Having no 
catalytic activity, it was described as a scaffold molecule.  
In macrophages, the function of SH2B2 has not been described yet, but its transcript is 
present. The SH2B2 mRNA possesses a very short 3´UTR (80 nucleotides), which was fully 
included in the luciferase reporter construct and which only displays one valid miRNA 
binding site. This site is predicted to be a target of hsa-miR-187-3p. Accordingly, transfection 
of hsa-miR-187-3p led to a 50 % down-regulation of signal as compared to the scramble 
sequence.  
The triggering receptor expressed on myeloid cells 2 (TREM2) has been described as a 
negative regulator of TLR signalling and hence as a modulator of macrophage activation 
[128]. Accordingly, it has been shown to be down-regulated in M1-polarized macrophages 
[129] (Fig. 3-19). According to initial prediction by miRanda, TREM2 mRNA is sensitive 
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toward hsa-miR-187-3p. This prediction has been revoked and is no longer listed in the 
database (Table 3-1). In the reporter setup, TREM2 turned out to be completely irresponsive 
to this miRNA (Fig. 3-20). 
 
Figure 3-22: Luciferase reporter assay with M2-associated miRNAs. Co-transfection of the shown vector 
construct and miRNAs into HEK293 cells was performed. The specific miRNA-sensitivity of Renilla luciferase 
mRNA that carries the 3´UTR insert from the indicated mRNAs was measured as a function of luminescence. 
PTK9 was included as positive control. RLU: relative luminescence units. *p<0.05; **p<0.01 (n=3; PTK9: n=2). 
  
Mannose receptor, C type 1 (MRC1/CD206) is a phagocytic carbohydrate receptor that 
detects both endogenous and foreign glycoproteins [130, 131]. It has been described to be 
inducible by IL4 and IL13, and it is acknowledged as a marker of M2-like macrophages [33]. 
The intronic hsa-miR-511 is encoded in the MRC1 open reading frame [132]. In addition, a 
putative binding site had been identified in the MRC1 3´UTR by an earlier version of the 
miRanda algorithm. The co-regulation of hsa-miR-511 and MRC1 and the affirmative target 
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prediction suggested a potential regulatory feedback mechanism that controls MRC1 
expression levels. However, this prediction has been annulled and is no longer available in the 
miRanda database (Table 3-1). This could be confirmed here, since no effect could be shown 
by the reporter system. 
PPARγ is a transcription factor which is activated by fatty acids or their derivatives. This 
receptor type is involved in cholesterol metabolism and immunoregulation, where it promotes 
macrophage differentiation toward the M2 type [133, 134]. The PPARγ construct showed 
downregulation of emitted luminescence upon hsa-miR-34c-5p transfection of approximately 
50 %, which is in accordance with the target prediction score. 
In close functional association with PPARγ, KLF4 has also been described to be a central 
factor in macrophage polarization [135]. It is a transcription factor downstream of STAT6 and 
is associated with numerous processes, such as anti-inflammation [136] and cancer 
progression [137]. Similar to PPARγ, signal decrease in the reporter assay amounted to 
approximately 50 % of the control scramble transfection, reflecting the affirmative prediction 
score. 
The PTK9 construct showed a strong sensitivity to hsa-miR-1. This pair was investigated for 
reference only, as it represents an established positive control (n=2, Fig. 3-22). 
 
3.4.2.2 The effect of selected microRNAs on native targets is limited  
In order to more closely mimic the physiological role of miRNAs in macrophages, miRNA 
precursors and inhibitors were transfected by lipofection into monocyte-derived macrophages, 
and the effect on the native target transcript as suggested by the reporter construct was 
monitored. The transfection efficiency of the introduced miRNAs was routinely validated by 
qPCR as exemplarily shown (Fig. 3-23). The high relative amount of the mature hsa-miR-
187-3p after transfection is due to its low-level occurrence in untransfected cells, as 
expression was normalized to the scramble-transfected sample. Accordingly, the moderate 
increase of mature hsa-miR-155-5p after transfection reflects the high native expression level 
of this miRNA in macrophages.  
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Figure 3-23: Representative example of relative miRNA expression levels after transfection. Over-
expression of transfected hsa-miR-155-5p and hsa-miR-187-3p (30 nM each) was verified in blood-derived 
macrophages before subsequent target validation assays were performed. Each miRNA was transfected at a final 
concentration of 30 nM by siPort-based lipofection. Detection of the mature miRNAs was performed 24 hours 
post transfection by Taqman-based qPCR. All miRNA signals were normalized to RNU48. 
SH2B2 mRNA regulation by hsa-miR-187-3p 
The regulation of the SH2B2 transcript was the first to be investigated. The short 3´UTR and 
the absence of binding sites other than for hsa-miR-187-3p made it a likely candidate for 
miRNA-dependent regulation. Transfection of a synthetic hsa-miR-187-3p precursor at 30 nM 
indeed conferred a marked down-regulation of SH2B2 transcript at 24 h post transfection, as 
detected by qPCR (Fig. 3-24). 
 
Figure 3-24: SH2B2 is down-regulated by hsa-miR-187-3p on mRNA level. Upon ectopic over-expression of 
hsa-miR-187-3p at 30 nM, the relative amount of SH2B2 transcript as normalized to RPS18 was shown to be 
reproducibly decreased. SYBR-Green based qPCR was performed at 24 h post transfection. *p<0.05 (n = 3). 
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The impact of the observed regulation on the protein level of SH2B2 was not conclusively 
investigated, because western blot experiments with macrophage cell lysate yielded no 
consistent results. This was in part due to the restricted number of suitable available 
antibodies. 
LAMP2 mRNA regulation by hsa-miR-155-5p and hsa-miR-187-3p 
Since the reporter assay suggested a synergistic mode of action by hsa-miR-155-5p and hsa-
miR-187-3p on the LAMP2 mRNA, it was investigated whether this regulation could be seen 
on the level of native transcript. To this end, monocyte-derived macrophages were transfected 
by lipofection. Single and combined application of hsa-miR-155-5p and hsa-miR-187-3p at 
30 nM each or combined yielded no regulation of the LAMP2 transcript that was detectable 
by qPCR, as shown (Fig. 3-25).  
 
 
Figure 3-25: Quantification of LAMP2 transcript after indicated miRNA transfection. The relative amount 
of LAMP2 transcript was shown to be unresponsive to ectopic over-expression of hsa-miR-187-3p and hsa-miR-
155-5p at 30 nM each or combined. Expression levels were detected by SYBR-Green based qPCR at 24 h and 
48 h timepoint after transfection and normalized to RPS18 (n=2). 
 
In order to exclude compensatory effects like enhanced transcription that might obscure 
degradation of transcript, a modified experimental approach was chosen [138], using the 
monocytic THP-1 cell line. The synthetic cytostatic actinomycin D (10 µM) was administered 
to the cells, thereby globally blocking transcription [139]. It could be shown that LAMP2 
mRNA is highly stable under the influence of actinomycin D, as it withstands degradation for 
a prolonged period of up to 4 hours. TNFα mRNA, which was used as a control for 
actinomycin D potency, was greatly diminished (> 80 %) after 120 min (Fig 3-26).  
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Figure 3-26: Transcript decrease of indicated genes after actinomycin D administration. THP-1 cells were 
treated with the cytostatic actinomycin D at a final concentration of 10 µM for the indicated time points. While 
TNFα mRNA is subject to rapid decrease, the LAMP2 transcript levels remain stable for up to 240 min as 
determined by SYBR Green based qPCR. The signal was normalized to RPS18 (n=1). 
In order to show a regulatory impact of hsa-miR-187-3p and hsa-miR-155-5p on LAMP2 
transcript levels, the actinomycin D treatment was supplemented by miRNA administration. 
In case of a functional interaction between miRNA and mRNA, which was assumed to exist 
given the affirmative reporter assay data, presence of either miRNA should be able to induce 
degradation of the LAMP2 transcript. Early time points were chosen to avoid cytotoxic side 
effects of actinomycin D and in accordance with literature [138]. 
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Figure 3-27: Relative quantification of LAMP2 transcript under the combined influence of actinomycin D 
and indicated miRNAs. Monocytic THP-1 cells were transfected with the indicated miRNAs at a final 
concentration of 30 nM. 18 hours after transfection, the cytostatic actinomycin D was added at a final 
concentration of 10 µM. RNA samples were taken at 15, 30 and 45 min and of untreated cells. Relative levels of 
LAMP2 transcript as normalized to RPS18 were determined by SYBR-Green based qPCR. Bars represent mean 
and standard deviation (n=4). 
As shown, indicated miRNA overexpression under the influence of actinomycin D did not 
increase LAMP2 mRNA degradation on a time scale from 15 to 45 minutes (Fig. 3-27). Even 
though such a tendency could be observed for miRNA co-transfection at 30 min timepoint, the 
consecutive 45 min timepoint showed no progressive decline of transcript. Additionally, the 
30 min timepoint shows a high standard deviation. 
The effect of miRNA on the LAMP2 protein 
Since no effect of either hsa-miR-155-5p or hsa-miR-187-3p could be detected on the 
transcript level, which stood in stark contrast to the data gained from the luciferase reporter 
assay, the possibility of miRNA-mediated translational inhibition was investigated. In order to 
explore the possible influence of hsa-miR-155-5p and hsa-miR-187-3p on LAMP2 protein 
levels, western blot analysis was performed with cell lysate from transfected monocyte-
derived macrophages (Fig. 3-28). As the half-life of LAMP2 has been shown to be 48 h [140], 
this time point was chosen for cell lysis after miRNA transfection.  
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Figure 3-28: Representative example of LAMP2 detection by western blot. Blood-derived macrophages 
were transfected with the indicated miRNAs at a final concentration of 30 nM each, and the cells were lysed 
under stabilizing conditions 48 h post transfection. From each sample, 80 µg of protein were loaded and 
transferred to a nitrocellulose membrane by wet blot. Total LAMP2 protein amount (Isoform A and B) was 
determined by LAMP2 antibody staining. Actin was used as loading control. One representative replicate of four 
is shown.  
As changes in LAMP2 expression were expected to be subtle, extracting robust data from the 
semi-quantitative western blot output required densitometric analysis. A set of 4 independent 
transfection experiments was blotted to calculate the numeric effect of the indicatd miRNAs 
on the LAMP2 protein level (Fig. 3-29). 
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Figure 3-29: Densitometric analysis of LAMP2 protein levels as determined by western blot in response to 
the indicated miRNA treatment. Blood-derived macrophages were transfected with the indicated miRNAs at a 
final concentration of 30 nM each, and the cells were lysed under stabilizing conditions 48 h post transfection. 
From each sample, 80 µg of protein were loaded and transferred to a nitrocellulose membrane by wet blot. Total 
LAMP2 protein amount (Isoform A and B) was determined by LAMP2 antibody staining. After digital image 
acquisition, the western blot band volume and density were determined by the LabImage1D software. LAMP2 
signal was normalized to the corresponding actin signal. Scramble transfected samples were set to 100 %. Bars 
represent mean and standard deviation (n= 4). 
Due to considerable fluctuations in the densitometry analysis that potentially obscured 
regulation of LAMP2 protein by miRNAs, transfected macrophages were subjected to 
immunofluorescence staining in order to alternatively visualize the amount and also the 
distribution of LAMP2 protein (Fig. 3-30). In addition, the M1-polarized subtype was 
included. This was done to test whether the predicted regulation of LAMP2 by miRNAs was 
restricted to a specific metabolic state of the cell. 
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Figure 3-30: LAMP2 staining of unpolarized and M1 polarized macrophages after indicated miRNA 
transfection. Blood-derived macrophages were transfected with the indicated miRNAs at a final concentration 
of 30 nM each. After 12 h, the cells were M1-polarized or left unpolarized. Upon fixation by 4 % PFA, cells 
were permeabilized with 1 % Triton X100. cell Finally, cells were stained with a LAMP2-specific antibody 
(1:500) and a nucleus-counterstain (DAPI). Representative sections are shown. LAMP2 in red, DAPI in blue. 
Bar = 20 µm 
Semi-quantitative screening of miRNA-transfected and scramble-transfected M0 and M1 
macrophages for LAMP2 occurrence yielded no discernible change in LAMP2 quantity, 
irrespective of the polarization subtype. The morphological change of LAMP2 positive areas 
in M1 polarized cells is probably not due to an active shuttling of LAMP2, but a passive 
consequence of a polarization-induced change of overall cell shape. M1 polarized 
macrophages acquire a spindle-shaped morphology, as routinely observed by microscopy.  
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3.5 Macrophage-associated miRNAs are regulated in an experimental murine model 
of asthma 
The macrophage as one of the most versatile cell types of the immune system is critically 
involved in a number of diseases, e.g. asthma (section 1.3.2). The gathering of a systemic, 
polarization-dependent macrophage miRNA and mRNA profile (section 3.3) established a 
referential basis that can hypothetically be used to assess the disease-driven macrophage 
polarization status in primary samples. Allergic asthma and the associated macrophage 
subtype as determined by its miRNA profile were in the focus of this effort. 
Macrophages and their various subtypes have been increasingly discussed as central to the 
pathogenesis of allergic asthma in recent years (section 1.3.2). The acute model of 
eosinophilic airway inflammation, induced by sensitization and challenge of BALB/c mice, 
served as an experimental approximation of asthma in this study. As discussed, an M2-like 
macrophage phenotype was expected to dominate in eosinopilic airway inflammation. 
A quickly accessible control parameter for the induction of allergic airway inflammation was 
the eosinophil count in the BAL fluid, which was determined by FACS analysis (Fig 3-31 and 
3-32). As shown in both BAL fluid and tissue homogenate, the relative amount of eosinophils 
(SiglecFhigh/CD11cint) increased upon OVA challenge.  
 
3.5.1 Cytometric macrophage isolation from healthy and asthmatic mice was 
performed by using specific surface markers 
While macrophages constitute almost 100 % of cells present in the alveolar lumen in healthy 
mice, the inflammatory infiltrate that accompanies eosinophilic airway inflammation 
necessitates a sorting strategy that specifically isolates alveolar macrophages. Macrophages as 
defined by SiglecFhigh/CD11chigh surface marker configuration were isolated from the BAL 
fluid of healthy and asthmatic mice by cytometric sorting. Interstitial macrophages from lung 
tissue homogenate were similarly isolated, using their SiglecFhigh/CD11blow signature or their 
SiglecFhigh/CD11chigh signature, dependent on the health status of the donor animal (Fig. 3-
31). Siglecs are lectins that mediate sialic acid binding, while CD11b and c are complement 
receptors. 
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Figure 3-31: Cytometric sorting of macrophages from lavage fluid (BAL) and lung homogenate (LH) of 
mock and OVA treated mice. OVA - sensitized mice were sacrificed at 48 h after the final challenge with 
nebulized OVA or PBS, respectively. BAL fluid and lung homogenate were recovered, and cells were stained 
with fluorochrome-labelled antibodies. Alveolar macrophages (AM, SiglecFhigh/CD11chigh) and interstitial 
macrophages (IM, SiglecFhigh/CD11chigh or SiglecFhigh/CD11blow) were purified from the indicated fractions by 
cytometric sorting and taken up in Isol RNA Lysis Reagent for further RNA analysis. Increase of eosinophils (E, 
SiglecFhigh/CD11cint) was routinely observed in OVA challenged mice and is indicative of eosinophilic airway 
inflammation. Cells from the pan-leukocyte CD45+ parent gate are shown from one representative experiment 
out of three. For each experiment and condition, material from six mice was pooled. PMN = polymorphonuclear 
neutrophil 
The relative cell counts from the pan-leukocyte CD45+ gate were averaged across three 
biologically independent experiments (Fig. 3-32). The high reproducibility was considered 
indicative of a stable induction of eosinophilic airway inflammation and warranted the 
subsequent isolation and analysis of the cell-type specific RNA. 
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Figure 3-32: Percentages of CD45+ cells in mock- and OVA-treated mice. The average relative amount of 
cells in the CD45+ gate at 48 h after the final OVA challenge of OVA- and mock-sensitized mice was determined 
by flow cytometry. Influx of eosinophils (SiglecFhigh/CD11cint) was considered indicative of eosinophilic asthma 
and leads to a relative decrease of alveolar macrophages (SiglecFhigh/CD11chigh). Bars represent mean and 
standard deviation. For each experiment and condition, material from six mice was pooled (n = 3). 
 
3.5.2 Systemic profiling of isolated macrophage specimens shows regulation of 
microRNAs as a function of health status and compartment of residence 
RNA was isolated from purified macrophage populations, and the miRNA profile was 
determined as described (section 2.2.2.4). The miRNA expression was found to be in parts 
dependent on both the macrophage´s compartment of origin and the disease status of the 
donor animal. The regulation pattern of the most strongly regulated miRNAs is shown as the 
log2 transformed expression data of asthma-related macrophages relative to the healthy 
control macrophages. Of all miRNAs that were probed, 32 were chosen on the basis of their 
statistical confidence of differential expression (Fig. 3-33). 
  Results 
106 
 
 
Figure 3-33: miRNA regulation in the alveolar and interstitial macrophage fractions of mice with acute 
eosinophilic airway inflammation as compared to corresponding macrophage fractions from mock-treated 
animals. At 48 h after the final OVA challenge, OVA- and mock-sensitized mice were sacrificed, the alveolar 
and interstitial macrophage fractions were purified, and RNA was isolated. The global asthma- and tissue-
dependent miRNA regulation pattern was determined by Taqman Low Density Array (TLDA). The 32 most 
reliably regulated miRNAs as determined by their p-values were chosen for display, and their average regulation 
across three biological replicates is shown as log2 transformed fold change expression. For each experiment and 
condition, material from six mice was pooled (n=3).  
 
These candidates included miRNAs with prominent modulatory roles in inflammation as 
described elsewhere (section 4.2), such as mmu-miR-155-5p, which is up-regulated in both 
the interstitial and alveolar macrophage fractions, and mmu-miR-146a-5p, which is down-
regulated, correspondingly. The displayed set of miRNAs furthermore includes mmu-miR-
126-3p, which shows opposing patterns of regulation upon eosinophilic airway inflammation. 
While up-regulated in alveolar macrophages, it is down-regulated in the interstitial 
macrophage fraction. The regulation of this miRNA is of particular interest, since mmu-miR-
126 has been shown to promote the TH2 response in a house dust mite model of asthma [103]. 
Likewise, mmu-miR-21a-5p has been shown to drive the immune response toward the TH2 
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axis in OVA-induced eosinophilic airway inflammation [102]. Albeit this miRNA failed to 
pass the criteria for differential regulation and is therefore not listed (Fig. 3-33), it was 
investigated because of its known impact on eosinophilic airway inflammation. Altogether, 
these four miRNAs of particular interest were regulated at the depicted levels of confidence 
(Fig. 3-34).   
 
 
Figure 3-34: Selected miRNAs with a potentially asthma-dependent expression pattern. Individual miRNAs 
that were found to be differentially regulated as a function of OVA administration were extracted from the 
miRNA screening experiments. The relative regulation as compared to the healthy control is shown as log2 
transformed fold-change expression. Expression values were computed by the ∆∆Ct method. p-values as 
adjusted for multiple testing are indicated. For each experiment and condition, material from six mice was 
pooled (n=3).  
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In addition to analyzing individual miRNA expression levels, the pattern of the combined set 
of the 32 differentiallly regulated miRNAs as identified above was considered to be a 
valuable indicator of the animal´s health status. Therefore, a principal component analysis 
was performed as described above (section 2.2.8.2) in order to visualize similarities and 
differences of the respective macrophage subset in health and disease. Prior to extraction of 
the first principal components, the Kaiser Meyer Olkin criterion (KMO) and the measure of 
sampling adequacy (MSA) were calculated to assess the extent of partial sample correlation. 
As in the human in vitro data (section 3.3.3), the partial sample correlation turned out to be 
moderate in the miRNA expression data gained from the murine alveolar (KMO = 0.82) and 
interstitial (KMO = 0.79) macrophages. Accordingly, some MSA values indicated weak 
sample correlation, ranging from 0.71 to 0.92. Altogether, these values argue for full 
eligibility of the data for subsequent factor analysis (Fig. 3-35).        
 
Figure 3-35: Principal Component Analysis of murine macrophage populations during eosinophilic airway 
inflammation. The ∆Ct values of 32 miRNAs that were determined to be regulated during eosinophilic airway 
inflammation were used to extract the first three principal components from the alveolar (a) and the interstitial 
(b) macrophage expression data. Total explained variance (PCA Mapping) amounted to 99.4 % (a) and 98.2 % 
(b). Each data point represents pooled material from six mice. healthy = red, asthmatic = blue (n=3). 
The visual correlation yielded moderate clustering of the alveolar (a) and interstitial (b) 
macrophages when displayed as a function of health status. Thus, the miRNA profile seems to 
be potentially suitable to identify the disease status of the animal.  
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3.5.3 Individual validation corroborates differential regulation of microRNAs in the 
context of asthma 
Selected candidates from the list of putative differentially regulated miRNAs (Fig. 3-33) were 
individually validated, as has been done for the human in vitro experiments (section 3.3.4). 
Only a limited amount of RNA was available due to the scarcity of murine cell material. Thus, 
the validation focused on material from the interstitial macrophage fraction and on three 
candidates which were considered to be crucial for macrophage biology in asthma. As mmu-
miR-21a-5p, mmu-miR-146a-5p and mmu-miR-126-3p have already been described to play a 
role in inflammatory responses [102, 103, 141], these three miRNAs were chosen for 
investigation. Interpretation of the TLDA analyses only revealed tendencies of their regulation 
at a low level of confidence (Fig. 3-34). However, the same tendencies could be shown in the 
interstitial macrophage fraction from a biologically independent sample that was not part of 
the TLDA analyses (Fig 3-36). Of note, the absolute expression of these miRNAs appeared to 
also be dependent the compartment of macrophage residence. As shown by the TLDA 
analyses, mmu-miR-126-3p was only barely detected in alveolar macrophages, while its 
expression was very robust in interstitial macrophages. In contrast, mmu-miR-146a-5p and 
mmu-miR-21a-5p were both robustly expressed in alveolar and interstitial macrophages. 
 
Figure 3-36: Expression of indicated miRNAs in interstitial macrophages in asthma. Upon induction of 
asthma, the indicated miRNAs responded by up- or down-regulation. Non-asthmatic baseline expression was set 
as a reference (red line). Pooled material from six mice per condition was used. The expression data were gained 
from an additional biologically independent sample that was not part of the TLDA analyses, so no statistics were 
performed due to the solitary nature of the data (n=1). 
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4 Discussion 
The goal of this study was to understand the molecular basis of miRNA involvement in 
macrophage polarization, and to translate this knowledge into the context of eosinophilic 
airway inflammation. To this end, the mRNA and miRNA profiles of the prototypical human 
M1 and M2 macrophage polarization types were assessed. Apart from exploring possible 
mRNA/miRNA interactions, these RNA profiles were envisaged to provide generally 
applicable patterns that can be used to determine the polarization status of macrophages 
isolated from in vivo material. In this study, murine eosinophilic airway inflammation was 
used as an experimental disease model, and lung macrophages from BAL fluid and lung 
homogenate were isolated in an attempt to determine their polarization status on the basis of 
their miRNA pattern. 
 
4.1 Human macrophage maturation and polarization can be monitored on both the 
mRNA and microRNA level 
The in vitro monocyte-to-macrophage maturation stood at the beginning of this thesis. 
Different published maturation protocols suggested various cultivation methods and the 
addition of supporting cytokines, such as M-CSF [142]. However, there was reasonable 
concern that cultivation of monocytes in the presence of M-CSF or GM-CSF might influence 
the polarization capacities of mature macrophages [143-145]. It has been shown that M-CSF 
alone skews macrophages toward the M2 axis, and it has been hypothesized that M-CSF- 
induced macrophages constitute the default subtype in homeostasis in vivo [31, 146]. On the 
other hand, GM-CSF has been described to increase cellular responses to pro-inflammatory 
stimuli [147]. While M-CSF circulates at high concentrations in the blood, GM-CSF is 
predominant in the lung and regulates alveolar macrophage differentiation [148]. It has been 
described that cultivation in the presence of human serum gives rise to macrophages that 
resemble tissue macrophages that develop in the GM-CSF rich environment of the lung [149, 
150]. In order to generate blood-derived macrophages in vitro that resemble alveolar 
macrophages to ensure maximal comparability with later in vivo lung studies, monocytes were 
cultured in the presence of human off-the-clot AB serum. Since naïve mature macrophages 
were of the utmost importance for unbiased polarization experiments, no auxiliary cytokine 
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was given to support the monocyte-to-macrophage transition. Macrophage maturation was 
closely monitored by microscopy. Furthermore, the response of the cells to the polarization 
stimuli was examined before RNA profiling was performed. The phosphorylation of p42/44, 
p38, and JNK, as well as the degradation of IκBα, indicated activation of pro-inflammatory 
M1-associated signalling pathways, whereas phosphorylation of STAT6 pointed to M2-related 
cellular activation. Functional characterization of the polarization routine was furthermore 
achieved by infection of polarized macrophages with Legionella pneumophila and subsequent 
assessment of phagocytic and bactericidal capacity. As described before [151], M1 polarized 
macrophages showed increased uptake and killing of bacteria as compared to M0 and M2 
macrophages (section 3.2). 
 As shown in subsequent RNA analyses, the in vitro polarization of human monocyte-derived 
macrophages yielded reproducible and stable miRNA and mRNA profiles that were 
characteristic of the respective macrophage subtype (Fig. 3.8 and 3.13). A closer investigation 
of mRNAs that were regulated as a response to the M1 polarization stimulus showed hallmark 
inflammatory gene expression such as IL1β and IL6 as well as TNFα among the most highly 
induced genes (Fig. 3-10). Of note, CCR7, a potential surface marker for M1 polarized 
macrophages that has been dismissed in cytometric screening experiments (section 3.2.3) also 
showed marked up-regulation on the mRNA level. This discrepancy between very high 
transcript occurrence and a total lack of response on extracellular protein level might either be 
a temporal effect, or it might be the consequence of translational repression. The 3´UTR of 
CCR7 mRNA was screened in silico for binding sites of highly expressed miRNAs in M1 
macrophages, but no matches could be found. Finally, CD80, the surface marker eventually 
used for M1 macrophage identification, proofed to be strongly up-regulated on mRNA level, 
as expected. 
The transcriptome analysis of the M2 polarized macrophages revealed CD23 as the most 
prominently up-regulated transcript (Fig. 3-11). The CD23 protein served as the M2 specific 
surface marker in this study. Furthermore, CD209 (DC-SIGN) was strongly up-regulated. 
CD23 and DC-SIGN have been shown to form a cluster on chromosome 19p13 [115] and to 
be inducible by IL4 [116]. Up-regulated genes with a known role in alternatively activated 
macrophage biology furthermore included HSD11B1 and PPARγ, which have been shown to 
cooperate in alternative macrophage activation [117]. Recently, transglutaminase 2 (TGM2) 
has been found to be the only consistent and functional M2 marker upon IL4 stimulation in a 
comparative study of human and mouse [118]. 
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As these subtype-defining factors were identified in polarized macrophages that have been 
raised without M-CSF, it is of particular interest to note that they are in good alignment with 
factors found in M-CSF-generated macrophages, on condition that the same polarization 
stimulus is applied [112]. In the referenced publication, CD80 was identified as a M1 surface 
marker, while CXCL10, CXCL11, CCL5, CCR7 and IDO1 were described as M1 mRNA 
markers after LPS and IFNγ administration, which is in full accordance with the data gathered 
from the macrophages herein that were raised without M-CSF (Fig. 3-10). This analogy was 
less robust in M2 polarized macrophages, where PPARγ was the only shared M2 marker on 
mRNA level among the investigated candidates. This might be explained by the fact that in 
the cited study, the M2 polarization was achieved by administration of IL4 alone, whereas in 
our model, a combination of IL4 and IL13 was given. Hallmark IL13 inducible genes [121] 
could hence be detected in the M2 polarized macrophages, such as SOCS1 and the 
aforementioned DC-SIGN and CD23 (FCER2), which are also described as IL4-induced. 
While DC-SIGN is a typical marker of alternatively activated macrophages [152], CD23, the 
low affinity IgE receptor, has been implicated in allergy [52], a property that will be discussed 
later (section 4.4). 
In summary, the obtained in vitro polarized macrophage subtypes appeared to be in good 
accordance with already described phenotypes. 
 
The affirmative data on the macrophage subtype manifestation encouraged the next step, 
which was the miRNA profiling of the three different polarization types (M0, M1, M2). In the 
light of the transcriptome data (section 3.3.2), the biological variance between the samples 
was considered sufficiently low. However, the data gathered from the TLDA experiments 
(section 3.3.3) turned out to bear considerably more variation than the mRNA data, even 
though the same RNA samples were used. This might be due to the technical differences of 
the employed detection methods. The TLDA method is based on compartmentalized qPCR 
reactions that run in parallel in a reaction volume of 1 µl each. Gathering of the miRNA data 
was accomplished by performing three individual arrays per day on three different days. The 
time effect variance (i.e. the variance introduced by doing experiments on different days) has 
been described to have the most serious impact on data collection when compared to 
biological, between-array and within-array variation [153]. The mRNA data were collected on 
an Illumina HT12 Beadchip Array by probe hybridization. The mRNA samples were 
measured in a single run, which minimized variation due to technical inaccuracies. 
Furthermore, this measurement was conducted on a standardized commercial platform (MFT 
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Services, Tübingen). Additionally, while 2119 differential genes were extracted from the 
transcriptome data, only 43 differential miRNAs were gathered from the TLDA experiments, 
which further increased variance of the miRNA data due to a lower number of measurements. 
Extraction of differentially regulated miRNAs and putative mRNA interaction partners 
therefore required extensive bioinformatic analyses. This work was done by Dr. Annalisa 
Marsico, assisted by Dr. Brian Caffrey, as part of a cooperation (Max Planck Institute for 
Molecular Genetics, Berlin). 
Due to the technical challenge of extracting significantly regulated miRNAs from the array 
data, each potential candidate was individually validated by qPCR. As a result, hsa-miR-146a-
5p, hsa-miR-146b-5p, hsa-miR-155-5p and hsa-miR-187-3p were shown to be up-regulated in 
M1 polarized macrophages, whereas hsa-miR-193b-3p and hsa-miR-511-5p were up-
regulated in M2 macrophages (Fig. 3-16 and 3-17). 
The evaluation of hsa-miR-34c-5p was complicated by very low or undetectable amounts in 
individual donor isolates. While this miRNA could be shown to be responsive to the M2 
stimulus in individual samples (Fig. 3-18), the effect across all probed samples was volatile 
and not conclusive. In qPCR, its reliable detection required a pre-cycling step for the pre-
amplification of starting material (section 3.3.4). Hypothetically, this miRNA, if present, is 
subjected to down-regulation upon the M2 stimulus, but this effect apparently depends on its 
physiologic expression value, which seems to fluctuate between donors. 
 
4.2 The effect of microRNAs on the polarization of macrophages 
The hsa-miR-146 family and hsa-miR-155-5p are very well known and broadly studied 
miRNAs that are centrally implicated in the immune response. In macrophages, TLR4 
stimulation leads to the subsequent downstream activation of NFκB, amongst others [154]. 
Both miR-146a/b and hsa-miR-155-5p are NFκB-induced upon TLR4 signalling [155, 156]. 
These miRNAs have been shown to act in a two-tier model of dampening the pro-
inflammatory immune response. While hsa-miR-146a/b contributes to subduing sub-
inflammatory levels of TLR4 signalling by targeting TRAF6, IRAK1 and IRAK2, hsa-miR-
155-5p is only up-regulated at supra-threshold TLR4 activity levels. It is hypothesized to take 
over the role of hsa-miR-146a/b, dampening TLR4 signalling by targeting TAB2 [141]. This 
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would make hsa-miR-155-5p, rather than hsa-miR-146a/b, the dominant negative regulator of 
NFκB-dependent inflammatory responses.  
In addition to their role in the inflammatory context, hsa-miR-146a-5p and hsa-miR-155-5p 
are crucial contributors to the maturation of macrophages from hematopoietic stem cells 
(HSC). During lymphomyeloid development, high amounts of the Ets family transcription 
factor PU.1 have been shown to induce differentiation to macrophages [157]. It has recently 
been shown that PU.1 exerts its role in macrophage maturation at least partly via inducing 
hsa-miR-155-5p and hsa-miR-146a-5p [158]. Additionally, PU.1 has been shown to be a 
direct target of hsa-miR-155-5p, thereby implying a negative feedback mechanism [159]. In 
summary, hsa-miR-146a-5p and hsa-miR-155-5p seem to substantially contribute to both 
macrophage development and macrophage activation by inflammatory mediators. 
hsa-miR-155-5p has furthermore been crucially implicated in macrophage polarization. 
IL13Rα1 (see section 1.2.1) has been shown to be a direct target of hsa-miR-155-5p. Via 
regulation of receptor expression, hsa-miR-155-5p can thus modulate pathways that are 
central to the M2 polarization process, most prominently the STAT6 pathway. Accordingly, 
STAT6 phosphorylation was shown to be significantly decreased after hsa-miR-155-5p 
overexpression, and this effect was shown to be caused by down-regulation of IL13Rα1 
[121]. As a consequence, the transcriptional profile of M2 polarized macrophages was 
markedly altered, which strongly suggested a pivotal role of hsa-miR-155-5p in balancing the 
M1/M2 macrophage polarization spectrum. 
As the hsa-miR-146 family and hsa-miR-155-5p have already been extensively studied by 
many different groups, the comparatively unknown remaining miRNA candidates were put 
into the focus of the target screening experiments in this study. 
 
The hsa-miR-511-5p has been reported to be present in two copies in the genome, which were 
originally described to be harboured by MRC1 and MRC1L1 in intron 5, respectively [120]. 
While MRC1L1 was up-regulated in M2-polarized macrophages (Appendix), MRC1 was not. 
This is in accordance with the dismissal of MRC1 (CD206) as an M2 surface marker (section 
3.2.3). The observed up-regulation of hsa-miR-511-5p thus seems to be dependent solely on 
concomitant MRC1L1 expression, which is also suggested by an equal magnitude of 
regulation upon M2 stimulus (Fig. 3-17 and 3-19). MRC1 and MRC1L1 were originally 
annotated as paralogues, i.e. two genes that arose from segment duplication. However, as of 
August 2013, an annotation information available for gene ID 4360 (MRC1) on NCBI states 
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the following: “In July 2010, the Genome Reference Consortium determined that the region 
contains a duplication error. Two of the clones on which MRC1L1 was based (AL928580, 
BX255924) will be removed from the reference assembly and only MRC1 will be present in 
the assembly. [28 Apr 2011]”. In the luciferase reporter assay, no functional relation between 
MRC1 and hsa-miR-511-5p could be established (Fig. 3-22), so it was excluded from further 
experimentation.  
The most prominently regulated miRNA in the M2 subtype was found to be hsa-miR-193b-
3p, which has already been described to be up-regulated in IL4-stimulated human blood-
derived macrophages [88]. Little is known about its role in macrophages, though. It was 
mentioned to indirectly regulate CCL2 mRNA levels in the THP-1 cell line as a side note in a 
study on miRNA expression in adipose tissue, which implicates its potential in inflammatory 
recruitment [160]. Its main function, however, seems to lie in tumour suppression [161-163]. 
As proliferative diseases were not central to the present thesis, the hsa-miR-193b-3p was no 
longer pursued.  
Even though hsa-miR-34c-5p is also primarily described as tumour-suppressive [164, 165], it 
has, unlike hsa-miR-193b-3p, some putative targets that are vitally implicated in macrophage 
biology, namely Krueppel-like factor 4 (KLF4) and Peroxisome proliferator-activated 
receptor gamma (PPARγ) (Table 3-1). As described (section 3.2.1), STAT6 is one of the 
central signalling molecules of the M2 response. Downstream of STAT6, KLF4 and PPARγ 
have been described to be critically involved in alternative macrophage activation. In a mouse 
model of alternative macrophage activation, PPARγ has been shown to inhibit IL6 production, 
which is central to the M1 polarization programme [166]. KLF4, the other putative hsa-miR-
34c-5p target, is a zinc finger class transcription factor. It is suggested to be a central regulator 
of the M2 polarization programme, as it negatively regulates recruitment of co-activators of 
NFκB, p300 and PCAF, in murine RAW264 cells, thereby inhibiting the M1 polarization 
programme. Accordingly, KLF4-/- macrophages exhibit enhanced M1 polarization. In addition 
to sequestration of NFκB co-factors, KLF4 has been shown to cooperatively bind with 
pSTAT6 at the PPARγ promoter and induce transcription [135]. This may further promote the 
M2 polarization status, given the important role of PPARγ in alternative macrophage 
activation. 
Altogether, KLF4 and PPARγ are, at least in mice, central promoters of the M2 response, and 
both were predicted to be regulated by hsa-miR-34c-5p. In both cases, the detected decrease 
of luminescence was significant and of a magnitude of approximately 40 % (Fig. 3-22). The 
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relevance of this observation has to be carefully evaluated in the given context, since hsa-
miR-34c-5p was not convincingly regulated upon M2 stimulation as shown by the TLDA 
analyses and the subsequent validation experiment (section 3.3.4). 
 
The hsa-miR-187-3p turned out to be the miRNA with the most robust perspective of 
involvement in macrophage biology. It was reliably and stably induced upon M1 polarization 
and predicted to regulate targets that are in part relevant for macrophage organization and 
function. Its scientific coverage is scarce. One of its few known targets is Disabled homolog-2 
(Dab2) [167], a mitogen-responsive phosphoprotein. It has been shown to interact with Grb2, 
thereby competing with son of sevenless (SOS), a GTP exchanger for RAS [125] . This 
displacement potentially influences the Ras/Raf pathway [168]. In turn, this pathway and 
Grb2 have been described to be linked to SH2B2 (APS) [125], a scaffold protein that bears a 
Pleckstrin Homology (PH) domain, a Shc homology 2 (SH2) domain and a tyrosine 
phosphorylation site. While the PH domain enables SH2B2 to bind to membrane-associated 
phosphatidylinositol-4,5-bisphosphate [169], it can bind the signalling molecule Grb2 upon 
tyrosine phosphorylation. Here, SH2B2 was identified as a possible target of hsa-miR-187-3p 
(section 3.4.1.2). Assuming that hsa-miR-187-3p could target the described signalling 
pathway from more than one angle (Fig. 4-1) supported the likelihood of a functional and 
conserved interaction of hsa-miR-187-3p and SH2B2, as it was bioinformatically predicted 
(see section 3.4.1). This hypothesis could be solidified by luciferase reporter experiments 
(Fig. 3-20) and the documentation of native SH2B2 transcript decrease after hsa-miR-187-3p 
transfection (Fig. 3-24). In a published screen of hematopoietic cell lines, SH2B2 was only 
found in Burkitt´s Lymphoma-derived B cells, where it was described to be tyrosine-
phosphorylated upon B cell receptor stimulation. The interaction of the BCR and SH2B2 is 
enabled by the membrane localization of SH2B2 via its PH domain. Growth-factor-receptor 
bound-2 (Grb2) associates with SH2B2 after activation, while Src-homology-2 containing 
(Shc) binds irrespective of the activation state. Both factors are adaptor molecules that are 
situated upstream of the Ras signalling pathway. Thus, it was hypothesized that SH2B2 
couples the B cell receptor to the Ras signalling cascade [125]. Additionally, SH2B2 was 
found to be tyrosine-phosphorylated in response to platelet-derived growth factor (PDGF), 
insulin-like growth factor (IGF) and granulocyte-macrophage colony stimulating factor (GM-
CSF) in a human osteosarcoma cell line [126]. The role of SH2B2 in insulin signalling and 
regulation of insulin receptor protein expression has been tentatively described but remains 
elusive. SH2B2 can associate with the tri-phosphorylated insulin receptor, and SH2B2 
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kockout mice display enhanced insulin sensitivity [170]. Initially, this was attributed to 
SH2B2-mediated ubiquitination of insulin receptor by recruitment of c-Cbl [171]. However, 
this observation did not hold true in a more recent study [172]. While SH2B2 does seem to be 
able to negatively regulate sensitivity to insulin [170], this process does not appear to involve 
regulation of insulin receptor protein expression [173]. 
Another recent study suggests that SH2B2 can homodimerize (or heterodimerize with SH2-B) 
and then bind JAK2 by SH2 domain – pTyr813 interaction, yielding a heterotetrameric 
complex of JAK2-(SH2B2)2-JAK2. Accordingly, while activation of JAK2 could be achieved 
by stimulating the growth hormone receptor, it could be further increased by SH2B2 
overexpression. This was attributed to transactivation that was enabled by the close spatial 
proximity of two JAK2 molecules in the tetrameric complex [127]. Downstream signalling of 
JAK2 then includes STAT5 dimerization, which drives the induction of gene expression 
depending on the cellular context. 
The importance of SH2B2 in macrophage biology remains elusive. On the protein level, 
regulation of SH2B2 by hsa-miR-187-3p could not be conclusively shown in this work. This 
was in part due to the restricted number of suitable available antibodies. Issues with 
specificity and signal intensity precluded a robust assessment of SH2B2 protein expression. 
Still, a significant impact of hsa-miR-187-3p on SH2B2 mRNA was detectable. If this 
phenomenon extends to cells which at least partially rely on SH2B2 for Ras/Raf signalling, 
e.g. B lymphocytes, hsa-miR-187-3p could be a negative regulator of this pathway by 
targeting both Dab2 and SH2B2, thereby modulating downstream signalling events, e.g. the 
phosphorylation of ERK. 
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Figure 4-1: Hypothetical regulation of the BCR signalling pathway by hsa-miR-187-3p. Dab2, a validated 
target of hsa-miR-187-3p, has been proposed to be a negative regulator of the RAS/RAF pathway by displacing 
SOS from Grb2. SOS is a GTP exchanger for RAS, and its replacement by Dab2 shuts down RAS/RAF 
signalling. The C-terminal tyrosine phosphorylation site of SH2B2 is a docking site for Grb2, while the 
membrane localization of SH2B2 is mediated by its PH domain. SH2B2 is hypothetically required to link the 
BCR to the RAS/RAF signalling pathway. Targeting of either Dab2 or SH2B2 by hsa-miR-187-3p might thus be 
positively (Dab2) or negatively (SH2B2) influencing the BCR-RAS/RAF signalling axis.  
 
In contrast to SH2B2, another predicted target of hsa-miR-187-3p, LAMP2, appeared to be of 
greater importance in the context of macrophage biology. Furthermore, the synergetic 
regulation of the LAMP2 reporter plasmid by hsa-miR-155-5p and hsa-miR-187-3p made it 
an interesting target also from a mechanistic point of view. As outlined above (see section 
3.4.2.1), LAMP2 is a structural component of the lysosomal membrane, and it is hypothesized 
to work as a trans-membrane transporter [124]. It possesses three splice variants (LAMP2A, B 
and C). While isoform A and C both carry the hsa-miR-155-5p and hsa-miR-187-3p target 
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sites, LAMP2B is devoid of these sites and thus not a candidate for miRNA-directed 
regulation. All three isoforms have identical aminoterminal domains facing the endosomal 
lumen, but their cytosolic domains differ [174]. In terms of function, LAMP2A has been 
implicated in chaperone-mediated autophagy by mediating protein uptake into lysosomes 
together with heat shock protein 70 (hsc70) [175]. LAMP2C, on the other hand, has been 
shown to bind DNA and RNA for lysosomal uptake, a process which is part of a phenomenon 
that has been termed DNautophagy or RNautophagy, respectively. This mechanism has been 
hypothesized to make exogenous nucleic acids accessible for immune receptors such as 
TLR3, TLR7 and TLR9, as their nucleic acid sensing domains face toward the endosomal 
compartment [176].  
As LAMP2B does not contain the miRNA binding sites of interest, and LAMP2C was found 
to be very weakly expressed in macrophages, LAMP2A was assayed for miRNA-induced 
regulation. On the mRNA level, no regulation could be seen upon miRNA overexpression 
after 24 h and 48 h (Fig. 3-25). Since the luciferase reporter assay strongly suggested an effect 
of hsa-miR-187-3p and hsa-miR-155-5p (Fig. 3-20), a further method was employed to show 
a regulatory effect on native LAMP2 transcript. A global transcriptional stop was enforced by 
application of actinomycin D, a synthetic cytostatic. Naturally, a decrease of transcript amount 
ensues because of the inherent half-life of each mRNA molecule. It has been published before 
that the additional administration of miRNAs can enhance specific mRNA degradation [138]. 
However, this approach showed no impact of either miRNA on LAMP2A transcript levels 
(Fig. 3-27). This might be due to the highly stable nature of the LAMP2A mRNA, as it 
withstands degradation under the influence of actinomycin D for at least 4 h. TNFα transcript, 
which was used as a positive control for actinomycin D potency, was massively down-
regulated after 90 min of treatment (Fig. 3-26).  
 
As miRNAs can also exert their function through translational silencing, LAMP2 was 
addressed on the protein level. The half-life of LAMP2 protein has been shown to be 48 h 
[140]. At this time-point after transfection, LAMP2 protein levels were investigated. No 
regulation of LAMP2 could be detected by western blot after transfection of hsa-miR-155-5p, 
hsa-miR-187-3p, or both (Fig. 3-28, 3-29). This might be due to the three LAMP2 isoforms A, 
B and C. The antibody used to detect LAMP2 by western blot binds both the LAMP2A and 
LAMP2B isoform. As LAMP2B does not possess binding sites for hsa-miR-187-3p and hsa-
miR-155-5p, it might mask changes of LAMP2A protein amount that potentially occur in the 
wake of miRNA overexpression. 
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As an alternative to the western blot procedure, LAMP2 amount and cellular distribution were 
displayed by immunofluorescence microscopy (Fig. 3-30). In order to provide an additional 
molecular context for the regulation to take place, M1 polarized macrophages were included. 
While visual quantification of LAMP2 signal revealed no response to either hsa-miR-155-5p 
or hsa-miR-187-3p overexpression or polarization, the localization of LAMP2 was altered in 
M1 polarized cells. This effect has to be attributed to a change in cell morphology that was 
routinely observed upon M1 polarization. It is thus most likely a consequence of cellular 
behaviour and not induced by specific miRNA properties. Still, the enforced re-localization of 
LAMP2 in polarized macrophages might obscure changes in protein amount and distribution.  
Following the actinomycin D mRNA degradation study, a similar approach could be taken to 
investigate degradation of LAMP2 on the protein level. The massive glycosylation of LAMP2 
confers protection against the constant acidic exposure in the lysosomal lumen. 
Administration of endoglycosidase H cleaves asparagine-linked oligosaccharides from 
lysosomal membrane proteins, which leads to their rapid decomposition [124]. In such a 
setup, the effect of hsa-miR-187-3p and hsa-miR-155-5p on translation of the LAMP2 
transcript could be closely monitored. Assuming that LAMP2 transcript is targeted by hsa-
miR-155-5p and hsa-miR-187-3p, as suggested by the reporter assay, degradation of the 
LAMP2 protein would occur faster in the presence of these two miRNAs, as replenishment of 
protein would be impaired due to translational inhibition.  
In conclusion, no decisive effect of the studied miRNAs on macrophage biology in the 
context of polarization could be shown. While hsa-miR-187-3p seems to be able to down-
regulate SH2B2 transcript to a significant extent, this observation lacks perspective in the 
context of macrophage biology so far. On the other hand, LAMP2, which has been implicated 
in central aspects of macrophage organization, turned out to be completely irresponsive to 
miRNA treatment both on protein and mRNA level, even though the reporter system strongly 
suggests otherwise. This illustrates that the luciferase reporter system is only of limited value 
for the identification of bona fide miRNA targets. The introduction of putative miRNA – 
sensitive sequences into the Renilla luciferase transcript seems to only partially mimic the 
regulation of the native target mRNA by miRNA. One aspect limiting the value of the reporter 
system as it was used in this work is the, in most cases, incomplete 3´UTR that was 
introduced into the Renilla luciferase transcript. The sequences were truncated to various 
degrees (Table 2-1) and thus lacked binding sites for collateral miRNAs that are present in the 
native transcript and might be targeted under physiologic circumstances. An additional 
obstacle that precludes direct transfer of an observation from the reporter assay into the native 
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cell is the secondary RNA structure. The accessibility of the 3´UTR might be decreased in the 
native target transcript due to e.g. hairpin structures, while an exposed Renilla luciferase 
3´UTR might accommodate miRNA binding. Site accessibility has been shown to be as 
important as seed sequence match for the determination of miRNA efficiency [177]. As a 
consequence, it should be avoided to use truncated 3´UTR sequences for the design of further 
reporter vectors. 
An additional limiting aspect of the chosen approach is the multitude of regulatory 
mechanisms that any mRNA is subjected to. The miRNA target prediction on the basis of the 
miRNA and mRNA array data relied in part on down-regulation of transcript. In case of 
parallel up-regulation of putatively specific miRNAs, this combined observation was 
interpreted as a potential regulatory mechanism. However, there are other factors besides 
miRNAs that determine mRNA stability. Tristetraprolin, or zinc finger protein 36 (ZFP36), 
has been described to bind AU rich elements in the 3´UTR of mRNA, thereby causing de-
adenylation and enhanced transcript degradation. TNFα is a well-known target of ZFP36 
[178], which is why TNFα was used as an indicator of actinomycin D potency (Fig. 3-26). In 
accordance with literature [179], M1-polarized macrophages showed a slight up-regulation of 
ZFP36 (Appendix), thereby potentially accounting for subtle down-regulation of transcript. 
These unmonitored regulatory events that invariably occur in the chosen system might both 
obscure or exaggerate miRNA effects on any given mRNA.  
 
4.3 Macrophage polarization phenotypes are known to differentially influence 
asthma pathogenesis  
Building on the human in vitro - generated macrophage polarization profiles, I aimed to 
categorize macrophage subtypes that were isolated from murine lungs in a model of 
eosinophilic airway inflammation. As outlined above (section 4.1), GM-CSF plays a crucial 
role in macrophage activation, and is particularly important for alveolar macrophage 
homeostasis. It has been hypothesized that a shift toward an M-CSF dominated environment 
in the wake of allergic bronchial inflammation could change the activation status of alveolar 
macrophages in the lung [180]. Macrophages both require and promote a distinct 
microenvironment, and their activation status is the product of this delicate interplay. In the 
TH2 dominated environment of an eosinophilic lung inflammation, alveolar macrophages 
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have been described to further skew the immune response toward the TH2 axis and thereby 
promote lung eosinophilia [50, 59, 181]. A series of studies in two different rat strains could 
identify the cytokine secretion of alveolar macrophages as a possible reason for the different 
susceptibility to allergic asthma as observed in these strains [182, 183]. While the Brown 
Norway strain (BN) shares many features of human allergic asthma upon allergen challenge, 
Sprague Dawley rats (SD) do not develop allergic asthma. It was hypothesized that different 
patterns of cytokines that are secreted by alveolar macrophages are the cause of this 
differential susceptibility. Alveolar macrophages from SD rats were shown to produce more 
TNFα in comparison to BN rats, while the latter produce more IL10 and IL13. In the case of 
TNFα, the TH1 impact on the local immune response is suggested to protect SD rats against 
asthma, while the TH2 skew provoked by IL10 and IL13 is thought to predispose BN rats to 
allergic airway inflammation. Along this line of reasoning, it was shown that adoptively 
transferred alveolar macrophages from SD rats could attenuate airway hyper-responsiveness 
upon OVA challenge in BN rats [183]. As this effect was attributed to the macrophage 
activation status, a consecutive study was performed that addressed the crosstalk of lung 
microenvironment and alveolar macrophages. It was shown that ex vivo culture of alveolar 
macrophages from allergic lungs of BN rats could reduce airway hyper-responsiveness (AHR) 
upon re-introduction into the lung. This effect was attributed to the withdrawal of the TH2 
skewed lung microenvironment. Ex vivo culture was shown to induce the TH1 cytokines IFNγ 
and IL12p40 in alveolar macrophages. Instillation of these re-programmed macrophages 
protected BN rats against development of AHR [61]. In summary, these studies strongly 
suggest an influence of the macrophage subtype on the manifestation of allergic airway 
inflammation that depends on the polarization status.  
A study in mice further stressed the importance of the TH1 and TH2 dichotomy in the 
development of AHR. It was reported that an OVA pulse combined with an inflammatory 
mediator (IFNγ) increased the antigen presenting capacities of lung macrophages. This 
skewed the T cell response toward the TH1 axis, thus weakening the TH2 inflammation that 
drives AHR [184]. This observation is of particular interest since it was described before that 
OVA-sensitization alone seems to eliminate the protective role of alveolar macrophages in 
AHR [59]. The additional IFNγ stimulus seems to vitally contribute to the regulatory 
properties of lung macrophages, most likely increasing their M1-like properties and thus 
enabling them to more efficiently establish a protective TH1 environment. 
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The clear model of a protective (TH1) and permissive (TH2) microenvironment in allergic 
airway inflammation is not universally applicable, though. There are severe forms of asthma 
that are insensitive to glucocorticoid treatment and that seem to originate from a different 
immunological context. As outlined above, a TH1 skew of the microenvironment can confer 
protection against AHR in the context of a TH2 driven eosinophilic airway inflammation. 
Severe corticosteroid resistant asthma, on the contrary, has been described to be caused by 
classical activation of alveolar macrophages by LPS in the BALF [49, 185]. M1 polarized 
alveolar macrophages are thus hypothesized to play a crucial role in the exacerbation of 
asthma. Hence, the full extent of the macrophage polarization spectrum needs to be 
considered when evaluating the detrimental or beneficial effect of these cells on the different 
manifestations of allergic asthma. 
 
4.4 Macrophage polarization phenotypes as defined by their microRNA profile seem 
to be heterogeneous in experimental asthma  
The versatility of macrophages as discussed above (sections 1.2 and 1.3.2) requires a 
thorough investigation of marker molecules when assessing their polarization status in any 
given setup. The identification of prototypical human in vitro - derived M1 and M2 
macrophages was performed on the basis of a single surface molecule (M1: CD80, M2: 
CD23). While those markers were suitable for macrophage isolation, they are by no means 
sufficient for a comprehensive subtype characterization. In spite of presenting confirmed 
polarization markers, cells can functionally divert from their stereotypic M1 or M2 properties. 
CD80, a T cell co-stimulatory molecule, has been reported to be increased on the alveolar 
macrophages of asthmatic subjects, enhancing their antigen presentation to TH2 lymphocytes 
[186]. Thereby, they support TH2-driven inflammation, showing that their polarization state is 
not bona fide M1. Furthermore, it was shown that the low affinity IgE receptor (CD23) is 
present on alveolar macrophages from healthy and asthmatic patients. While stimulation with 
IgE leads to the release of both pro- and anti-inflammatory cytokines, it was demonstrated 
that alveolar macrophages from asthmatic donors initially secrete more TNFα and less IL10 
compared to their healthy counterparts, thus favouring a pro-inflammatory microenvironment 
in the airways and the lung [187]. This bias in the TNFα/IL10 axis is commonly associated 
with M1 polarized macrophages.  The inflammatory nature of asthma implies a range of pro-
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inflammatory mechanisms at work that dynamically shape the disease manifestation. Hence, 
both M1 and M2 macrophages and their dynamically shaped hybrid forms seem to contribute 
at different stages of the disease [49]. The pro-inflammatory nature of airway macrophages 
that has been described in patients with corticosteroid-resistant asthma as discussed above 
(section 4.3) has been documented by higher expression levels of typical M1 associated 
genes, such as TNFα, IL1β, IL8, CXCL1, CCL3 and CXCL2, all of which can be confirmed 
by the mRNA profiling experiments of the present study (Fig. 3-10 and Appendix). The 
proinflammatory properties of airway macrophages in severe asthma have been attributed to 
activation of the TNFα axis [188, 189], which is also crucially involved in classical 
macrophage polarization [190].  
The complexity of macrophage activation in the pathogenesis of allergic airway inflammation 
requires in-depth analyses of subtype-defining regulatory events. As miRNAs have been 
shown to vitally contribute to many aspects of immunology in general and macrophage 
biology in particular, the global miRNA setup of alveolar and interstitial macrophages from 
the lungs of mice with acute OVA-induced eosinophilic airway inflammation was investigated 
with a special focus on their potential in macrophage polarization. In a first step, a principal 
component analysis was performed on the basis of the 32 most stably differentially regulated 
miRNAs in the investigated setup. The miRNA profile from both the alveolar and interstitial 
macrophages showed a certain dependency on the health situation of the animals (Fig. 3-35). 
This finding encouraged further investigation. To this end, three miRNAs were selected for 
individual validation in the interstitial macrophage samples, being mmu-miR-21a-5p, mmu-
miR-126-3p and mmu-miR146a-5p. Due to material scarcity, no RNA from the alveolar 
macrophage fraction was left after the TLDA analyses, so validation was restricted to the 
interstitial macrophage pool. This revealed an opposing pattern of mmu-miR-21a-5p, which 
was up-regulated, and mmu-miR-126-3p, which was down-regulated (Fig. 3-36). The mmu-
miR-21 has been described to target IL12p35 in T cells, thereby contributing to an attenuated 
TH1 response by limiting the activation of the IL12/IFNγ axis [102]. As IL12 is an important 
molecule in the macrophage M1 subtype manifestation, this regulatory property of mmu-miR-
21 is of particular interest when assessing the macrophage polarization status in the TH2 
dominated microenvironment of eosinophilic airway inflammation. The observed up-
regulation of mmu-miR-21a-5p in the interstitial macrophage fraction (Fig. 3-34, 3-36) 
suggests an active suppression of M1-associated signalling pathways in these cells. This 
assumption is complicated, however, by the observed concomitant down-regulation of mmu-
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miR-126-3p. This miRNA has been described to reduce allergic airway inflammation when 
antagonized by limiting the TH2 effector function. This has been attributed to an up-regulation 
of the transcription factor PU.1 and a subsequent down-regulation of GATA3 upon anti-miR-
126 treatment [103]. It was furthermore described that mmu-miR-126 was up-regulated in the 
airways of chronically OVA-challenged mice, and that antagonizing this miRNA led to 
reduced eosinophil recruitment [191]. In summary, antagonizing mmu-miR-126 seems to 
attenuate the TH2-dominated pathogenesis of eosinophilic asthma, which is at odds with the 
observed down-regulation of this miRNA in the interstitial macrophage fraction from OVA-
challenged mice (Fig. 3-34, 3-36). However, the observed miRNA pattern has not been 
described in macrophages before. PU.1 is an important transcription factor in macrophages 
with a broad role in both maturation and pro-inflammatory activation [192], which might 
exceed its function in T cells. 
In order to assess the extent of M1 type pro-inflammatory activation patterns of interstitial 
macrophages in the acute OVA model, the regulation of the hallmark pro-inflammatory mmu-
miR-146a-5p was investigated. As suggested by the TLDA analyses, it was confirmed to be 
down-regulated in these cells, which argues against a prototypical, fully M1-type activation, 
as this miRNA is described as up-regulated in M1 macrophages, as is shown in the present 
study in the context of in vitro polarized human macrophages (Fig. 3-16). For a further 
investigation of the miRNAs that were differentially regulated in asthma, no validation 
experiments of individual candidates could be performed, because the scarce RNA material 
was exhausted after the analyses described above. It is noteworthy, however, that more 
candidates are included in the list of differentially expressed miRNAs (Fig. 3-33), e.g. the 
mmu-miR-155-5p, which appears to be solidly up-regulated in both alveolar and interstitial 
macrophages, and could also be shown to be induced in M1-type macrophages (Fig. 3-16). 
The apparent reciprocal regulation of mmu-miR-146a-5p (down) and mmu-miR-155-5p (up) 
(Fig. 3-34) is of particular interest, since both miRNAs have been shown to often be co-
induced [141]. If this observation can be corroborated, it might be a defining feature of 
eosinophilic airway inflammation.  
Additionally, the let-7 family seems to be regulated in repsonse to OVA. This miRNA family 
has been shown to down-regulate IL13 in T cells and thereby alleviate allergic airway 
inflammation [193]. As they all share the same binding site in the IL13 3´UTR, there is a 
sterical competition. In the alveolar macrophage fraction, there seems to be OVA-induced 
regulation of let-7b (up) and let7c (down), while in the interstitial macrophage population, a 
down-regulation of let-7e can be observed (Fig. 3-33). It remains to be investigated whether 
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these patterns are functionally permissive of IL13 up-regulation and thereby contribute to the 
TH2 - dominated condition of eosinophilic airway inflammation. As shown in the human 
miRNA screening experiments, hsa-let-7b is slightly induced in M2-polarized macrophages. 
Whether this observation can help to define the activation status of macrophages in 
eosinophilic asthma remains to be investigated.  
In summary, the envisioned global comparison of murine miRNA profiles with their in vitro-
derived human counterparts is currently hindered by the limited intersection of the human and 
murine data material. This can potentially be improved by including more mice in the study 
and by employing an additional model, e.g. house dust mite-induced airway inflammation. 
However, individual miRNAs show reliable patterns of induction or repression upon OVA 
challenge, as described above. These miRNAs and their role in experimental and clinical 
asthma as well as their contribution to macrophage polarization will be in the focus of future 
research. 
 
4.5 Outlook 
In order to further employ the knowledge that has been gained in this study, the question of 
macrophage polarization and their involvement in asthma will be addressed from additional 
angles. Shortcomings of the chosen approach that have been identified will thus be 
minimized. 
The in vitro subtype generation of human blood-derived macrophages has some inherent 
limitations that hinder the application of the identified mRNA and miRNA patterns to the 
specimens obtained from the mouse model. Apart from the species barrier, the extreme 
phenotypes that were obtained by in vitro polarization are not likely to be present in primary 
lung macrophages, as the latter are shaped by the complex and volatile dynamics of an 
ongoing immune response. In order to more accurately mimic the situation as found in the 
animal model, we are planning to mix in vitro generated macrophage subtypes at defined 
percentages by cytometric sorting. This will yield hybrid populations with mixed 
characteristics, which will be more suitable as a reference for macrophage subtypes obtained 
from in vivo sources, because it takes sample heterogeneity into account and allows 
quantification thereof. 
In order to complement the miRNA data from the murine model of eosinophilic airway 
inflammation, global mRNA profiling has been performed in order to find putative 
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mRNA/miRNA interaction partners as has been done in the human in vitro model. The data 
are currently being interpreted. Once available, it will constitute an additional data basis to 
assess the macrophage polarization status in eosinophilic asthma. Furthermore, alveolar 
macrophages from human healthy and asthmatic donors are currently being acquired. Their 
miRNA profile might be more suitable for comparison with the in vitro polarized human 
reference samples.  
The investigation of direct miRNA/mRNA interaction partners by luciferase reporter assay 
and qPCR turned out to only scarcely shed light on the mechanisms of macrophage 
polarization in the chosen models. Nevertheless, miRNA expression patterns do change upon 
in vitro polarization and in in vivo inflammation models. In an attempt to explore the sum of 
miRNA-mediated regulatory events, including indirect effects, ectopic disturbance of the 
miRNA profile in the context of polarization was performed. To this end, unpolarized and M1 
polarized macrophages were transfected with hsa-anti-miR-155-5p and hsa-pre-miR-187-3p, 
respectively. In the present study, both miRNAs have been found to be regulated in response 
to the M1 stimulus. As hsa-miR-155-5p is strongly expressed in macrophages even at basal 
levels, it was chosen to silence it by anti-miR application. In contrast, hsa-miR-187-3p, only 
weakly expressed even upon induction, was over-expressed by pre-miR administration. The 
resulting global impact on the mRNA profile was investigated by microarray screening. As of 
submittal of this thesis, the data were not fully interpreted. The analysis will focus on both 
direct miRNA-mediated translational control and on indirect effects. These indirect effects 
include, e.g., miRNA-mediated regulation of a transcription factor, which potentially has 
downstream effects on gene expression, or down-regulation of an inhibitor, with subsequent 
de-repression of an agonist. If enrichment of putative candidates in functionally linked 
processes can be shown, this will yield important insights into their role in cellular 
organization. These data will be used, if suitable, to further define the properties of polarized 
macrophages and to understand the underlying RNA-based mechanisms.  
The effect of a given miRNA on cellular biology has to ultimately be shown on the protein 
level. Identification of individual targets by Western Blot, as attempted in this study, could be 
too narrow-focused in some cases, as it might miss important secondary effects. This problem 
might be addressed by a proteomics approach, e.g. 2D gel electrophoresis, which visualizes 
the composition of heterogeneous protein samples by a combined approach of isoelectric 
focussing and gel electrophoresis. Changes in the characteristic protein pattern after miRNA 
over-expression or silencing (as employed above) can then be interpreted by use of annotation 
databases (like UniProt-GOA).  
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In summary, the envisioned approaches might help to identify the polarization status of 
macrophages collected from the lungs of mice within the model of OVA-induced airway 
inflammation, and from the BAL fluid of healthy and asthmatic human donors. Knowledge 
about the physiologic and disease-driven polarization state of primary lung macrophages 
might provide clues on their involvement in asthma and on how to ameliorate disease 
progression by manipulating macrophage subtype manifestation.  
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Appendix 
Table 1: Gene expression profiles of M1 vs. M0 macrophages, ranked by expression value 
Gene Description log2 fold change vs. M0 P-value Rank 
IDO1 indoleamine 2,3-dioxygenase 1 9.95 1.80E-09 1 
CXCL9 chemokine (C-X-C motif) ligand 9 9.54 8.41E-10 2 
EBI3 Epstein-Barr virus induced 3 8.37 2.29E-09 3 
CD38 CD38 molecule 8.20 9.44E-09 4 
IL1B interleukin 1, beta 8.16 1.25E-09 5 
IL6 interleukin 6 (interferon, beta 2) 7.72 2.38E-06 6 
CCL1 chemokine (C-C motif) ligand 1 7.43 5.07E-05 7 
CCL5 chemokine (C-C motif) ligand 5 7.24 2.34E-08 8 
LOC730249 
PREDICTED: Homo sapiens similar to 
Immune-responsive protein 1 
(LOC730249), mRNA. 
7.24 2.02E-07 
9 
CCL8 chemokine (C-C motif) ligand 8 7.09 3.33E-06 10 
CCR7 chemokine (C-C motif) receptor 7 6.96 5.95E-07 11 
IL7R 
PREDICTED: Homo sapiens interleukin 
7 receptor (IL7R), mRNA. 6.94 1.35E-06 
12 
CFB complement factor B 6.82 1.63E-07 13 
PTGS2 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
6.79 4.64E-08 
14 
ISG20 
interferon stimulated exonuclease gene 
20kDa 6.77 5.44E-08 
15 
IFI27 interferon, alpha-inducible protein 27 6.62 6.34E-05 16 
CCL20 chemokine (C-C motif) ligand 20 6.52 2.63E-07 17 
MCOLN2 mucolipin 2 6.51 3.56E-08 18 
SLAMF1 
signaling lymphocytic activation 
molecule family member 1 6.34 9.52E-07 
19 
ANKRD22 ankyrin repeat domain 22 6.31 5.44E-08 20 
UBD ubiquitin D 6.29 4.79E-07 21 
NFS1 
NFS1 nitrogen fixation 1 homolog (S. 
cerevisiae)25 6.28 2.34E-08 
22 
GBP5 guanylate binding protein 5 6.25 2.19E-06 23 
HSD11B1 
hydroxysteroid (11-beta) dehydrogenase 
1 6.24 5.96E-07 
24 
IFI44L interferon-induced protein 44-like 6.12 1.93E-07 25 
GBP4 guanylate binding protein 4 5.95 2.33E-07 26 
ADORA2A adenosine A2a receptor 5.63 5.06E-08 27 
PTGES prostaglandin E synthase 5.62 1.51E-05 28 
CCL19 chemokine (C-C motif) ligand 19 5.62 2.40E-07 29 
TNIP3 TNFAIP3 interacting protein 3 5.61 5.44E-08 30 
IL2RA interleukin 2 receptor, alpha 5.45 9.52E-07 31 
TNFAIP6 
tumor necrosis factor, alpha-induced 
protein 6 5.42 1.29E-06 
32 
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CRISPLD2 
cysteine-rich secretory protein LCCL 
domain containing 2 5.38 2.13E-07 
33 
LAMP3 
lysosomal-associated membrane protein 
3 5.35 5.74E-05 
34 
CXCL10 chemokine (C-X-C motif) ligand 10 5.32 3.25E-06 35 
CA12 carbonic anhydrase XII 5.30 1.67E-07 36 
G0S2 G0/G1switch 2 5.21 5.48E-07 37 
STAT4 
signal transducer and activator of 
transcription 4 5.17 1.70E-05 
38 
IFITM3 
interferon induced transmembrane 
protein 3 (1-8U) 4.99 0.0003 
39 
OSM oncostatin M 4.95 6.90E-06 40 
MUCL1 mucin-like 1 4.89 0.0028 41 
PDE4B 
phosphodiesterase 4B, cAMP-specific 
(phosphodiesterase E4 dunce homolog, 
Drosophila) 
4.88 7.40E-06 
42 
CXCL2 chemokine (C-X-C motif) ligand 2 4.85 6.85E-06 43 
CD80 CD80 molecule 4.84 4.39E-07 44 
CYP26A1 
cytochrome P450, family 26, subfamily 
A, polypeptide 1 4.77 2.33E-07 
45 
TNF 
tumor necrosis factor (TNF superfamily, 
member 2) 4.73 3.85E-05 
46 
IL27 interleukin 27 4.72 5.37E-07 47 
IL12B 
interleukin 12B (natural killer cell 
stimulatory factor 2, cytotoxic 
lymphocyte maturation factor 2, p40) 
4.71 0.0005 
48 
SOD2 superoxide dismutase 2, mitochondrial 4.66 8.83E-07 49 
GCH1 GTP cyclohydrolase 1 4.66 2.75E-06 50 
    
 
IL8 interleukin 8 3.84 0.0001 76 
CXCL1 
chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha) 
3.69 1.71E-05 
88 
CCL3 chemokine (C-C motif) ligand 3 3.07 1.70E-05 128 
CXCL11 chemokine (C-X-C motif) ligand 11 2.65 0.0007 177 
ZFP36 
zinc finger protein 36, C3H type, 
homolog (mouse) 1.48 0.0046 
465 
 
 
Table 2: Gene expression profiles of M2 vs. M0 macrophages, ranked by expression value 
Gene Description log2 fold change vs. M0 P-value Rank 
FCER2 
Fc fragment of IgE, low affinity II, 
receptor for (CD23) 6.08 1.34E-04 
1 
CH25H cholesterol 25-hydroxylase 5.29 3.94E-05 2 
CD209 CD209 molecule 5.28 1.55E-03 3 
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MMP12 
matrix metallopeptidase 12 
(macrophage elastase) 4.70 3.94E-05 
4 
HOPX HOP homeobox 4.68 2.26E-03 5 
RAMP1 
receptor (G protein-coupled) activity 
modifying protein 1 4.47 2.36E-04 
6 
FCGR2B 
Fc fragment of IgG, low affinity IIb, 
receptor (CD32) 3.89 1.74E-04 7 
CCL4L2 
Homo sapiens chemokine (C-C motif) 
ligand 4-like 2 (CCL4L2), mRNA. 3.84 2.63E-04 8 
GUCA1A guanylate cyclase activator 1A (retina) 3.81 3.94E-05 9 
CCL26 chemokine (C-C motif) ligand 26 3.81 3.94E-05 10 
CISH 
cytokine inducible SH2-containing 
protein 3.80 9.02E-04 11 
SOCS1 suppressor of cytokine signaling 1 3.71 1.78E-04 12 
MAOA monoamine oxidase A 3.69 3.03E-05 13 
FARP1 
FERM, RhoGEF (ARHGEF) and 
pleckstrin domain protein 1 
(chondrocyte-derived) 
3.62 1.63E-04 
14 
CTNNAL1 
catenin (cadherin-associated protein), 
alpha-like 1 3.55 4.43E-03 15 
SPINT2 serine peptidase inhibitor, Kunitz type, 2 3.54 9.09E-05 16 
ESPNL espin-like 3.51 2.02E-03 17 
SLAMF1 
signaling lymphocytic activation 
molecule family member 1 3.51 1.30E-03 18 
C17orf87 
Homo sapiens chromosome 17 open 
reading frame 87 (C17orf87), mRNA. 3.39 6.19E-04 19 
ALDH1A2 
aldehyde dehydrogenase 1 family, 
member A2 3.27 3.94E-05 20 
F13A1 coagulation factor XIII, A1 polypeptide 3.25 6.80E-02 21 
FAM110B 
family with sequence similarity 110, 
member B 3.23 2.25E-04 22 
FOXC1 forkhead box C1 3.23 1.34E-04 23 
EFNA1 ephrin-A1 3.15 8.38E-03 24 
BATF3 
basic leucine zipper transcription factor, 
ATF-like 3 3.14 2.89E-04 25 
SIGLEC10 sialic acid binding Ig-like lectin 10 3.13 2.89E-04 26 
CLEC10A 
C-type lectin domain family 10, 
member A 3.09 1.45E-02 27 
FAR2 fatty acyl CoA reductase 2 2.97 2.22E-04 28 
DNASE1L3 deoxyribonuclease I-like 3 2.96 1.61E-03 29 
C10orf128 chromosome 10 open reading frame 128 2.93 4.34E-04 30 
TGFA transforming growth factor, alpha 2.93 3.84E-02 31 
STAMBPL1 STAM binding protein-like 1 2.90 2.44E-03 32 
SYT17 synaptotagmin XVII 2.89 4.53E-03 33 
HSD11B1 
hydroxysteroid (11-beta) dehydrogenase 
1 2.84 3.59E-03 34 
ACOT7 acyl-CoA thioesterase 7 2.78 2.32E-03 35 
MS4A6E 
membrane-spanning 4-domains, 
subfamily A, member 6E 2.76 1.33E-02 36 
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ENPP2 
ectonucleotide 
pyrophosphatase/phosphodiesterase 2 2.73 2.01E-02 37 
IRF7 interferon regulatory factor 7 2.69 1.09E-03 38 
HOMER2 homer homolog 2 (Drosophila) 2.65 0.0002 39 
CDH1 
cadherin 1, type 1, E-cadherin 
(epithelial) 2.63 9.02E-04 40 
FCRLB Fc receptor-like B 2.62 0.0001 41 
DACT1 
dapper, antagonist of beta-catenin, 
homolog 1 (Xenopus laevis) 2.60 7.13E-04 42 
ANPEP alanyl (membrane) aminopeptidase 2.60 1.92E-03 43 
SLC47A1 solute carrier family 47, member 1 2.59 9.78E-03 44 
LIMA1 LIM domain and actin binding 1 2.57 2.25E-04 45 
TRAF5 TNF receptor-associated factor 5 2.50 1.40E-03 46 
PARM1 
prostate androgen-regulated mucin-like 
protein 1 2.50 1.43E-03 47 
CCL3 chemokine (C-C motif) ligand 3 2.49 0.0006 48 
CCL5 chemokine (C-C motif) ligand 5 2.46 1.86E-03 49 
ABCG2 
ATP-binding cassette, sub-family G 
(WHITE), member 2 2.41 2.58E-03 50 
     
TGM2 
transglutaminase 2 (C polypeptide, 
protein-glutamine-gamma-
glutamyltransferase) 
2.12  0.0091  66 
MRC1L1 mannose receptor, C type 1-like 1 2.03 0.0383 73 
PPARG peroxisome proliferator-activated receptor gamma 1.73 0.0073 100 
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